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Definition of terms as used in this thesis
1/ Dysfunctional uterine bleeding:-
abnormal blood loss, either regular or irregular, occurring from a uterus which on
clinical examination is equivalent to or smaller than ten week pregnancy size and
exhibits no endometrial atypia.
2/ Menorrhagia:-
heavy menstrual blood loss, either regular or irregular, as reported by the patient,
which leads to medical consultation.
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AIMS
The management of women with heavy menstrual loss is a common problem for
every gynaecologist yet there are wide variations in practice. Much of this has
arisen through lack of both evidence based practice and a robust evidence base
itself. The work contained in this thesis aims to determine baseline epidemiological
information on women referred from primary care with menorrhagia and also to
evaluate endometrial ablative surgical techniques in the context of randomised
trials. This will hopefully contribute to the evidence base to which we should
continually add, and base our practice upon.
It was felt necessary to perform a survey of all women who were first time referrals
with heavy menstrual loss to the gynaecology outpatient department over one year.
The socio-demographic and epidemiological features of this population including
their preferences regarding management, expectations, and also an assessment of
their quality of life would be ascertained. This was considered to be essential
baseline information. These data are not available for the Grampian or Scottish
population and it was felt that the results should enhance the generalisability of the
randomised trials undertaken in this thesis. The data will also serve as a
benchmark for auditing changes over time with the implication of new information
and guidelines on the management of women with heavy menses.
Endometrial ablative techniques had been previously compared with hysterectomy
as potential alternatives to this procedure for women with menorrhagia. The
satisfaction rates achieved were high (around 80%), but significantly lower than for
hysterectomy, which also guaranteed amenorrhoea. Recommendations were made
that ablation should only be offered once medical management of menorrhagia had
failed. A randomised trial comparing transcervical resection of the endometrium
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against traditional medical treatment for women complaining of heavy menstrual
loss was undertaken. This set out to establish satisfaction with and acceptability of
the two forms of management, effects on menstrual symptoms and health related
quality of life, and subsequent additional management required. Follow-up was
planned in the short-term, at four months and medium term at two years.
This trial was felt necessary to establish the true place of endometrial ablative
techniques in the management of menorrhagia, to evaluate the effectiveness of
present medical regimes and to determine what additional treatments are required.
Importantly the trial was designed to be pragmatic. This determined that normal
clinical practices were to be followed for general practitioner referral and patient
assessment. Investigations which were not part of the standard patient assessment
(e.g. ultrasound or diagnostic hysteroscopy), were also avoided. In addition,
medical treatments prescribed were at the discretion of the consultant to whom the
women was referred, and not a specific medication in a pre determmed dose/
timing. The pragmatic approach, through reflecting normal practice should
enhance the external validity of the results, by maximising recruitment of a diverse
population of women with dysfunctional uterine bleeding. However, pragmatism
can only to serve to demonstrate differences and cannot explain why they occur.
The second randomised trial was undertaken to formally evaluate a "new
generation" ablation endometrial ablative technique, microwave endometrial
ablation. Microwave ablation has been described as a simple fast and safe
technique for destroying the endometrium, but has never undergone rigorous
evaluation. A randomised trial comparing it with the gold standard procedure,
transcervical resection of the endometrium, was undertaken. Outcomes in terms of
patient satisfaction, acceptability and changes in menstrual status and quality of life
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after four months were determined. Operative parameters were also measured
including operating and recovery times, complications and analgesia requirements.
As traditional hysteroscopic surgical techniques are technically difficult procedures,
proving satisfactory outcomes for a potentially simple and safe procedure has
important implications for both gynaecologist and patient. If shown to be safe and
effective, microwave ablation could be undertaken in the outpatient setting using
local anaesthesia, freeing valuable theatre space and anaesthetists.
Recommendations based on the findings from these studies can be made.
Undertaking this work, including the background reading should also uncover
areas that require further investigation, and these will also be discussed.
Summary of aims
1/ To determine characteristics of women in Grampian district referred to the
gynaecologist with heavy menstrual loss in the context of:-
a/ socio-demographic data
b/ epidemiological features
c/ patterns of G.P. referral and treatment
d/ treatment preferences and expectations
e/ effect of menorrhagia on health related quality of life
2/ To compare transcervical resection of the endometrium with traditional medical
treatments for women first referred to a gynaecologist with heavy menstrual loss.
This is to establish the role of endometrial ablation in the management of this
condition. Outcomes were determined by measuring at four months and two years
with particular reference to:-
a/ patient satisfaction and acceptability of treatment
b/ changes to menstrual status
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c/ changes to health related quality of life
d/ additional treatments required
3/ A new generation endometrial ablative technique, microwave endometrial
ablation was compared in a randomised trial with transcervical resection of the
endometrium to establish its effectiveness in terms of:-
a/ patient satisfaction with and acceptability of the procedure
b/ change in menstrual symptoms
c/ changes to health related quality of life
d/ operative data
e/ recovery times and return to work
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ABSTRACT
The research described in this thesis endeavours to rationalise certain aspects of the
secondary care management of women with heavy menstrual loss, in particular the
place of endometrial ablative surgery. The work was undertaken in a gynaecology
department with an established record in research evaluating endometrial ablative
techniques. The hospital is the regional referral centre for all women with
menstrual disorders, hence a centralised and stable study population was available.
Chapter 1 outlines the aetiological and known epidemiological factors for
dysfunctional uterine bleeding. A review of the medical treatment options for
menorrhagia is undertaken. The equipment requirements and techniques of
transcervical resection of the endometrium (TCRE) and microwave endometrial
ablation (MEA) are described. The randomised controlled trials evaluating TCRE
that have been published to date, are discussed and critically reviewed.
Chapter 2 presents the patterns of referral, socio-demographic and clinical details,
primary care treatment, and effect on health related quality of life of women
referred to this centre, over one year with heavy menstrual loss. Issues of treatment
preference and expectations of treatment were also explored. 273 women were
referred for the first time with heavy periods making up 7% of new gynaecological
referrals to Aberdeen. 21% had their complaint for less than one year. 64% of
women were disabled for more than two days per cycle, despite 78% having
received treatment from their general practitioner. The women as a group exhibited
a significant reduction in all dimensions of health related quality of life. 31% of
women had a strong treatment preference and they differed from women with no
preference. Those preferring medical treatment were less restricted by their
menstrual problems, fewer had been treated previously by their GP, and they had
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near normal quality of life levels. Those preferring TCRE were more likely to have
completed their education by age sixteen, had all tried medical management, and
had a greater desire for amenorrhoea.
Chapter 3 describes the subjects, methods and outcomes at four months of a
prospective randomised comparison of medical management with TCRE for
women with heavy menstrual loss. Women allocated medical treatment were
significantly less likely to be totally or generally satisfied (27% versus 76%), to find
the treatment acceptable (36% v 93%), and would be less willing to have the
treatment again (31% v 93%). Although pain and bleeding were significantly
improved by medical treatment, the reduction was modest in comparison with
TCRE. Haemoglobin levels were significantly increased only following TCRE.
Quality of life scores improved in both trial arms, although only transcervical
resection returned them to normal values
Chapter 4 outlines the clinical and quality of life outcomes at two years for the
randomised trial of medical treatment versus TCRE. Women allocated medical
treatment were significantly less likely to be totally or generally satisfied (57% v
79%), to find their management acceptable (77% v 93%), or to recommend their
allocated treatment (24% v 78%). 59% of women in the medical cohort had
undergone TCRE, hysterectomy or both, whereas 17% in the TCRE cohort had
undergone further surgery. Bleeding and pain scores were similar in the groups
and highly significantly better than at recruitment. Quality of life scores were
significantly improved from baseline for five of the eight health scores in the
medical arm, and seven in the TCRE arm.
Chapter 5 describes the subjects and methods for a prospective randomised
controlled trial comparing MEA with TCRE. Operative details and outcomes at
four months are presented. MEA was a significantly faster technique than TCRE
(11.4 v 15 minutes). Postoperative stay was less with microwave, though not
significantly so, and analgesia requirements were low and equivalent (< 30%) for
both techniques. Satisfaction rates were slightly lower following MEA (74% v.
81%), whilst acceptability of treatment rates were equivalent (92% v 94%). MEA
lead to more significant improvements in health related quality of life
measurements than TCRE.
Chapter 6 concludes that:- Primary care management guidelines need to be
implemented, whilst treatment preferences and expectations should be established
prior to deciding on treatment. Quality of life measurements should be used to
determine degree of debilitation and to ascertain treatment success. Medical
treatment was less effective than TCRE, irrespective of previous treatment or type
of medical management received. Early recourse to endometrial surgery should
therefore be considered, with the choice made by the woman after discussing the
advantages and disadvantages of all the therapeutic options. MEA was shown to
be a quicker technique than TCRE, which is equally effective, and is also simple to
learn.
Areas for future research include: identification of an acceptable and accurate
method of measuring menstrual blood loss, the search for a medical treatment
effective in the long term, the assessment of ablative surgery under local
anaesthesia in the out patient setting and investigation of immunological therapies
such as antibodies to specific endometrial factors.
Chapter 1
Heavy Menstrual Loss:
aetiology, epidemiology, and management options
an overview and critique of the literature
INTRODUCTION
This thesis will attempt to clarify the place of endometrial destructive surgery in the
management of heavy menstrual loss. Randomised studies have shown
transcervical resection of the endometrium and endometrial laser ablation to be
effective alternatives to hysterectomy for the treatment of menorrhagia, but no trials
exist comparing medical management with transcervical resection of the
endometrium. Descriptions of alternative endometrial ablative techniques which
are simple to undertake, and quick to perform are appearing more commonly in the
literature. Few have been evaluated in the context of a randomised controlled trial.
In this chapter current aetiological and epidemiological factors pertinent to
menstrual dysfunction are considered, followed by a review of traditional medical
therapies. The development of endometrial surgical techniques is traced and the
mechanisms of action of electrodiathermy and microwave technology described.
The preparation, equipment and techniques utilised for these surgical procedures
will be outlined next. Finally, a critical review of published studies evaluating
endometrial surgical techniques for heavy menstrual loss is undertaken in order to
highlight the need for prospective randomised controlled trials in this area.
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Chapter 1 is subdivided as follows:
1.1 menorrhagia:- aetiology and epidemiology
1.2 medical management of heavy menstrual loss - a critical review of the
literature
1.3 development of endometrial surgical techniques
1.4 mechanisms of action of electrodiathermy and microwave
1.5 requirements for endometrial surgery (equipment, preparation and
techniques)
1.6 The place of endometrial surgery in the management of heavy menstrual
loss - a critical review of the literature
1.1 Menorrhagia: - aetiology and epidemiology
1.1.a - aetiology
The mechanisms governing the control of menstruation and in particular, severity
of bleeding are poorly understood. An interplay of a number of factors control
menstruation whicfi are "local" uterine, rather than hypothalamic-pituitary in
origin. Vascular spasm of the endometrial spiral arterioles, local uterine
haemostasis / fibrinolysis, and endometrial regeneration all contribute to the
mechanism of menstruation. Defective haemostasis may result from a breakdown
of these resulting in excessive blood loss, which, in the absence of demonstrable
pathology, is called dysfunctional uterine bleeding.
Menstruation is preceded by intense vasoconstriction of the spiral arterioles(l).
This is followed by a period of relaxation for 4 to 24 hours, during which time the
majority of endometrium is shed. A return of intense vasoconstriction is probably
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the principal haemostatic event, rather than platelet-fibrin plug formation(2).
Endothelin-1 may directly, or by causing production of prostaglandin YjOL, exert
local control on the endometrial vascular bed, causing this intense vasoconstriction
seen immediately prior to menstruation, and also may be required in the cessation
of menstruation(3). Endometrial proteinases and tissue factor may contribute to
systemic factors to control the mechanisms of regulation of tissue dissolution, tissue
shedding, and vascular bleeding during menstruation(4). This paracrine response
could be further mediated by nitric oxide which is a potent vasodilator and
inhibitor of platelet aggregation through initiation and control of menstrual
bleeding(5). Uterine bleeding can be triggered in the menstrual cycle by dropping
progesterone levels, regardless of oestrogen levels(6). A drop in progesterone levels
also initiates inflammatory mediators and an influx of monocytes which may be
essential to endometrial shedding(7), implying a pivotal role for this hormone.
Menstruation, has many hallmarks of an inflammatory process in which the
cascade of events involving the interaction between the stroma-epithelial cells of the
endometrium and the lympho-haemopoetic cells are utilised to reject, remodel and
regrow the endometrium each month(8). Mast cell regulation of human
endometrial matrix metalloproteinases which lead to focal menstrual breakdown(9),
and the aforementioned leucocyte infiltration pre-menstrually(7) both support this.
Endometrium also has its own fibrinolytic system and there is evidence that
excessive fibrinolytic activity may cause dysfunctional uterine bleeding(10,ll).
Elowever, one study comparing women with normal and pathological blood loss,
little differences were found in fibrinolytic products(12).
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Little is known about the factors which govern endometrial regeneration, although
local oestrogen effects, epidermal growth factors, prostaglandins^), and
endothelins are all felt to contribute. Local hypoxia causes vascular endothelial
growth factor to increase in the endometrium which may be a stimulus to
endometrial regrowth(13), whilst an interaction of many growth factors which
predispose to endothelial proliferation and angiogenesis have been
demonstrated(14). The mitogenic actions of endothelin may also play a role in
endometrial regeneration and remodelling, particularly following menstruation(3).
Breakdown in this regenerative process could also play a role in defective
menstruation.
Prostaglandins seem to plav an integral role in the pathogenesis of dysfunctional
uterine bleeding(8,15-18). Prostaglandins E2, D2 and prostacyclin are vasodilators,
whilst prostaglandin F2a and thromboxane A2 are vasoconstrictors. Platelet
aggregation is also promoted by thromboxane A2 and inhibited by Prostaglandin D2
and prostacyclin. An imbalance in the production or potency of prostaglandins
from these two groups, in favour of vasodilation, has been demonstrated in women
with excessive menstrual loss(19). The role of prostaglandins in menstrual
dysfunction is further compounded by the fact that non steroidal anti-inflammatory
drugs, which inhibit prostaglandin synthesis, are effective in reducing menstrual
flow in women with pathological menstrual blood loss(20-25). Prostaglandin
production by the endometrium is influenced by changing levels of oestrogen and
progesterone; withdrawal of progesterone enhances prostaglandin synthesis(26).
Other postulated mediators of endometrial function include leukotrienes, and
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endothelins. Whereas no correlation with leukotriene function and disordered
menstruation has been demonstrated, endothelin-1 is a potent vasoconstrictor,
found in the endometrium. Endothelin is reduced in glandular epithelium in
women with menorrhagia, and does not exhibit the same cyclical variation(27).
One definition of menorrhagia is "menstrual bleeding lasting for longer than seven
days or blood loss exceeding 80mls from normal secretory endometrium after
normal ovulation"(American College of Obstetricians and Gynaecologists, 1982).
80mls blood loss per cycle represents the 95th percentile, with a mean between 30
and 40 mis, based on large population studies(28,29). Menstrual history is an
unreliable method for truly determining whether blood loss is pathological; only 11
to 13% of women complaining of menorrhagia have menstruation lasting more than
seven days(30,31), and 62% have objectively measured blood loss of less than
S0mls/cycle(31). As 92% of blood loss occurs in the first 3 days, duration of
menstruation has little influence on total menstrual blood loss(32). 60 mis /' cycle
blood loss has been proposed as a more sensible value as iron deficiency anaemia
cart occur at this level(28,33). Even at this lower cut off, 40% of women with
subjective menorrhagia will lose less than this amount(31). Objective menstrual
blood loss measurement is a laborious and specialised task not suited to everyday
clinical practice. Unfortunately, alternative, non laboratory methods for estimating
blood loss such as tampon / pad counting and weighing are unreliable(30),
although pictorial blood loss assessment charts seem to have a sensitivity and
specificity of above 80%(34). In everyday practice it is usual to offer reassurance,
advice and if necessary treatment based on history, clinical experience and an
estimation of how much the women's quality of life is affected by her change in
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menstruation. Only rarely is an objective estimation of menstrual blood loss
undertaken outwith the context of clinical trials. In this thesis "menorrhagia" is a
subjective increase in menstrual blood loss, either regular or irregular, which has
led the woman to consult with a doctor. Similarly, the term dysfunctional uterine
bleeding, when used in this thesis, pertains to abnormal blood loss, either regular or
irregular, occurring from a uterus which on clinical examination is equivalent to or
smaller than ten week pregnancy size and exhibits no endometrial atypia.
The majority of menorrhagia, about 80%, is idiopathic in that there is no
demonstrable causal pathology; this is described as dysfunctional uterine
bleeding(35). The most common known and postulated causes or factors which
contribute to heavy periods are
1 / pathological:-
fibroids, adenomyosis, endometrial hyperplasia, hypothyroidism and platelet
disorders such as VonWillebrands disease.
2/ iatrogeriic:-
intauterine contraceptive devices
3/ other associated factors
genetic, parity and obesity
The proportion of pathological causes of menorrhagia will obviously be determined
by how rigorously they are sought. Standard practice would include a general
examination to exclude thyroid disease and bleeding diatheses in combination with
a pelvic assessment and endometrial biopsy(36), but will undoubtedly miss some
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identifiable causes of menorrhagia. Hormonal screening for polycystic ovarian
syndrome and hypothyroidism should not be undertaken routinely, and there is
good evidence that dilatation and curettage (D&C) is neither therapeutic(37,38), nor
effective in excluding intrauterine pathology(39,40). Also, the use of D&C for
excluding endometrial carcinoma is not cost effective in women less than 40 years
old because of the very low prevalence(37). Despite this, D&C remains one of the
commonest operative procedures performed on women in Britain(41). Out-patient
endometrial biopsy, which is well tolerated and similarly effective in sampling the
endometrium, should replace D&C in the vast majority of cases(36,42-44). There is
no doubt that hysteroscopic evaluation of the uterine cavity will increase the
chances of identifying intauterine pathology(45,46), but we await evidence from
randomised controlled trials as to how this effects subsequent treatment and
outcomes for these women.
1.1.b - epidemiology
A complaint of excessive menstrual blood loss is one of the commonest reasons for
referral to a gynaecologist accounting for 12% of new appointments(47). It has been
estimated that 30% of women will complain of excessive menstrual loss at some
time(29,48). At primary care level, consultation rates for heavy periods have been
estimated at between 20.4(35) and 30.7 per 1000 women (Royal College of General
Practitioners, 1986), with up to a third of these referred on to secondary care(49). If
women in the age group spanning 30 to 49 years are selected from England and
Wales, then 5% of women consult their general practitioners for excessive
menstrual blood loss each year(50). In 1993 this amounted to 822,000 prescriptions,
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40,000 hysterectomies and 10,000 endometrial ablative procedures all as treatment
for excessive menstrual loss(51).
Of women referred to a gynaecologist with a complaint of excessive menstrual loss,
only 40% will have true menorrhagia, >80mls/cycle blood loss(30,31). Despite this,
a large number end up having surgical treatment. 60% of women had undergone
hysterectomy within five years of gynaecological referral with heavy periods in one
population study(49). What is known, is that as a group, women with a subjective
complaint of heavy menstrual loss do suffer a significant reduction in health related
quality of life, as measured using the health survey questionnaire short form 36 (SF-
36) (52,53), (Appendix la). Few studies have evaluated health related quality of life
following treatment, those undertaken demonstrate a greater improvement in those
treated surgically rather than medically(54), and similar global improvements for
transcervical resection of the endometrium and hysterectomy (55).
The likelihood of menorrhagia has been shown to increase significantly with age
over 40 years. Parity, smoking and body mass index have no significant effect once
corrected for age(56). A genetic link has been postulated, as have associations with
smoking, diet and body mass index. Psychiatric illness and psychological features
have also been associated with menstrual disorders, initially by the ancient Greeks
who blamed abnormal behaviour and mental instability on the uterus, hence the
term "hysteria". More recently, the converse is acknowledged, that anxiety and
depression can manifest as menstrual problems in a proportion of women. This has
been shown in population studies, especially of women undergoing
hysterectomy(57,58).
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There is strong evidence that consultation rates for menstrual problems are rising, a
73% increase in consultations was noted by the Royal College of General
Practitioners from 1971 and 1981 (RCGP, 1986). There has been a steady increase in
surgical treatment for these conditions, particularly for endometrial ablative
techniques(59,60). There is also wide national and international variation in
hysterectomy rates(61). Increases in rates of surgery cannot simply be explained by
an increase in pathological bleeding. A number of theories which all essentially
hinge around the changing role of the female in the western world have been
postulated. The term "menstrual intolerance" has been coined to describe those
women who have completed their families who now regard menstruation as an
unnecessary nuisance. The increasing consultation rates may also reflect a media
derived awareness that simpler treatments or techniques are available which might
improve menstrual symptoms.
There is a paucity of national data regarding patterns of referral for treatment,
treatment preferences, expectations of treatment and sociodemographic features of
women with heavy menstrual loss. What little there is has centred on a population
in one regional health authority of England, Oxford, and concentrates principally
on primary care(49,62,63). One study demonstrated that 43% of women with
menorrhagia were referred to a gynaecologist within a month of seeing their
general practitioner and that 45% had not been prescribed medical treatment(49).
Another that 36% of women referred to the gynaecologist had a treatment
preference(63). Many experts have argued that patient preference should be an
important guide to treatment choice, and may strongly influence outcome
success(23,35). Care must be taken however when extrapolating statistics based on
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the population surrounding Oxford to other parts of the UK which may not have
similar populations. Ideally epidemiological data should be available from the
geographical area of the population under investigation.
1.2 medical management of heavy menstrual loss
Treatment of menorrhagia has two related goals: to control menstrual blood loss,
either by reducing or stopping it altogether, and to improve quality of life(51).
When a demonstrable pathology is present, specific treatment of this is indicated.
The majority of women however, have dysfunctional uterine bleeding and for them
medical therapy is traditionally regarded as the first line treatment of choice. The
choice of therapy is dependent on the age of the patient, their current need for
contraception, the side effects which may be experienced whilst receiving therapy
and actual cost(64). In addition proven long term efficacy of the chosen drug,
safety, and acceptability(23) should be included. These factors have not been
adequately established for the majority of non surgical menstrual treatments, with
most trials concentrating on reduction in objective menstrual blood loss and for
under six months follow-up. The management of women with heavy periods by
their general practitioner should improve and become standardised following the
introduction of the Royal College of Obstetricians and Gynaecologist guidelines
regarding management the of menorrhagia in primary care(65).
Drug treatments can be broadly divided into non-hormonal treatments taken
perimenstrually, and hormonal, which are used continuously or for varying
duration throughout the cycle. Within these two groups are individual treatments
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which have different modes of action, and they will be discussed individually
under the two headings.
1.2a Non-hormonal drug treatment
Non steroidal anti inflammatory drugs (NSAID's)
The role of prostaglandins has been discussed in the previous section, aetiology arid
epidemiology of menorrhagia. NSAID's certainly inhibit the production of
prostaglandins, although different NSAID's give varying responses not only in
level of inhibition, but also between different organs(66). The fenemates, of which
mefenemic acid, is the most widely known, may also act by inhibiting binding of
the vasodilator, PGE2(67). One randomised controlled trial measuring objective
menstrual blood loss demonstrated mefenemic acid to be more effective than non-
fenemates(68). Mefenemic acid is most effective in reducing menstrual loss when it
is pathological(24). Used in a dose of 500mg three times daily for the first five days
of the menstrual cycle results in a reduction of menstrual blood loss ranging from
22% to 46%(22-24,68,69). This was the regime used in this thesis for women
prescribed these drugs. Dysmenorrhoea can be effectively treated by mefenemic
acid, with symptomatic relief in up to 70% reported(23,24). Side effects can occur in
up to 30% of patients and acceptability of treatment was assessed as 31% by
patients(23). The only follow-up longer than one year shows a sustained effect on
mean blood loss reduction at over one year of 35%.
Tranexamic acid
There is evidence that excessive fibrinolytic activity is a cause for dysfunctional
uterine bleeding(10,ll), although one study comparing women with normal and
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pathological blood loss, little differences were found in fibrinolytic products(12).
Tranexamic acid, an anti-fibrinolytic agent has been shown in many randomised
trials to significantly reduce menstrual blood loss from between 36% to
54%(20,70,71), including for women with intrauterine devices(72). None of these
studies evaluate the treatments beyond six months and report drop-out rates
between 10% and 20%, but with low rates of side effects, and a 77% acceptability
rate in one trial(20). It is the drug of choice in Scandinavian countries for
menorrhagia where hysterectomy rates are 50% lower than the UK(20).
Recommended dosage is lg six hourly for the first three to five days of
menstruation. In this thesis, if tranexamic acid was prescribed it was in a dose of lg
four times a day for the first five days of the period. Concerns regarding increased
risks of thrombo-embolic phenomena, which limited its use in the UK are
unsubstantiated, with rates equivalent to the normal population(73). Tranexamic
acid is certainly an effective medical treatment for women with pathological blood
loss, but there is a paucity of evidence on long term treatment, continuation rates
and quality of life improvement.
Ethamsylate
The exact mode of action of this drug in the treatment of menorrhagia remains
obscure, but is thought to be through capillary stabilisation and haemostasis. Early
trials suggested very effective (50%) reductions in menstrual blood loss for women
with true menorrhagia(74). More recent larger randomised controlled trials have
shown a more modest reduction of 20%(75), and the largest trial failed to show any
beneficial effect(20). Dosage is 500mg, six hourly, for the first five days of the
menstrual cycle. Side effects were reported in 10 - 16% of cases with short term
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discontinuation in 20 - 30% of the above studies. In the largest study, only 33% were
prepared to continue with ethamsylate after completing the trial at four months(20).
There is no evidence to support its use in the dose and timings presently
recommended (65), and this drug was not prescribed to any women in studies
undertaken in this thesis.
1.2b Hormonal drug treatment
The potential advantages of hormonal therapy for women with problematic menses
are that the cycle can be regulated or prolonged if necessary, whilst the severity of
the bleeding reduced. The disadvantages of hormonal treatment are their extended
use through the menstrual cycle and possible side effects.
Combined oral contraceptive
Combined oral contraceptives, apart from inhibiting ovulation, induce endometrial
atrophy which is the probable mode of action for reducing blood loss. Reductions
in menstrual blood loss of 43% - 53% have been reported in randomised controlled
trials involving women with menorrhagia(68,76). As contraceptives, these drugs
have good long term compliance records, but this has not been established for the
management of menstrual disorders. The newer, low dose preparations which are
more suitable for the woman over 35 years of age, have been evaluated in a small
cohort of twenty women and significantly reduced both duration and severity of
bleeding(77). Combined oral contraceptives containing the progestogens
desogestrol and gestodene should be avoided in women who have an increased risk
of venous thromboembolism (Committee on Safety of Medicines 1998). Combined
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oral contraceptive pills prescribed in this thesis were 30 microgram ethinyl-
oestradiol, second-generation progestogen preparations.
Progestogens
Oral norethisterone is the most commonly prescribed drug for the treatment of
menorrhagia in the UK(51). Studies assessing its use in objectively proven,
ovulatory menorrhagia have shown it to be of little value at the doses and timings
used(21,78). From these results other researchers have made sweepmg
generalisations stating that progestogens are the least effective treatments for
menorrhagia(20,51). All that can be stated from these trials is that progestogens
used for 7-10 days in the luteal phase are useful only for regulating an irregular
cycle or to cause a predictable withdrawal bleed. Progestogens are known to cause
amenorrhoea if used continuously at high dosage, and a small trial had shown
effective reduction in menstrual blood loss for women with ovulatory and
anovulatory menorrhagia(79). The recent publication of a randomised controlled
trial with larger numbers which has definitively proven that oral norethisterone
used in a dose of 5mg three times a day from day 5-25 lead to a 87% reduction in
objective menstrual blood loss(80), has reinstated its position in the treatment
armamentarium. However, despite the highly significant reduction in blood loss
only 44% found the treatment acceptable and only 22% would continue using it.
Although short cycle progestogen treatment maintains a secretory endometrium,
long cycle, as used in the above study actually leads to endometrial atrophy, which
undoubtedly serves to cause effective reduction of blood loss. Those prescribed
progestogens in this thesis received either norethisterone 5mg three times a day, or
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medroxyprogesterone acetate lOmg twice daily, from days 5 to 25 or 12 to 25 of the
cycle.
Progestogens used locally, on intrauterine contraceptive devices also result in
profound endometrial atrophy, leading to highly significant reductions in
menstrual blood loss(80,81). Additional advantages are reversible contraception
and improved compliance as replacement need only be every five years. Systemic
side effects are reduced as a small dose of progestogen acts locally with little
systemic absorption, however problematic breakthrough bleeding can occur in the
first six months. Recent studies have shown a reduction of women on a
hysterectomy waiting list using a levonorgestrol intrauterine contraceptive
device(82), and a randomised controlled comparison with transcervical resection of
the endometrium achieving high (84%), but slightly lower satisfaction rates and
equivalent scores for health related quality of life(83). This last trial unfortunately
did not have sufficient power to show meaningful differences in any parameter
ether than menstrual blood loss between the two treatments. The Mirena
intrauterine system was not a management option for women in this thesis as it was
not licensed for the treatment of menorrhagia.
Danazol
rQiis drug is a testosterone derivative, which through a variety of direct and indirect
mechanisms, induces endometrial atrophy(84). Its effectiveness in reducing
menstrual blood loss has been demonstrated in a number of randomised controlled
trials(ll,23,85-87). A significant proportion become amenorrhoiec and overall
reductions in blood loss of 60% - 80% can be expected. Danazol has also been
16
shown to reduce the number of bleeding days and to have a carry over effect with
significant reductions in blood loss continuing three months after stopping
treatment(88). Side effects including weight gain, headaches, musculoskeletal pain
and acne are experienced by over 70% of users(23,87), and this, along with its cost
make it unsuitable for long term use. Danazol was not used as a first line treatment
for women with heavy menstrual loss in this thesis, but when used it was
prescribed at 200mg a day for ninety days continuously.
Only one drug trial has evaluated effect in the medium to long term(15), and none
have measured changes in health related quality of life, or adopted a
pragmatic(89,90) approach to there use in everyday practice. These are major
deficiencies when investigating such a common and debilitating complaint. The
need to rectify this, and to identify and compare the most effective medical
treatments with each other, and with conservative surgical techniques, have been
stated in the literature(51,91).
1.3 the development of, and types of endometrial surgical techniques
The development of hysteroscopic surgery is attributed to Pantaleoni(92) who in
1869, visualised a uterine polyp through a straight endoscope and cauterised it.
During the 1900's modified cytstoscopes were more frequently used for diagnostic
procedures, but it was not until the 1960's, with the advent of fibre optic
technology, which provided good illumination, that hysteroscopic views became
reliable. In the 1970's uterine distension media improved the view further and
paved the way for operative hysteroscopic procedures. Electro-resection of the
endometrium was described by Neuwirth and Amin in 1976(93) for the removal of
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submucous fibroids. De Cherney and Polan performed myomectomies using an
unmodified urological resectoscope in 1983(94) and later, successful resection of the
endometrium in a series of 21 women in 1987(95). The first UK results were
presented by Magos in 1989(96) who called the procedure transcervical resection of
the endometrium (TCRE). Other exponents of electrocautery proposed a technique
of rollerball coagulation / ablation of the endometrium, rather than resection, and
reported high rates of satisfaction with outcome(97-99). In the early 1980's,
Goldrath pioneered an alternative effective method of endometrial ablation using a
laser fibre, under direct vision, down a hysteroscope(lOO). Davis reported his series
of laser ablations in the UK in 1989(101). Following observational, series
reports(102,103), a number of randomised controlled trials were undertaken in the
1990's. These compared transcervical resection of the endometrium and / or laser
ablation with hysterectomv(104-108), and one has compared the two endometrial
procedures(109). These will be discussed later.
Hysteroscopic endometrial surgical techniques, although effective, require a lot of
training and skill to become proficient at them. A number of "blind" endometrial
destructive procedures, utilising various energy sources have been developed,
which claim simplicity of use, and have been reported in the literature. These
ablative techniques include, radio frequency-induced endometrial ablation
(RaFEA)(110), the uterine thermal balloon(lll), cryoablation(112), photodynamic
therapy(113) and microwaves(114). All report high levels of success, but none have
been rigorously evaluated in the context of a randomised controlled trial. Eater in
this thesis, the results from the first comparative randomised controlled trial of
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transcervical resection of the endometrium versus microwave endometrial ablation
will be presented.
1.4 mechanisms of action of electrodiathermy and microwave ablation
Endometrium has extraordinary regenerative powers if the basal layer is left in
tact(115) therefore, if endometrial destructive techniques are to be successful,
endometrium and endometrial glands must be destroyed. These glands may
extend up to 3mm into the myometrium, therefore this must also be removed or
destroyed to be effective in preventing regeneration(116). The depth of destruction
must not disperse much beyond this depth as the myometrium at the cornual
regions may be only 4 - 6 mm in depth(117).
The mechanisms of action of the two endometrial surgical techniques used in tire
trials described in this thesis are outlined here.
1.4a - Elecrodiathermy
Transcervical resection of the endometrium is the principal endometrial surgical
procedure used in the UK(59,118) and utilises electrodiathermy as the energy
source. Modern electrosurgical generators utilise a primary oscillator circuit to
generate a basic electrical wave frequency of 475 - 750 kHz. In cutting mode, this
sinusoidal waveform is amplified, but otherwise unaltered to produce a continuous
output. Coagulation or blend modes are produced by modulation of the reference
signal through an electronic gate using a burst oscillator, which produces an
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interrupted waveform. This results in a low frequency (22 - 33kHz), high voltage
output.
During monopolar electrosurgery, as used in transcervical resection of the
endometrium, this electrical current passes down the active electrode (cutting loop)
to a passive electrode, and back to the generator. This initially high frequency
electrosurgical energy can be modified, as described above, to achieve certain
actions within tissues. Resection with a cutting loop or coagulation with the
rollerball can both be utilised within the uterus and often a combination of the two
is used in clinical practice. The ultimate tissue effect is mediated through the
production of local heat(119). Focused, high frequency heating to high temperature
(100 - 1000°C) leads to mechanical injury and produces an incision through
complete tissue vaporisation; cutting mode. Less focused, low frequency heating to
lower temperahires (45 - 100 °C) has a coagulative effect due to desiccation and
denaturation of protein; coagulation mode.
Detailed studies on the effects of electrosurgery on uterine tissue have been
undertaken in vitro and in vivo by Duffy et al(l 17,120). In vitro cutting mode
electroresection resulted in a narrow zone of thermal necrosis (ZTN) which did not
vary with power output, but was related to duration of exposure. In vitro
coagulation mode desiccation resulted in a depth of destruction of 3.24 - 3.49 mm
that did not vary with power output or duration of exposure. In vivo, these
findings were confirmed for both cutting and coagulation modes. Although
clinically significant thermal transmission through the uterus could not be shown,
prolonged application of an activated electrode for more than five seconds in the
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same area could be dangerous. The use of desiccation mode in the cornual region
was felt to be safer because of its more consistent ZTN and hence lower risk of
perforation than with the resection loop.
Loop resection of the endometrium can be undertaken using a pure cut, or blended
mode for additional haemostasis. Power settings vary between 80 - 120 Watts, with
100 Watts generally recommended(121). The optimal electrical setting for rollerball
ablation has not been established and all three modes, cutting, coagulation oi blend
can be used. Power settings are lower than for loop resection, varying between 40 -
100 Watts(97).
1.4b - Microwave
Microwaves are electromagnetic waves with a wavelength of 0.3 to 30 cm and
frequency, 300 to 300 000 MHz ( between radiowaves and infrared radiation). A 9.2
GHz microwave frequency was determined to be the most effective at producing
the 5mm depth of necrosis necessary to completely destroy the basal layer of the
endometrium. A microwave generator, or magnetron, supplies microwave energy
to a hand held applicator. The applicator is an 8mm diameter, 15cm circular metal
pipe with a dielectric filled waveguide to propagate microwave energy at 9.2 GHz
into the uterine cavity. The dielectric extends beyond the tip of the pipe to form the
radiating tip. With power levels of 30 Watts, energies of 1.5 - 9.3 kj result and a
hemispherical field pattern emanates from the dielectric tip, which if placed in egg
white, causes a symmetrical ball of coagulum of constant thickness. Extensive
testing on animal tissue, excised perfused uteri and pre-hysterectomy in vivo
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specimens have been undertaken and a depth of necrosis of 5 - 6 mm can be
consistently achieved.
Uterine tissue has a very high water content so the microwave field amplitude is
reduced by about 90% approximately 3 mm from the surface of the applicator tip.
Beyond this zone of intense microwave heating, further tissue destruction occurs by
thermal conduction from the heated region. The total depth of necrosis depends
upon the power level used and the length of time it is applied. The pattern of
heating at the tip is hemispherical and monitoring the temperature of the adjacent
tissue allows control over the depth of necrosis. A thermocouple on the applicator
tip measures the temperature on the endometrial surface. There is a second
thermocouple in the base of the applicator as a control and to show the temperature
gradient. The temperature at the tip is displayed graphically allowing the surgeon
to monitor the process of heating and hence treatment. The system computer screen
provides the surgeon with a proven temperature band of 75 80°C. An alarm is
activated if the temperature exceeds 85°C and automatically shuts off power at
90°C. Another safety feature is that potential perforation can be determined quickly
by a failure to establish a temperature gradient if the machine is activated. No
earthing is required and there is no energy transmission at the pre-set power levels
beyond 6 mm from the applicator tip.
1.5 requirements for transcervical resection of the endometrium and
microwave endometrial ablation
The main indication for endometrial destructive surgery is heavy menstrual blood
loss in a women who has completed her family in whom surgical treatment is
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indicated, but amenorrhoea is not a priority. Excessive uterine size, the presence of
acute pelvic infection and evidence of pre-malignant or malignant disease are
regarded as absolute contraindications(122). Ideally the uterus should be of normal
size and should not have a cavity length of more than 12 cms(121). Small benign
intrauterine lesions are not a contraindication to these techniques.
Transcervical resection of the endometrium
1.5al - Equipment
Transcervical resection of the endometrium is modelled on transurethral resection
of the prostate and equipment requirements are similar. A 26 gauge modified
urological resectoscope fitted with a fore-oblique lens of up to 30° is necessary
which has separate inflow and outflow channels allowing continuous irrigation.
Resection loops used in this centre are 7mm wide and 3mm deep and rollerballs are
4mm diameter cylinder / barrel type. A cold light source of 150 - 300 watts with
flexible light cable is required for adequate visualisation alongside a modern
camera system. A high frequency diathermy machine with variable waveform
settings to enable supply of cutting, coagulative and blended currents as required,
is also essential. A fluid distending medium is necessary to give a clear view of the
uterine cavity when operating, it also has to be non-ionic to allow use of
electrocautery. 1.5% glycine is the most commonly used irrigating fluid, as it has
good optical qualities, is poorly miscible with blood and is not caramelised by
electrocautery. It has the disadvantage of being a hypotonic solution and
significant absorption can lead to hyponatraemia, hyperammonaemia and fluid
overload which can lead to pulmonary and cerebral oedema, convulsions and death
("TURP syndrome")- It is important that input and output totals are measured and
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the operation stopped once a deficit of 1500mls is reached. It has been shown that
electrolyte disturbances does not occur at fluid deficits less than this(123). The
deficit can be calculated by subtracting the amount collected from that infused, this
is made easier by the use of a spring balance on the fluid bag(124). More accurate
deficit calculation can be achieved by labelling the irrigating fluid with ethanol and
measuring its concentration in expired respiratory gases(125). In order to distend
the uterine walls, a pressure of 40 - 50 mm Hg is required. This is equivalent of
gravitational pressure when a bag of fluid held one metre above the patients supine
body(122), so peristaltic pumps or hysteromats are not strictly necessary.
Hysteromats have a built in pressure limiting facility which may reduce the risk of
sudden intravasation of irrigating fluid, and have been shown to reduce the fluid
deficit by up to 85%(126). Outflow can be achieved through gravity, suction,
peristaltic pumps or a combination of these.
1.5a2 - Preparation
All endometrial surgical techniques aim to destroy or remove 3 mm ofmyometrium
so that endometrial glands are destroyed(120). In order to increase the chances of
destroying these myometrial glands, endometrial thinning has been proposed to
enhance the view and reduce the total amount of tissue that is required to be
removed. Thin endometrium is present in the early proliferative stage of the
menstrual cycle, but the practicalities of modern operating make it difficult to
schedule operations by menstrual cycle. Although some surgeons undertake
transcervical resection of the endometrium without endometrial thinning(127), the
majority advocate the use of thinning agents for safer and more effective
surgery(121,122). Endometrial atrophy can be induced using high dose
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progestogens, danazol or gonadotrophin releasing hormone (GnRH) analogues.
Progestogens cause patchy, unreliable atrophy leading to poor views(128) and are
not used often now. Danazol and GnRH analogues both result in a predictable thin
endometrium and their effectiveness has been shown in randomised controlled
trials(129,130) and a large audit series(118). Both drugs also result in decreased
fluid absorption, reduced operating times and improved menstrual outcomes(129).
Danazol, although cheaper than GnRH analogues, has unpleasant side effects in the
doses of 600 - 800mg/day for 4-6 weeks required, and hence compliance is a
problem. The GnRH analogue, goserelin can be given subcutaneously and the
effects last for 6 weeks(106), therefore compliance is not a problem. Goserelin
3.6mg can cause menopausal symptoms and has been shown to increase cervical
resistance which is not reversed by prostaglandin administration pre¬
operative^131).
1.5a3 - Technique
The majority of transcervical resection of the endometrium procedures are
performed under general anaesthesia, although local anaesthesia can be
used(96,132). The resectoscope is assembled and the light source, camera system
and diathermy are connected. The cervix requires dilatation to 9mm before the
resectoscope is introduced into the uterine cavity and irrigating fluid is started.
Correct siting within the cavity is confirmed by identification of the tubal ostia
before commencing treatment. Rollerball ablation of the fundus and cornual
regions is undertaken followed by radial resection of the walls with a 90° loop. The
resulting chippings of tissue are sent for pathological examination. Once completed
the cavity is inspected and any troublesome bleeders or areas missed can be treated
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with the rollerball. If bleeding persists an intrauterine foley catheter can tamponade
the uterine cavity for 6-12 hours and invariably results in haemostasis. Broad
spectrum antibiotic cover is recommended(102,103), and has been shown to
significantly reduce peri-operative bacteraemia(133).
Microwave
1.5bl - Equipment
The microwave generator, magnetron, (Microsulis PLC, UK) is housed in a
protective casing which also contains a computer for data storage and a keyboard to
initiate commands and input data. A computer screen allows patient information
to be viewed and, in treatment mode, a visual display of temperature against time is
shown with a band from 75-80°C, which represents optimal operating temperature.
Two flexible cables, one transmitting microwave energy the other for data collection
are connected from the operating probe to the generator. The hand held operating
probe is 8mm in diameter and is 15 cms long, graded in centimetres. Microwaves
generated at 9.2 GHz are transmitted to the tip of the probe when the footpedal is
activated. At 30 W, energies of 1.5 - 9.3 kj result. A ball of microwave energy is
created at the probe tip, which at the predetermined energy setting, ensures depth
of tissue penetration to a maximum of 6 mm. Thermocouples are present at the
base and tip of the operative probe allowing accurate measurement of the
temperature gradient, which is displayed on the screen.
1.5b2 - Preparation
As depth of tissue penetration is constant, at < 6mms, with the microwave, a thick
endometrium may result in failure to destroy deeper endometrial glandular tissue.
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For this reason endometrial thinning agents are required for all patients undergoing
this ablative technique. These are as previously described in 1.5a2
1.5b3 - Technique
Tire procedure is generally performed under general anaesthesia, although local
anaesthetic can be used(134). The cervix is dilated to 9mms and the length of the
cavity measured. The probe is inserted until the tip reaches the fundus, ensuring
that the length inserted is the same as that previously measured. The microwave
generator is then activated by depressing the footswitch. Once the tissue
temperature reaches 75-80°C the probe is moved laterally into the cornual region.
The temperature reading will transiently fall, then once the operating temperature
is attained again the probe is moved to the opposite cornua and the process
repeated. The probe is then gradually withdrawn whilst maintaining the
temperature in the 75-80°C range. The technique effectively "paints" the uterine
cavity with a broad brush of destructive microwave energy(114). The treatment
phase should be stopped once a coloured area appears on the probe shaft. This is
set 3cms from the tip and ensures that the endocervical canal is not treated which
could result in stenosis with subsequent haematometria or pain. The treatment
time varies with cavity length, but is usually between 2-3 minutes.
1.6 The place of endometrial surgery in the management of heavy menstrual
loss - a critical review of the literature
Endometrial resection was initially used to treat intractable uterine bleeding in
women who were unfit for hysterectomy because of blood dyscrasias or extreme
anaesthetic risk(95). Follow-up of these women revealed high amenorrhoea rates.
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Endometrial ablative surgical techniques were then proposed as alternatives to
hysterectomy for healthy women and were advocated for use after medical
treatment had failed(96,121,135,136). The enthusiasm of surgeons and patients alike
resulted in the development and promotion of endometrial resection techniques
without randomised controlled trials(137). The expected fall in hysterectomy rates
has not yet materialised, despite a substantial increase in the number of ablative
procedures rmdertaken(51,60/138), although there is evidence of regional exceptions
to this trend(139). In 1991, 56% of NHS gynaecological units in the UK were
offering one of these ablative techniques, by 1993 this had risen to 83%(140). There
is a concern that the threshold for surgical intervention has fallen with the
introduction of these procedures, although alternatively, women who would never
previously considered having a hysterectomy could be presenting for treatment
now that a less invasive surgical solution is available(56,91). Despite not replacing
hysterectomy for dysfunctional uterine bleeding, these techniques have become
very popular with clinicians and it would seem, with women themselves.
Endometrial ablation has reached the fourth and final phase of validation. The
indications for its use are now clear as are the advantages and disadvantages of the
procedure(136). This statement was based on the progression from innovation of
these new techniques in the 1980's, through reports of personal series to finally, in
the 1990's, the completion of a number of randomised controlled trials. Five
randomised controlled trials(104-108) have compared hysteroscopic surgery with
hysterectomy, one has compared ELA with TCRE(109), and another, TCRE with a
progestogen loaded IUCD(83). These, in conjunction with two large national audits
have confirmed the safety and effectiveness of these hysteroscopic surgical
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techniques(59,118). Few surgical techniques have been so rigorously evaluated and
yet its true place in the management of women with excessive menstrual loss
remains to be fully established.
In the early 1990's a large prospective series of endoscopic laser ablation(102)
reported satisfaction rates of 97%, amenorrhoea rates of 60%, a hysterectomy rate of
3% after six month and no major complications. Similar results were presented at
the same time for 250 transcervical resection of the endometrium operations(103)
over follow up times of up to 2.5 years. Advocates of rollerball ablation had
presented equally high satisfaction rates with low complications for their patients,
but in smaller series of women(97,98). Although these results were encouraging
and seemed to suggest that these techniques were safe and effective, these reports
were subject to a number of obvious biases. The operations were undertaken by
enthusiastic proponents of these procedures, whilst it is also likely that only highly
motivated patients were recruited. No baseline data are available to estimate the
patients degree of dysfunction, hence making outcome data difficult to interpret.
No comparative controls are present and if there were, could not be matched for all
prognostic and confounding variables. Nothing is known of how many women
were lost to follow up, the number of eligible women who had the operation, or
indeed what proportion of those operated on completed questionnaires.
Observational studies of this type are subject to many problems the most serious of
which is selection bias(141). This can lead to over optimistic claims being made
about the intervention under investigation(142). The only way to convince the
medical and scientific world of the merits of hysteroscopic surgery was to
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undertake randomised controlled trials and this was acknowledged by proponents
of these techniques(143).
1.6a - Hysteroscopic endometrial surgery versus hysterectomy
The obvious reference for comparison for these procedures was the hysterectomy.
This was based on the possibility of reducing the number of hysterectomies
undertaken, at least 50% of which are for excessive menstrual loss(51). One obvious
drawback, was that hysterectomy guaranteed amenorrhoea, whereas even the most
optimistic reports gave amenorrhoea rates of only 60% for endometrial ablation.
Morbidity, recovery times and economic evaluations of each procedure were
tangible end points that could be measured. Other, more global criteria for
treatment outcome were required which were tangible to the patient, such as
satisfaction with, and acceptability of procedures, improvements in quality of life
and changes in psychological and sexual functioning. Unfortunately, suitable
measurement tools, and more importantly, normative reference values had not been
established for most of these outcome parameters when many of these trials were
commenced.
The first randomised controlled trial evaluating endometrial ablation, from 1991,
compared transcervical resection of the endometrium with hysterectomy(104). 51 of
54 randomised women received their allocated treatment (26/28 had hysterectomy,
25/26 had TCRE), operating time, post-operative recovery, morbidity and costs of
surgery (£400 v £1270), all favoured transcervical resection of the endometrium.
Despite critical flaws of small numbers, no a priori hypothesis or a power study
based on it, and the bias that women were recruited from a waiting list for
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hysterectomy; the results were similar to and supported the reports from the
published observational data.
The next randomised controlled trial was published in 1991(105). This was
methodologically more robust, with a power study calculated on the basis of
differences in patient satisfaction, and clear and sensible entry criteria were made.
100 women were required in each arm, however, after withdrawals, 97 underwent
hysterectomy and 99 TCRE, and at four month only two women, from the
hysterectomy arm were lost to follow-up. The only recognised and validated
assessment tool used was the general health questionnaire (GHQ)(144). All
operative data significantly favoured TCRE, including operating times, post
operative pain and complications, and recovery time. Three (4%) of those
undergoing TCRE suffered blunt uterine perforation. Those women very satisfied
were significantly more likely to have had hysterectomy (94% v 85%), although 95%
in each arm were satisfied and would recommend their operation. Premenstrual
symptoms were significantly reduced by both techniques, but significantly more so
by hysterectomy for most symptoms. Dysmenorrhoea was absent in 94% of women
following hysterectomy, but only 62% of women with TCRE (15% of women at
baseline had no dysmenorrhoea). Four of the six women who were dissatisfied
with their hysterectomy, had baseline GHQ scores greater than 12, indicating
psychiatric morbidity. After four months, 11% of women in the TCRE arm had
requested further surgery, 4% having a hysterectomy. An amenorrhoea rate of only
16% was obtained for TCRE which was much lower than previously reported. It
must be noted that pre-operative endometrial thinning was not administered in this
study. An economic evaluation of health service costs of each procedure was also
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undertaken at four months(145) which showed TCRE to be significantly less costly
than hysterectomy (£513 v £1230).
These women were followed up by postal questionnaire again at an average of 2.8
years later and a repeat economic evaluation was also undertaken(55). A 79%
response rate was obtained, 155/196 women, which is only 75% of the requirements
for the power study. By now tools for measuring health related quality of life were
available which were validated for the UK population. Two of these, SF-36(146)
and EuroQol(147) were utilised. Marginally, but not significantly better scores were
achieved for the hysterectomy group for both quality of life questionnaires, but both
groups scores for SF-36 were comparable to normative data for the healthy female
population aged 35 - 50 years(148). Unfortunately the most important outcome,
change in scores from baseline could not be determined. Women remained
significantly more satisfied in the hysterectomy group (93% v 79%), and a
significant change occurred in those who would recommend their allocated
operation (75% TCRE v 96% hysterectomy). Pain, premenstrual symptoms and
workdays lost were all significantly less in the hysterectomy arm by this stage. The
retreatment rates had risen from 11% at four months to 23% at 2.8 years, with a 16%
hysterectomy rate. Excluding those who had undergone hysterectomy, the
amenorrhoea rate in the TCRE group was only 13%. Health services costs, still
favoured TCRE, although the gap had narrowed between the two procedures (£790
v £1110).
The next randomised controlled trial, conservative alternatives to hysterectomy
(CATH 1), was published in 1994(106). It was similar to the Bristol trial in terms of
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power study numbers, again based on patient satisfaction. Important differences
were that endometrial thinning was undertaken in the ablation arm using goserelin
3.6mg five weeks pre-operatively, TCRE and ELA were allocated equally amongst
those randomised to ablation, and five different surgeons undertook the ablative
procedures. Health related quality of life was not assessed although psychiatric
and psychosocial parameters were measured. No significant differences were
detected between TCRE and ELA, and so were combined and compared to
hysterectomy, of which 90% were abdominal procedures. Operative results again
favoured the ablation arm, with significantly shorter operating times, less post
operative morbidity and shorter hospitalisation and time to recovery. At twelve
months satisfaction rates were significantly better after hysterectomy (89% v 78%).
Dysmenorrhoea and premenstrual symptoms were both greatly reduced by all
operations at one year, with no significant difference between ablation and
hysterectomy. Psychometric parameters were assessed and presented in a
complimentary paper(149). Both treatments reduced anxiety and depression scores
and there were no differences in mental health or sexual function between the two
at twelve months. Personality and duration of menstrual dysfunction had no
influence on outcome. 10% had undergone repeat TCRE and 16% hysterectomy. A
third paper assessing the economic issues of this trial concluded that the NHS costs
of ablative surgery were significantly less than hysterectomy by 20 - 24% (£1001 -
TCRE; £1024 - ELA; v £1315, hysterectomy)(150). On average women undergoing
the hysteroscopic procedures incurred 71% less costs to themselves than those
undergoing hysterectomy (£21 v £73.40).
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Four year follow-up data are now available for the clinical and economic
outcomes(151). The risk of having any further surgery if initially allocated to TCRE
was 36%, and by hysterectomy was 24%. Satisfaction remained high in both arms,
80% for TCRE and 89% for hysterectomy, remembering that analysis was by
intention to treat. Premenstrual symptoms and pain remain significantly better
than at baseline, the effect size being greater with hysterectomy. Psychosocial
parameters remain significantly improved from baseline and equivalent between
groups, but no different from one year results. The economic differences between
the two procedures had narrowed from the one year figures with ablation being
93% of the cost of hysterectomy (£1231, TCRE/ELA; v £1332, hysterectomy). As
women recruited to this trial were initially referred for hysterectomy, 76% have
avoided it at four years.
Tire fourth trial to be published was the Medical Research Cormcil (MRC) funded
randomised trial of endometrial resection versus hysterectomy(107). This although
having an a priori hypothesis and power study based on it turned into an
inadequate study from a methodological point of view. It gains credibility by virtue
of the similarity of its results to the Bristol and Aberdeen randomised controlled
trials. Its strong points were sensible entry criteria, potentially increased
generalisability as teaching centres and district general hospitals participated, and
half of the hysterectomies were vaginal. The power study calculation determined
202 patients required at three years, however subsequent randomisation was
unequal, 2:1 in favour of TCRE, and the power study was not adjusted for this. The
power study numbers were achieved by the end of recruitment phase with 68 in the
hysterectomy arm and 134 in the TCRE arm, but no extra were recruited to
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compensate for inevitable drop-out. By three years data were available for only
28/68 and 54/134 respectively, well below the required numbers. Another major
problem affecting external validity of the results was that only 25% of eligible
women participated. Women not recruited invariably had a strong treatment
preference. This could have been predicted had a pilot study been undertaken.
Essentially the results concurred with those previously published, but because of
the methodological flaws, the results are difficult to interpret in their own right. Re¬
operation rates were 22% in the TCRE arm and 9% in the hysterectomy arm at three
years.
The final randomised controlled trial compared TCRE with vaginal
hysterectomy(108), suffered from similar power study flaws as the MRC trial above.
A power study was calculated on the basis of a difference in means, but for a
subjective variable, in which one arm the outcome was known to be 0 with 0
standard deviation, (pictorial assessment of menstrual blood loss). This was then
not used as the principal outcome measure, but the power study calculation kept.
Statements of no difference in satisfaction rates, (95% hysterectomy v 87% TCRE)
and sexual functioning scores cannot be made from the 77 women in whom results
were obtained at two years. Health related quality of life was measured at two
years by SF-36 and hysterectomy was better for all parameters and equivalent to
Italian normative values. Unfortunately, baseline SF-36 scores were not obtained
and so change scores were not available.
Two national audits have been undertaken in Scotland(118), and in England(59).
The Scottish audit, took place over two years between December 1991 and
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December 1993, relatively early in the introduction of hysteroscopic surgery into
gynaecological practice in the country. 978 cases were registered of which 732
women were followed up at six months, 554 at twelve and 80 at 24 months. The
numbers were too small to confidently estimate procedure mortality or life
threatening complications but were encouraging. Complications occurred in 12% of
cases including one death from toxic shock syndrome(152). Uterine perforation and
significant fluid overload occurred in 1%. At twelve months satisfaction rates were
84% whilst repeat procedures had been undertaken in 13% and hysterectomy in
11%. At two years there was a 17% repeat ablation and 15% hysterectomy rate.
There was no statistical evidence of an association between occurrence of
complications and operator experience. The majority of procedures were TCRE's
(65%), ELA's contributed 32%, the rest were rollerball ablations.
The results of the RCOG Clinical Audit Group (MISTLETOE survey) (59) reported
on 10 686 procedures undertaken over 18 months from April 1993. This survey had
sufficient numbers to assess mortality, and crude differences between the different
hysteroscopic techniques. Two deaths were directly attributable to the procedures,
immediate complication rates ranged from 2.6% (ELA) - 6.4% (loop resection).
Combined rollerball / loop resection was the most widely practised technique, and
had immediate complication rates of 4.6%. TCRE by any method accounted for 75%
of all endometrial destructive procedures. These results certainly confirm that these
procedures have a low morbidity and mortality. The statements made with regards
to ELA being the safest procedure with total loop resection the least safe, although
evident from the data surveyed must be regarded with caution. It is more likely
that expensive laser systems are in tertiary teaching centres and with the
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prerequisite safety requirements, surgeons are more likely to have been trained in
its use. Equipment for TCRE is cheap and readily available, and at the time of the
survey there were no necessary training requirements for its use. It is possible that
these factors may have contributed to the differences, as in the only randomised
controlled trial comparing ELA with TCRE techniques these differences were not
detected(109).
Overall the results of these randomised controlled trials and national audits
generally support the results and claims of the previously published observational
studies, though with slightly more cautious enthusiasm and with the
acknowledgement that long term results, not only in terms of outcome, but of
unsuspected co-morbidity must be awaited. They also confirm that hysterectomy is
an effective treatment for heavy menstrual loss. Despite methodological
shortcomings in some of the trials, the results are remarkably consistent. Operating
times, complications hospital stay and recovery times are significantly less than for
hysterectomy. Satisfaction rates are maintained at around 80% at four years and
dysmenorrhoea is significantly reduced. Re-operation rates average out at about
16% at one year, rising to 22% at two to three, and reaching 34% at four to five
years. Accepting that these were all women who would otherwise have had a
hysterectomy, then at four years 76% of women who fulfil the trial criteria, could
have avoided a major operation. The worsening menstrual flow and increasing
pain rates in these trials were in keeping with a previous series report(153). What is
not known yet is the effect on subsequent endometrial malignancy rates,
presentation and behaviour. A number of carcinomas have been detected from
resection loop specimens despite pre-surgery negative endometrial biopsy(154,155)
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and there are reports of late presentation of carcinoma arising following TCRE's
with negative chippings(156).
Prognostic variables which influence success rates for these procedures have been
identified from large series reports as well as randomised controlled trials. It seems
that women with true menorrhagia, menstrual blood loss of >80 mis/cycle, have a
better outcome than those whose menstrual loss is less than this(157). Women over
the age of 35 - 40 years do better than those younger than this(103,158). Superficial
adenomyosis can be treated definitively with endometrial ablation, but deep
adenomyosis responds poorly(159), however the ability to differentiate between
varying extents of adenomyosis cannot be made at ablation and adenomyotic
changes may in fact represent thermal artefact on resection chips. Polyps or small
submucous fibroids are not contraindications to treatment(160). Dysmenorrhoea
and premenstrual syndrome symptoms diminish following ablative
procedures(106,109), the reduction in PMS symptoms correlates with the reduction
in menstrual blood loss(161). For uterii clinically under ten weeks size, 95% of
TCRE or ELA operations were completed without prior diagnostic
hysteroscopy(106), suggesting that this investigation is only routinely indicated if
the uterine size cannot be assessed or feels enlarged. Overall the best results can be
expected in women over the age of 45 who have proven menorrhagia due to
dysfunctional bleeding, which is unresponsive to drug treatment, and who are
otherwise faced with hysterectomy. There is no difference in outcome for women
with regular or irregular periods(162). Women without a preference and who do
not expect amenorrhoea will also have a lower failure rate(163).
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1.6b - Hysteroscopic endometrial surgery versus other modalities
Three published randomised controlled trials exist comparing ablative techniques
with a treatment other than hysterectomy. One compares two hysteroscopic
surgical techniques, TCRE and ELA(109); the second compares TCRE with the
levonorgestrel intrauterine device(83) whilst the third compares rollerball ablation
with the uterine thermal balloon(164).
The randomised trial comparing TCRE with ELA continued recruitment from a
previous trial comparing endometrial surgery with hysterectomy which did not
have sufficient power to detect differences between the two hysteroscopic
techniques. This was an a priori decision, and women were randomised to either
ELA or TCRE in the original trial. A further 167 women were subsequently
randomised, making 382 in total, exceeding the 350 required for the power study.
Satisfaction rates after one year were high and equivalent at 90%. TCRE was
significantly quicker, resulted in less fluid absorption, and was cheaper. Re¬
operation rates were lower for TCRE (16% v 20%), but this was not significant.
Morbidity rates were low for both techniques. These results are at one year follow-
up and may alter with time. The second phase of randomisation undertaken to
fulfil the power requirements will almost certainly have recruited different women
from the first phase, although as equal randomisation took place this should not
have affected the results. The first 105 women randomised had been referred for
surgical treatment when hysterectomy was the option, whereas in the second phase
women were recruited who were not expecting or offered hysterectomy as an
option. These results have been upheld by the national audits(59,118), although the
largest of these found that ELA was the less morbid procedure.
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The most promising non-surgical advance in the management of excessive
menstrual loss is the levonorgestrel intrauterine device, which has only recently
gained a license in the UK for this use despite evidence of its efficacy. Reductions
in menstrual loss of over 90% have been achieved in series reports(81,165). Similar
results were achieved in a randomised controlled trial comparing it with oral
progestogens for women with objectively proven menorrhagia(80). A further study
showed its ability to significantly reduce the hysterectomy rate of women on the
waiting list for hysterectomy who were randomised to have the Mirena intrauterine
system or not(82). There were limitations to this trial, the most obvious being the
initially biased waiting list population (nothing to lose), no power study, and a high
(14%) number of women in the control arm who did not have a hysterectomy
anyway. The corrected number avoiding hysterectomy was therefore 50%.
The only randomised controlled trial comparing levonorgestrel with endometrial
ablation again was methodologically flawed. Crosignani et al(83) randomised 70
women, aged 38 or more, who were referred for hysterectomy, to TCRE or the
levonorgestrel intrauterine device. The power study was based on detecting a 30 ml
difference in observed menstrual blood loss, using a difference in means, although
subjective, pictorial charts were used and the standard deviation estimated. This
allowed them to fulfil the power study requirements easily as only thirty women
were required in each arm. These numbers are far too small to detect differences in
important subjective parameters such as satisfaction and quality of life which were
nevertheless still measured and commented on. After one year side effects were
higher in the levonorgestrol arm, but satisfaction rates of 85% were achieved
compared to 90% for TCRE. Pictorial blood loss assessment revealed a 79%
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reduction for the intrauterine device, significantly less than the 89% achieved for
TCRE. The distribution of SF-36 scores were equivalent for both methods of
treatment, baseline scores were not measured and so changes in scores were not
ascertained. There is mounting evidence that the levonorgestrel intrauterine device
has many potential advantages, the avoidance of an operation, reversible effective
contraception and appears to be effective in reducing menstrual blood loss. In this
trial it did not perform as well as TCRE although better designed randomised
controlled trials are required comparing this treatment with the best of the ablative
techniques in the future.
The thermal balloon was compared to rollerball ablation in America in a
multicentre randomised trial with adequate numbers(164). Unfortunately, neither
technique has been previously evaluated in the context of a randomised controlled
trial, and so two new techniques were being compared without an established
"benchmark" control group. Secondly, the entry criteria determined that only
women with regular endometrial cavities of up to 8 cms could be included. This
significantly limits the generalisability of the results when all women referred with
heavy menstrual loss are considered. The results from the trial are however
encouraging. Satisfaction rates were equivalent and similar to previous trial results,
with a marked improvement in quality of life parameters and highly significant and
equal reduction in menstrual loss. The only difference was that the thermal balloon
was significantly faster and possibly safer, although numbers were too small to
detect a significant difference.
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There is no doubt that endometrial surgical techniques have been subjected to more
rigorous evaluation than almost any other surgical procedure and all in a timescale
of under ten years. Despite methodological shortcomings in some of the trials, the
overall results are consistent and encouraging. Two areas of research remain
deficient however; establishing the place of these techniques in the management of
women with excessive menstruation, and a comparison of the most promising new
ablative techniques with a proven hysteroscopic technique. This thesis will present
results from two randomised trials which attempt to correct these deficiencies. The
first randomised controlled trial compares traditional medical therapy with TCRE,
the second compares microwave endometrial ablation with TCRE.
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Table1.1:-Summaryofrando isedcontrolletriaeva uatingransce vic les ctionhndome rium StudyComparisonNumberofFollow-up
Procedure
Complications
Satisfaction(%)
TCRE-Hypo/
patients
time
time(mins)
amenorrhoea%
(TCRE+other)
1.Gannon,etal(104)991
abdominal
51
9-16months
30-TCRE
0%TCRE
84%TCRE
80%TCRE
hysterectomy
(26+25)
50-TAH
46%TAH
(64%amen.)
2a.Dwyer,etal(105),1993
abdominal
196
4months
35-TCRE
4%TCRE
85%TCRE
89%TCRE
hysterectomy
(97+9)
45-TAH
47%TAH
94%TAH
(13%amen.)
2b.Sculpher,etal(55)1996
24months
77%TCRE
70%TCRE
96%TAH
(13%amen
3.Pinion,etal(106),1994
hysterectomy
204
12months
45-ablation
1%ablation
78%ablation
76%ablation
(105+99)
61-hyst
5%hyst.
89%hyst
(22%amen.)
4.O'Connor,etal(107)1997
hysterectomy
172
upto4years
32-TCRE
13%TCRE
85%TCRE
TCRE,21%amen.
(116+56)
66-hyst
45%TAH
96%hyst
at21months
5.Crosignanietal(108),1997
vaginal
85
2years
13-ablation
0%ablation
87%ablation
64%ablation
hysterectomy
(41+44)
71-hyst
2%hyst
95%hyst
(22%amen.)
6.Bhattacharya,etal(109)1997
endometrial
372
2years
21-TCRE
10%TCRE
91%TCRE
86%TCRE
laserablation
(188=1 4
30-laser
14%laser
90%laser
85%laser
7.Crosignanietal(83),1997
levonorgesterol
70(35+3 )
12months
notgiven
none
95%TCRE
75%TCRE
IUCD
85%IUCD
65%IUCD
w
Chapter 2
Epidemiology, Demography and Preferences ofWomen
Referred for Management of Heavy Menstrual Loss.
(patterns of referral, socio-demographic details, history and perceived severity of
presenting complaint, primary care treatment, effect on health related quality of life,
and expectations of treatment).
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INTRODUCTION
It is well known that rates of hysterectomy vary widely at international level(166),
although there is conflicting evidence when rates between different health
authorities in Britain are compared(61,167). General practice referral rates for
menstrual problems also show wide regional variations(168)/ as do drug
prescribing patterns for menorrhagia(169). These variations may reflect differing
expectations of treatment, perception of severity of complaint, doctor and patient
preferences, but most likely represent an interplay of all these factors.
There is a paucity of national data regarding patterns of referral for treatment,
treatment preferences, expectations of treatment and socio-demographic features of
women with heavy menstrual loss. What little there is has centred on a population
in one regional health authority of England, Oxford, and concentrates principally
on primary care(49,62,63,169). One study demonstrated that 43% of women with
menorrhagia were referred to a gynaecologist within a month of seeing their
general practitioner and that 45% had not been prescribed medical treatment(49).
36% of women referred to the gynaecologist had a treatment preference and the
strongest predictors for having a preference were higher education and previous
consultation with gynaecological problems(63). Many experts have argued that
patient preference should be an important guide to treatment choice, and may
strongly influence outcome success(23,35).
Traditionally, menorrhagia has been a diagnosis based on measured menstrual
blood loss above 80mls per cycle(48), and 67% of women losing more than this
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show evidence of anaemia. On an average Western diet a blood loss of over 60mls
per cycle will result in a negative iron balance(35). These measurements are not
very helpful in everyday management of women complaining of excessive
menstrual loss as their symptoms and complaints are not usually related to
anaemia. Indeed the majority of women complaining of heavy menstrual loss do
not have true menorrhagia(30-32,48). What is more important to the majority of
women is the effect of their menstrual loss on their everyday function, or health
related quality of life. Baseline "normative" values of health related quality of life,
using the generic health questionnaire, SF-36(146,170) have been obtained for the
general population(148). It has been demonstrated that for women with heavy
menstrual loss in primary care in Grampian, that seven of the eight dimensions of
SF-36 were significantly reduced(53). It has also been shown, in a prospective
observational study, that women treated surgically had greater improvements in
their quality of life scales than those without treatment or those treated
medically(171). What has not been demonstrated is whether women with a
particular treatment preference have different quality of life scores at baseline,
which may influence choice of management, or the degree of improvement in
quality of life they can expect to gain.
There is evidence that consultation rates for menstrual complaints are on the
increase (Royal College of General Practitioners 1994). In order that this extra work
is not automatically accepted and transferred to specialist clinics, epidemiological
work is needed to detect any recognisable patterns or reasons for its occurrence.
This requires baseline questioning of women referred with menstrual problems and
establishing a programme of guidelines for menstrual management in primary care
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and education programmes / information packages for patients. Ideally this should
be a national undertaking, but determining local values is important because of
regional variation between populations. Once this is established, an audit cycle can
be initiated to ascertain the impact of such guidelines on primary care, for example
as compiled by the Royal College of Obstetricians and Gynaecologists(65), on
changes in referral and treatment rates.
The population study described in the following chapter outlines the socio-
demographic background, clinical status and levels of health related quality of life
of women referred for the first time to the gynaecology clinic in Aberdeen with
heavy menstrual loss. It also seeks to determine the proportion of women who
have treatment preferences and whether these women are different from those with
no preference, who accepted randomisation to medical treatment or endometrial
destructive surgery.
PATIENTS AND METHODS
Eligibility
From 1st October 1994 until 30th September 1995, all women with heavy menstrual
loss who were first time attendees at the clinics of the nine participating
gynaecologists at Aberdeen Royal Infirmary, were identified by screening referral
letters. Women were excluded who had been previously seen at the hospital for
heavy menstrual loss and those who had clinical evidence or concern of underlying
pathology which excluded a diagnosis of d.u.b., or which necessitated
hysterectomy.
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Protocol
Following local research ethics committee approval, eligible women were all given
a socio-demographic questionnaire, which also contained a clinical component
(Appendix 2.1), Short form 36 (SF-36)(146), (Appendix la), and the hospital anxiety
and depression scale (HADS)(172), (Appendix lb). These questionnaires were self
completed by the women at the gynaecology clinic. Non-directive assistance for
questions that were not understood was available. Specifically, questions
determined length of times with complaint, number of visits to the general
practitioner with it, number of treatments received, their perception of the severity
of their heavy menstrual loss, their treatment preference if this existed, and
expectations of treatment. Level of education, employment and type of domicile
were also determined, and finally effect of their complaint on health related quality
of life. These women were the target population for the randomised trial
comparing TCRE with medical treatment which is described in chapter 3. Women
with treatment preferences and hence were not suitable for randomisation
completed a short questionnaire to determine reasons for preference (Appendix
2.2).
Women who did not agree to randomisation to the trial of TCRE versus medical
treatment were asked to give their reason for refusal. If this was because of a
specific preference for one type of treatment, then this was established. After
completing their questionnaires women were then allocated treatment according to
their wishes, if appropriate, or as determined by randomisation. Those expressing a
treatment preference were asked what factors influenced this.
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Statistics
Data were entered onto a database created on SPSS for windows, and all analyses
were undertaken using this programme or by InStat version 2 (GraphPad software).
In general results are statements of prevalence and rates within the target
population with means or medians stated where necessary. Where between group
comparisons are made then categorical data were compared using the chi square
test, continuous data with normal distribution were analysed using the Student t
test or by analysis of variance (ANOVA), and if not normally distributed the Mann-
Whitney U test was utilised.
RESULTS
Patient characteristics
273 women with excessive menstrual loss were referred for the first time to the
gynaecology clinic of the nine participating gynaecologists over a twelve month
period from 1st October 1994 rmtil 30th September 1995. All 273 self completed the
baseline socio-demographic and clinical questionnaires and the results are outlined
in table 2.1. This reveals that the majority of women had previously consulted their
general practitioner and received treatment from them prior to referral, but 21% had
their menstrual problem for less than twelve months and 22% had never received
any medical treatment prior to referral. A high proportion, 64% were disabled for
more than two days per cycle. The baseline SF-36 scores (table 2.2 and figure 2.1),
reveal a global and significant reduction for all eight components when compared
with the normative values for the UK population(148).
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Patient preference
A treatment preference was expressed by 31% of the target population. Compared
to those without a preference, women who exhibited a treatment preference were
significantly more likely to have less than two children and to have been previously
treated by their general practitioners for heavy menstrual loss (table 2.3). Women
with a preference had higher scores for seven of the eight SF-36 dimensions and
also for the anxiety component of the HAD scale (table 2.2) although these
differences did not reach the 5% significance level.
When the preference group were analysed separately, differences were evident
between those who preferred surgery and those preferring medicine. Significantly
more women with a preference for TCRE had previously received treatment for
heavy periods, were more likely to hope for amenorrhoea, and were more likely to
be disabled for more than two days per cycle by their period. They were also
significantly less likely to own their own property whilst fewer had continued their
education past the age of 16.
Those with a medical preference scored significantly better for all components of
SF-36 except physical functioning and general health (table 2.1, figure 2.2). Their
HAD scale depression scores were also significantly better than those with no
preference or preferring TCRE, although all groups were within the normal range
(table 2.2). The anxiety component of HADS was within the normal range (score <
8), for those preferring medical treatment, and higher than 8 for those preferring
TCRE or with no preference, although there was no statistically significant
difference between the groups (table 2.2, 2.4).
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Health related quality of life
Health Related Quality of Life was measured in all participants at baseline using the
generic health questionnaire, SF-36. At baseline, those women preferring medical
treatment scored significantly better for six of the eight parameters, whereas those
without a preference or preferring TCRE, which had similar mean scores that were
significantly lower than mean normative values (table 2.2 and Figure 2.2). The
mean scores for women in the preferred medical therapy group were, in fact,
similar to mean normative values for British women of this age group for five of the
eight variables(148), with little scope for improvement with treatment for the other
three.
Reason for preference
The reasons given for having a treatment preference were also ascertained from
these women. Both medical treatment and TCRE had been recommended equally
often by the patients' general practitioners. No patients had been "recommended"
medical treatment by friends or through the media, whereas 52% of those choosing
TCRE had. The majority (84%) of patients choosing TCRE would not consider
medical treatment at all whereas all those choosing medical treatment would
consider having a TCRE later. The most important consideration for those choosing
medical treatment was the desire to avoid having an anaesthetic or surgery if
possible, whereas the most important reason for choosing to have a TCRE was the
desire to avoid long term medication.
DISCUSSION
This represents the first assessment of the socio-demographic, clinical and quality of
life status of women referred to a gynaecologist for the first time with excessive
menstrual loss. 273 women who fulfilled the criteria attended the gynaecology
clinic representing 7.3% of all new general gynaecological referrals to the nine
participating gynaecologists in Aberdeen. If re-referrals to gynaecology clinics with
excessive menstrual loss(48) are included then proportion rises to 8.3%. This figure
does not take into account referrals to peripheral clinics in Grampian or private
referrals. The two non-participating gynaecologists should not alter the figures as
the general referrals are equally distributed amongst the eleven consultants. The
proportion of women with heavy menses will be slightly underestimated as the
total number of referrals incorporates some women referred to specialist
psychosexual and menopause clinics. Even so the total is less than the 12% quoted
by Bradlow and colleagues for Oxford (47), which may represent a combination of
variations in thresholds for referral, patient expectations and tolerance of
symptoms.
Few women under thirty or without children were referred for treatment and the
majority (89%), had consulted their general practitioner on a previous occasion
regarding excessive menstrual loss. It is perhaps disappointing to note that 21%
had their complaint for less than one year and a similar number had received no
treatment from their own doctor prior to referral. These are better figures than
obtained from primary care in Oxford region where 45% were referred without
treatment and 43% within one month of consulting their general practitioner(49).
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These regional variations may represent a reluctance to treat menstrual problems in
primary care, perceived or real patient pressure for referral, or the knowledge of
longer waiting times for specialist treatment in different parts of the UK. Caution
must be used when using Oxford data as the British reference as although it is the
only presently available comparison it is highly unlikely to be representative of the
whole of the country. There is little doubt that the differences in previous
treatments received, number of consultations, and time from consultation to referral
reflect wide variations in primary care management. If the Royal College primary
care guidelines(65) had been available, and instituted at the time of this study then
approximately 20% of the women were inappropriately referred.
Each year in the UK £7 million is spent on prescriptions in primary care to treat
menorrhagia(65), this is despite the fact that between 22% and 45% have received
no treatment prior to specialist referral. A high proportion of women (64%) are
disabled for more than two days per cycle, despite the aforementioned treatment
rates in primary care. A previous study revealed that only 12% of women with
menorrhagia are maintained on drug therapy after five years and 60% will have had
a hysterectomy(49). These figures were obtained between 1984 and 1989, before the
introduction of endometrial ablative surgery and the progestogen intrauterine
device in the UK. These statistics have enormous resource implications through
work days lost and possibly ineffective prescribing, making the initiation of
effective and acceptable treatment at primary care level a priority.
Traditionally, assessment of heavy menstrual loss and treatment with medical
managements has been based on objective menstrual blood loss and its effect on
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haemoglobin levels or iron stores. This is of little relevance to the vast majority of
women who seek help for their troublesome bleeding. Totally subjective
assessment of menstrual blood loss, particularly retrospectively is notoriously
unreliable. Semi-quantative, prospectively completed, pictorial menstrual charts
have been devised which have been shown to be high levels of sensitivity and
specificity(34,157). These may have been useful additions to this and other studies
involving women with menstrual problems as the results are amenable to statistical
analysis making inter and between group comparison more reliable. Secondly in
this study it would enabled determination of the prevailing level of true
menorrhagia (loss >80 mis/cycle). More recently, measurements of health related
quality of life issues have been recognised as important determinants, not only of
level of suffering, but also as measures of response to treatment(51). Health related
quality of life can be effectively measured using a number of tools, although the
generic health questionnaire SF-36 has been shown to be sensitive in detecting
changes in quality of life for specific medical conditions, including
menorrhagia(52,53,171,173). Women have been shown to benefit from a greater
improvement in quality of life parameters following hysterectomy than after non¬
surgical treatment of menorrhagia(54). Normative values for SF-36 are available for
the healthy population, of different age groups, and both sexes(148). Ideally
normative data at a regional level would be available, although comparing a
woman's score with these national values allows an assessment of her heavy
periods for the different health dimensions measured, and can predict how effective
certain treatments might be in improving these.
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This study reveals that women referred for the first time to a gynaecologist with
heavy menstrual loss have a global and significant reduction in all eight dimensions
of quality of life as measured by SF-36. This demonstrates that these women are
deserving of treatments to try to return these levels towards normality. Advocates
of measuring menstrual blood loss and treating only those who lose more than 80
mis per cycle would not treat the majority of women, yet have not demonstrated
that reassurance alone for those with normal blood loss will improve their quality
of life. Importantly this study also reveals that differences in quality of life scores
vary according to treatment preference. Women with a strong preference for
medical treatment have SF-36 scores that are near normal and have little scope for
improvement irrespective of type of treatment. It would be sensible to concur with
their wishes, or if necessary demonstrate that no treatment is required so that
interventions with increased morbidity, which may not afford them tangible
benefit, are avoided. Those with a surgical, or no preference were equally
debilitated by their heavy periods with respect to quality of life.
Patient preference is regarded by some experts as an important arbiter of treatment
choice in menorrhagia(23,35). There is a paucity of information in the literature
describing rates of preference, on differences in baseline characteristics of those
exhibiting a preference, and of the expectations of these women. Our rate of
expressed preference (31%) is lower than the rate of 36% described by Coulter and
colleagues in a large primary care based observational study of women attending
their general practitioner with heavy menstrual loss(63). Treatment preference was
identified as the principle reason for refusal of randomisation when medical and
surgical management were compared in a randomised trial involving termination
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of pregnancy(174). Outcomes with regards to patient satisfaction and acceptability
also varied on the basis of preference. This study highlighted the importance that
patient preference can have on determining outcome and generalisability of trials.
The importance and effect of patient preference was made evident by the
randomisation rate of only 25% achieved in the MRC trial of TCRE versus
hysterectomy because of strong patient opinions regarding their treatment(107).
This prolonged recruitment and decreased generalisability could have been
predicted if piloting had been undertaken to identify the very high preference rates
for these treatments in that region.
There were systematic differences between the preference groups and those who
expressed no treatment preference. Women who preferred medical management
tended to have better general health, were less restricted by their menstrual
problems, and fewer had been treated previously by their GP. On the basis of their
SF-36 scores they were not as severely affected by their periods, with near normal
quality of life levels. Those preferring surgery were more likely to have completed
their education by age sixteen, had all tried medical management, and had a greater
desire for amenorrhoea. Those without a preference, who were prepared to accept
either management tended to fall between the preference groups in terms of their
socio-demographic and menstrual history.
The marked differences between the two preference groups highlights the need to
look at these groups individually, rather than en masse, as including them all in a
single preference group has the effect of equalising their traits. This would almost
certainly give rise to misleading information, and would detract from any potential
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advantages in generalisability(175,176) gained from including preference groups in
studies. The reasons given for having a particular preference also reinforce this
view as although there was no treatment bias exhibited by general practitioner's,
the media and women's friends both strongly recommended endometrial ablation.
The other reasons for preference such as a desire to avoid a general anaesthetic or
refusal to take medication because of failure of previous, different medication, are
perhaps more obvious, but no less important. Attempts to coerce women with a
strong preference for one treatment into having another, especially in the context of
a trial will almost certainly lead to patient dissatisfaction, unreliable results and
perhaps loss of trust. Baseline traits and outcome for women with heavy periods
who have strong treatment preferences are undoubtedly different from each other
and also from women without a preference(163).
It will be important to repeat these baseline socio-demographic questions once the
Royal College of Obstetricians and Gynaecologists guidelines for the management
of menorrhagia in primary care(65) are in widespread use. These in conjunction
with the proposed Scottish Intercollegiate Guidelines Network recommendations
for the management of menstrual disorders should rationalise primary care
management and referral patterns. Once these are established we will be able to
detect any changes in baseline traits of women complaining of heavy menstrual
loss, duration of level of suffering, treatments received and patterns of referral.
Only then will we be able to determine any shifts or changes in practice and
whether the guidelines have been effective.
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Table 2.1. Socio-demographic and clinical details of women referred with heavy
menstrual loss to Aberdeen Royal Infirmary from October 95 to September 96
Number Percentage
Total 1st time referrals 273 100
Age
20-29 4 2
30-39 88 32
40-49 170 62
50 or more 11 4
Marital status
single 11 4
co-habiting/married 239 88
widowed/separated 22 8
Number of children
none 19 7
one 27 10
two 120 44
more than two 106 39
Age education completed
16 118 43
17-18 89 33
19 or older 66 24
Domicile
rented 5 2
council 72 27
own property 186 70
other 3 1
Occupation
student 6 2
unemployed 49 18
part-time 107 39
full-time 107 39
housewife 4 2
Smoker
yes 116 42
Time with heavy menses
< 6 months 17 6
6-12 months 40 15
more than one year 215 79
Days disabled with period
none 56 22
one 37 14
two or more 167 64
G.P. visits for heavy menses
one consultation 30 11
more than one consultation 242 89
Treatment received
none 58 22
medication 210 78
Treatment preference
none 189 69
prefers medication 36 13
prefers surgery 40 15
reassurance only 8 3
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Table:2.2MeanHADSandSF-36scores(95%confidenceint rval )fopati trefe redw thh vyme st uall ss
Patient group
numberof women
HADS: Anxiety
Depression
SF-36: Physical functioning
Social functioning^
Role- physical
Role- emotional
Mental health
Energy/ fatigue
Pain
General health
allwomen
273
8.19 7.45,8 93
5.18 4.58,5.78
79.23 75.67,82.78
68.68 64.57,72 80
58.27 51.87,64.67
58.21 50.81,65.60
61.02 57.64,64 41
42.91 39.48,46.33
56.92 52.74,61 10
67.36 64.06,70 67
no preference
189
8.42 7.49,9.35
5.18 4.50,5 86
78.33 74.00,82 65
65.14 60.33,69.94
55.83 48.14,63 53
55.19 46.29,64 08
58.97 54.96,62 7
41.74 37.97,45.51
53.83 48.80,58.86
67.72 63.80,71 64
preference
84
7.67 6.45,8 88
5.18 3.89,6.47
81.25 74.78,87 2
76.67 69.08,84 25
63.75 51.88,75 62
65.00 51.35,78.65
65.60 59.25,71.95
45.50 38.10,52.90
63.89 56.25,71
66.58 60.19,72 96
prefer medical
36
7.06 5.27,8 84
4.06* 2.43,5.68
86.84 77.93,93.17
85.96* 75.58,96.34
75.00* 59.44,90 56
77.19* 60.21,94.17
71.37** 63.28,79 45
53.16* 43.31,63.00
67.84* 57.14,78 53
66.21 56.34,7 08
prefer surgical
40
8.19 6.42,9 96
6.14 4.17,8.11
76.19 72.85,84 39
68.25 57.85,78.65
53.57 35.84,71.31
53.97 32.79,75.14
60.38 50.68,7 0
38.57 27.77,49 3
60.32 49.52,71.11
66.90 57.82,75 99
Theeightwomenpref rringreassuranceonlyhavnotb analysedseparately TheeightscalesoftSF-36aror dfr m0-100;repres n sw stpossiblend10bhe lt . ThetwoscalesofHADSaror dfr m0-21;repres ntslo spos iblend21high tsev sxi tyd p i n. Asterisksdenotesignificantc reviat onfromthellwo egr up:*p<0.05;*. 1. ui
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Table2.3
Characteristicsofwomenbypref ren eftre tm nt nopreferenceX2significa n=189(%)n=84(%)
(d.f.)
2P
Age>40
127
(68)
54
(63)
0.69(1)
0.4
Twoormo echildren
163
(87)
63
(73)
10.0(3)
0.02
Married
163
(87)
76
(88)
0.08(1)
0.78
Livinginowproperty
126
(67)
60
(70)
0.15( )
0.69
Unemployed
40
(21)
19
(22)
0.55(2)
0.76
Smoker
73
(42)
26
(32)
2.15(1)
0.14
Heavyperiods>1y ar
150
(80)
66
(77)
0.43(1)
0.51
>1G.P.consultationf r menorrhagia
172
(92)
70
(82)
5.52(1)
0.02
Previousmedicalt atment
150
(81)
60
(72)
2.61(1)
0.11
Disabledfor2moredays
70
(39)
26
(32)
4.9(3)
0.18
Hopingf ramenor hoea
14
(7)
10
(12)
0.48(1)
0.37
H.A.D.S. anxiety depression
5.18 8.42
S.D (3.8) (3.4)
5.18 7.67
S.D (3.7) (3.8)
tvalue 0.0 1.64
1.0 0.1
ON
o
Table2.4
Characteristicsofwomenbyspecifiedtre t e tpref r n e PreferredM dical n=36(%)PreferredTCRE n=40{%)Nopreference n=189(%)
X2(d.f.)
significance 2P
Age>40
23
(64)
25
(62)
129
(68)
0.65(2)
0.73
Twoormo echildren
27
(74)
29
(72)
163
(86)
6.5(2)
0.048
Married
34
(95)
32
(81)
163
(87)
3.38(2)
0.18
Educationcompletedag16
14
(38)
23
(58)
81
(43)
5.13(2)
0.07
Livinginowproperty
30
(83)
24
(60)
126
(67)
44.5(2)
<0.001
Unemployed
8
(21)
4
(10)
40
(21)
2.8(2)
0.25
Smoker
16
(44)
13
(33)
73
(39)
1.2(2)
0.5
Heavyperiods>1y ar
32
(89)
36
(90)
150
(79)
3.8(2)
0.14
>1G.P.consultationf rmenorrhagia
32
(89)
36
(90)
172
(91)
0.17(2)
0.91
Previousmedicalt atment
22
(61)
40
(100)
150
(79)
18.0(2)
<0.001
Disabledfor2mo edays
16
(44)
27
(67)
122
(67)
5.7(2)
0.05
Hopingf ramenor hoea
0
(0)
10
(25)
14
(7)
16.4(2)
<0.001
H.A.D.S. anxiety depression
7.06 4.06
S.D. (3.6) (3.3)
8.19 6.14
S.D. (3.8) (4.3)
8.42 5.18
(3.8) (3.4)
Fvalue(d.f.) 1.96(2) 3.28( )
0.19 0.04
Figure2.1SF-36scor sfoallnewref rralswithh avymen esa dc ualnormative valueswith-1standardde ia ion(SD),fothhealthyfem leUKpopulation. OQ ♦—normativevaluesO-1SD—*—allref rrals
Figure2.2:acomparisonfthSF-36scoresft referencegr ups withnormativevaluesf rthU.K.fem lepopulation •normativevalues—■—noprefere ce—A—prefersTCRE•—prefersmedical
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Chapter 3
A Randomised Controlled Trial Comparing Medical Management
with Transcervical Resection of the Endometrium forWomen with
Heavy Menstrual Loss:
Patients, methods and outcomes at four months
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INTRODUCTION
Heavy menstrual loss is a common complaint accounting for between 8% (Chapter 2),
and 12%(47) of all new referrals to gynaecology out patient departments. Traditionally,
many of these women are initially prescribed medical treatments by gynaecologists. A
number of these drugs have been shown to reduce blood loss in a significant
proportion of women with objectively proven menorrhagia(20,22/23/68/77,79/80,85).
The majority of women who seek treatment for their heavy menstrual loss do not have
greater than average menstrual loss(29-31,48). In addition, without a simple and
acceptable method of measuring menstrual blood loss, those with pathological loss are
difficult to identify. There has been little work undertaken to determine the effects of
these medications on women with subjectively heavy menstrual loss. There is also a
paucity of data pertaining to the acceptability of these treatments, and whether they
improve health related quality of life on women with heavy menstrual loss.
Amongst women seeking surgery, hysteroscopic techniques for endometrial ablation,
such as transcervical resection of the endometrium (TCRE), have been shown to be
effective, achieving high rates of patient satisfaction(105,106,118,177). Present
recommendations are that these techniques are offered as an alternative to
hysterectomy once medical managements have failed(118). The pragmatic(89,90)
randomised comparison of medical treatment with TCRE, described in this chapter,
was undertaken to clarify the place of hysteroscopic surgery in the management of
women when first referred to a gynaecologist with heavy menstrual loss. The women
65
who participated were equally willing to accept medical or hysteroscopic management,
as those with a treatment preference had been identified (chapter 2).
PATIENTS AND METHODS
Eligibility
Women were eligible for this trial if consulting a gynaecologist for the first time with a
complaint of heavy menstrual loss, their family was complete, they had a clinical
diagnosis of dysfunctional uterine bleeding (uterus less than ten weeks pregnancy size
and normal endometrial pathology) and had not been referred specifically for surgery.
They also had to be willing to be randomised to either medical or hysteroscopic
management.
Sample size
Based on expected satisfaction rates of approximately 80% at four to six months after
transcervical resection of the endometrium(105,106,118) it was calculated that a
minimum of 180 women would be required to have 80% power to detect an absolute
difference in satisfaction of 20% at the 5% level of significance(178).
Recruitment
With local research ethics committee approval, women were recruited from the
gynaecology clinics of nine of the eleven consultants at this large teaching hospital
between October 1994 and September 1995. All women were seen routinely at the
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outpatient clinic and if eligible were given a TCRE description sheet (Appendix 3.1), a
standard patient information sheet (Appendix 3.2), and were then seen and counselled
by the same researcher, Dr K G Cooper. As this was a pragmatic study, preoperative
assessment by scan or hysteroscopy was not routinely performed. Initial clinical
assessment of uterine size and if indicated, endometrial biopsy were used as criteria for
eligibility. Women were randomly allocated to either "transcervical resection" or
"medical treatment" by opening sealed, serially numbered, opaque envelopes; the
order was determined by computer generated random numbers within balanced blocks
of twenty.
Protocol
After giving informed consent, a clinical questionnaire (Appendix 3.3), Short Form
36(146,170) (SF-36), (Appendix la), and the Hospital Anxiety and Depression Scale(172)
(HADS), (Appendix lb), were completed and blood was taken for haemoglobin
estimation. Bleeding and pain scores were determined by assigning a score from zero
to five for heaviness of bleeding or severity of pain for each menstrual day, for a
maximum of ten days.
Those women allocated to the medical arm had their treatment chosen by the senior
gynaecologist responsible for the clinic. The medication prescribed had to be a
recognised treatment for menorrhagia, which should not have been used by the patient
before, and was to be continued for at least three cycles.
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Patients allocated surgery received an injection of the gonadotrophin releasing
hormone analogue, goserelin 3.6 mg. Five weeks later they were admitted under the
care of one of the three participating gynaecologists who performed hysteroscopic
surgery. Transcervical resection of the endometrium was performed under general
anaesthesia using rollerball coagulation to the fundus and cornua with resection of the
cavity walls using a 90 degree, 7 mm diameter loop, with 1.5% glycine solution as the
distending medium, as described in the introductory chapter.
Patients were reviewed at four months when they self completed questionnaires prior
to a formal consultation (Appendix 3.4). The baseline questionnaires, except for HADS,
were repeated to assess outcome. Additional questions to establish satisfaction with,
and acceptability of treatment (using direct questioning and by Semantic Differential
Technique(174) (SDT), (Appendix lc), were included. At the following consultation,
subsequent management preference was ascertained. If further treatment was
requested then an appointment with their own consultant was made, otherwise they
were discharged to their general practitioner.
Statistics
Data was entered onto a database created on SPSS for windows, and all analyses were
undertaken using this programme or by InStat version 2 (GraphPad software).
Analysis was by intention to treat; that is women remained in their initial allocated
group irrespective of subsequent treatment received. Independent and paired t tests
were used for continuous variables (independent and related) with a normal
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distribution and the Mann-Whitney U test for ordinal or non-parametric continuous
variables. Chi-square test was used for independent nominal data and McNemars test
for paired data describing dichotomous variables. Secondary analyses were stratified
according to the number of medical treatments' used prior to gynaecological referral.
RESULTS
One hundred and eighty seven (69%) from 273 eligible women participated, 94
allocated to medical treatment and 93 to transcervical resection. The majority of those
who refused randomisation had a preference for one or other treatment (see chapter 2).
All women but one were assessed at follow up at an average of nineteen weeks after
treatment was initiated.
Patient characteristics
The participants are described in table 3.1; the trial groups had similar expectations of
treatment and were also of equivalent height, weight and social status. Almost 80% in
each arm were employed with about 30% in each group requiring time off work
because of menstrual symptoms. Similar numbers had heavy menstrual flow for more
than one year (77.6% and 83.8% respectively) whilst 24 of 82 women (29%) in the
medical arm and 22 of 85 (26%) in the surgical arm had haemoglobin levels of less than
12 g/dl. Baseline SF-36 scores were also comparable for each group (table 3.6). 22% of
women had received no previous medical treatment, 56% one, and 22% more than one,
from their general practitioner. 60% of women in both arms reported self treatment
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with analgesics perimenstrually. Overall, baseline anxiety scores were elevated (8.96
and 8.85) whereas depression scores were in the normal range (5.62 and 5.32)(172,179).
Medical treatment
Table 3.2 shows the actual treatment prescribed to the medical group. Progestogens
were prescribed from day 12 - 25, or 5 - 25 if there was also dysmenorrhoea. The
combined oral contraceptive pill preparations recommended were second generation
containing 30ug ethinyl oestradiol. Tranexamic acid was prescribed at a dose of lg
four times a day for the first five days of the period in women with regular periods,
with mefenemic acid 500 mg three times a day added if there was associated
dysmenorrhoea. Danazol was prescribed at a dose of 200 mg a day continuously for
ninety days. No women received a treatment that she had previously tried.
Progestogens were prescribed to women with heavy and irregular periods, who were
unsuitable for, or did not wish to take the combined pill or danazol. 80% of women
reported completing the treatment as prescribed, 9% occasionally missing tablets, and
11% stopping medication prior to follow up. There was no significant difference in
compliance between the medical treatments used (table 3.2). One woman underwent
transcervical resection after continual bleeding for two months on her allocated
medical treatment.
Transcervical resection of the endometrium
All those allocated transcervical resection were initially managed this way. The only
operative complication was persistent uterine bleeding which occurred in six women.
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This abated in all cases following the insertion of a uterine foley catheter at the end of
the procedure with removal six hours later. One woman had a two stage hysteroscopic
procedure and one woman later had a hysterectomy, both because of submucous
fibroids.
Menstrual status at follow up
Transcervical resection of the endometrium reduced bleeding and dysmenorrhoea
significantly better than medical treatment (table 3.3, p < 0.001 for all variables) and
achieved amenorrhoea in 37%. Although the number of heavy days, and bleeding and
pain scores, were significantly reduced by medical therapy the effect size was
significantly smaller than after surgery. This was reflected in the difference between
the groups in changes in mean haemoglobin levels. Medical treatment did not
significantly improve any of the five pre-menstrual symptoms, whereas all were
significantly improved following transcervical resection.
Satisfaction / acceptability
Transcervical resection resulted in significantly greater levels of satisfaction, symptom
improvement and acceptability (table 3.4). Semantic differential rating scores were
better on all parameters for hysteroscopic surgery and significantly so for all except
pain (table3.5). The commonest reasons for dissatisfaction with medical treatments
were no change in the severity of bleeding or pain, although "bad side effects" were
cited by twenty seven (45%) of the sixty women who found treatment unacceptable. A
total of forty six (48%) in the medical arm and twelve (13%) in the transcervical
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resection arm reported symptoms which they considered to be side effects, specifically
nausea, headaches and weight gain in the medical group and new pain equally in both
groups. One women prescribed danazol suffered a cerebro-vascular accident two
months into treatment, whilst another developed hypertension which resolved when
medication was stopped.
Health related quality of life
There was significantly greater improvement in all eight subscales of the SF-36
following transcervical resection (table 3.6, figure 3.1). The number of women
requiring time off work each month in the medical arm (29%) did not change with
treatment, but was significantly reduced (p< 0.001), in the surgical cohort (6%).
Secondary analysis stratified by previous medical management
Outcome in respect of bleeding and pain scores, menstrual symptoms, satisfaction, and
acceptability was significantly better amongst women allocated hysteroscopic
management in all strata characterised by the number of previous medical treatments,
including the 22% who had not previously had medical treatment.
DISCUSSION
The results of the hysteroscopic surgery group are clearly better than those of the
medically managed group, but are the results trustworthy, and if so to whom do they
apply?
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Bias between the two study groups in the way that they were selected, if it exists, is
likely to be small; the groups were randomly allocated, there was only one loss to
follow up, and the groups were similar at entry (table 3.1). Established and recognised
questionnaires were used to measure clinical and quality of life parameters, anxiety,
satisfaction and acceptability of treatment(106,146,170-172,174,180). It is recognised
that these are subjective outcomes. To minimise ascertainment bias, participation in
the trial was limited to women who were willing to accept either management. Those
who would not accept randomisation were identified and the reasons ascertained (see
chapter 2). Some will argue that the optimal medical treatments were not used for each
patient and that significant reduction in menstrual blood loss only occurs when the
original loss is objectively pathological. In this pragmatic(89,90) trial experienced
clinicians prescribed what they regarded to be the most appropriate standard medical
treatment for each women (table 3.2). The individual drug therapies were prescribed in
doses and timing used in studies demonstrating the effectiveness of these
medications(20,22,23,68,77,79,85) or as recommended by the British National
Formulary. We would emphasise that 22 out of the 31 patients for whom progestogens
were prescribed had these from days 5 to 25 which has been shown to significantly
reduce menstrual blood loss(79,80). More specifically no women received
progestogens in a dose or timing previously shown to be of little use in the
management of menorrhagia(21,78,87). Furthermore, the trial results consistently
favoured hysteroscopic management, irrespective of the type of medical treatment
prescribed by the gynaecologist or whether medical treatment had previously been
tried or not. Although a comparison of TCRE with medical treatment in women who
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had received no previous medical treatment would have given a more realistic
evaluation of the true treatment effect there are a number of reasons why this was not
done. Firstly this is not pragmatic, secondly it is contrary to recommendations of the
primary care guidelines(65), and lastly, recruitment would have taken five years to
obtain the same numbers. Analysis stratified on the basis of the number of previous
treatments received did not show any meaningful differences in primary outcome
measures.
Although the medically managed group showed improvement at follow-up this was
consistently less than in the resection group. This applied to all assessments of
menstrual status, including premenstrual symptoms and dysmenorrhoea (table 3.3).
Premenstrual symptoms have previously shown to improve following endometrial
ablation(106,181). Satisfaction and acceptability were also clearly higher in the
transcervical resection group (tables 3.4 and 3.5), and this was reflected in the numbers
of women who would have the same treatment again, would recommend it to another
person, and desired further treatment. Transcervical resection of the endometrium
achieved satisfaction and acceptability rates which were comparable to those obtained
in previous randomised trials(105-107), even though women in this trial were not
specifically seeking surgical treatment.
Menorrhagia is known to cause significant deterioration in general health and quality
of life(52,171,182,183) which has often been overlooked in the assessment of treatment.
The reduced SF-36 scores observed at baseline were consistent with the scores reported
74
for other women with menorrhagia(52). After medical treatment there were significant
improvements in all parameters except for general health, but normal scores were not
attained for any of the eight parameters. In contrast, scores equal to or better than
normal for all eight SF-36 scales were observed after transcervical resection (table
3.6)(148). This concurs with the findings of Coulter from observational series data(54).
Almost 30% of women felt unable to undertake their normal daily work routine
because of their period. Whilst this was highly significantly improved following TCRE,
the proportion remained essentially unchanged in the medical treatment group. This
lack of improvement is difficult to explain in light of the other medical arm outcome
measures, but is worrying as the ability to undertake normal daily activities is of
paramount importance.
Objective measurement of blood loss was not undertaken as this is not yet routine
clinical practice. Semi-quantitative measurement using pictorial blood loss assessment
charts(34) would have been useful in this trial potentially giving more meaningful
menstrual outcome values than the scoring method used. This would have been
helpful in determining those with true menorrhagia and for evaluating the different
medical treatments. An assessment of severity of menstrual loss and treatment success
was undertaken by measuring haemoglobin level at recruitment and follow up and by
calculating menstrual bleeding scores. The significantly greater mean increase in
haemoglobin concentration amongst women allocated transcervical resection is
consistent with the differences in the subjective measures of outcome.
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It is noteworthy that 48% of women in the medical arm reported side effects and over
half deemed these unacceptable. None of the six surgical complications was serious.
However, these women did undergo a general anaesthetic and the risks associated
with hysteroscopic surgery are too uncommon to evaluate reliably in a trial of this size.
These results should be generalisable to women first seeking advice from a
gynaecologist for management of heavy menstrual bleeding who have no treatment
preference. 70% of those fulfilling the entry criteria agreed to randomisation. Women
who refused randomisation had a preference for transcervical resection or medical
treatment in equal proportions.
A formal economic evaluation was not conducted. The cost of hysteroscopic surgery
has been estimated at £560(145) in the short term, rising to £1012 after four years(151).
These costs will be offset to some extent by the expense of medical management.
However, the resource implications of introducing transcervical resection of the
endometrium to all gynaecological centres and the training requirements involved
could be considerable, and these would need to be included in any assessment of cost-
effectiveness. Also, new, technically less demanding techniques for ablative techniques
that can be undertaken using local anaesthetic have been reported(l 12,114,184) whilst
the progestogen loaded coil seems effective in reducing menstrual loss(80,81). An even
more conservative approach could be adopted through reassurance and counselling for
those determined to have menstrual loss within normal limits. All these methods of
management require formal evaluation in randomised controlled trials before
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accepting them as effective advances in the management of women complaining of
heavy menses.
This trial indicates that early ablative surgery should be one of the options considered
for woman consulting a gynaecologist for the first time seeking treatment of excessive
menstrual loss, with the choice made by the woman after a full discussion of the
advantages and disadvantages of the various treatment options
PUBLICATION
The above trial was published in the British Journal of Obstetrics and Gynaecology in
December 1997(185).
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Table3.1Baselinecharacteristicsofe chrandomi edg ouptec ui nt.V lurnumbers(per ntag )wom unlessstatedotherwi e. Randomised Medical(n=94)
T.C.R.E.(n
=93)
Meanage(S.D.)
41.4
(5.2)
41.7
(5.2)
Meanhaemoglobing/dl(S.D.)
12.79
(1.19)
12.65
(1.63)
Menstrualsymptoms irregularperiods
49
(52.1)
52
(56.5)
3-5daysbleeding
15
(16.0)
11
(11.8)
>5daysbleeding
79
(84.0)
82
(88.2)
meanno.daysheavybl ding(S.D.)
4.56
(2.35)
4.28
(2.22)
regulardysmenorrhoea
53
(56.3)
48
(51.6)
Menstrualsymptomra ingcale mildorode ate
1
(1.1)
0
(0)
severe
59
(62.7)
53
(57.6)
verysevere
28
(29.8)
36
(39.1)
Bleedingscore-m an(S.D.)
24.2
(8.5)
25.0
(7.6)
Painscore-mean(S.D.)
14.7
(9.5)
13.5
(10.7)
Premenstrualsymp oms bloating
71
(76.3)
75
(82.4)
breastdiscomfor
65
(69.9)
65
(71.4)
irritability
65
(69.9)
68
(74.7)
headaches
63
(67.7)
54
(59.3)
depression
53
(57)
51
(56)
HospitalAnxietyandDepress onScal( ADS) anxiety-meanscore(95%C.I.)
8.96
(7.8,10.1)
8.85
(7.6,10.1)
depression-meanscore(95%C.I.)
5.62
(4.7,6.6)
5.31
(4.3,6.5)
vi
oo
Table3.2Drugtreatmentsreceiv dbyhosr ndomisemed caltr ntl e,ndatfs isfac ion, acceptabilitynddesiretoc ntinuehsamtr tmentfoll wup.Valu srnu bersfw (percentages) n=94SatisfiedwithTreatm ntCo inuet t treatmentacceptable Progestogensday12-25/5-31(33)10(34)
11
(36)
6
(19)
Combinedp ll
24
(25.5)
8
(33)
8
(33)
6
(25)
Tranexamicacid
22
(23.4)
7
(34)
6
(29)
4
(18)
Danazol
15
(16)
5
(33)
7
(47)
3
(20)
HRT(withNSAID)
2
(2.1)
1
(50)
1
(50)
2
(100)
Progestogensday5-25=2f31women,19om HRT=hormonereplacementth rapy,NSAIDnste idalanti-infl mm oryd ug vO
Table3.3Menstrualstat sndymp omst4monthfoll wu .V lueumb rofw m n(perce tages),nl s statedotherwise. RandomisedMedical n=93RandomisedT.C.R.E. n=93
95%C.I. fordiff
Pvalue
Meanincre senHblevel,g/d(S.D.)
0.18
(1.29)
0.76***
(1.62)
-1.04,0.12
0.014
Meanincre senHbfbas lin<12g/dl
0.93**
(1.5)
2.53***
(1.94)
-2.64,-0.56
0.003
Menstrualstatus unchangedorheavier
48
(51.6)
7
(7.5)
33%,56
<0.001
Durationofbleed none
3
(3.2)
34
(37)
<3days
3
(3.2)
17
(18.5)
37%,59
<0.001
3-5days
29
(31.2)
24
(26.1)
>5days
58
(61.9)
17
(18.5)
Meanno.ofdaysh vybl eding(S.D )
3.15***
(2.8)
0.76***
(1.3)
1.75,3.03
<0.001
Bleedingscore-m an(S.D.)
17.8***
(9.15)
5.1***
(6.97)
10.25,15.29
<0.001
Painscore-mean(S.D.)
9.7***
(8.92)
2g***
(6.14)
4.51,9.24
<0.001
Dysmenorrhoea sameorwors
42
(46.2)
14
(15.3)
18%,53
<0.001
Premenstrualsymp oms breastdiscomfort
55
(59.8)
40***
(44.0)
2%,31%
0.03
bloating
73
(79.3)
53***
(58.2)
8%,35%
0.002
irritability
62
(67.4)
49**
(53.8)
1%,28%
0.06
headaches
57
(62.0)
34**
(37.4)
11%,39
<0.001
depression
51
(55.4)
2i***
(23.1)
19%,46
<0.001
Asterisksdenotechangfrombas lin(*p<0.05,* 1*p. 01) Hb=haemoglobin(<12g/dl),n7824e ical82T.C.R.E. 95%C.I.fordiff=confidenceintervalsiff rencempr portions(%). oo o
Table3.4P tientsatisfaction,menstrualymptomr ingcale,eff ctive ssdc pt bilityotre nde ir futuretreatment.Valu srn b rsofwomen(percentag )u l ss at dthe wise RandomisedMedicalT.C.R.E95%C IPvalu n=93fordiff
Satisfactionwi htreatment totally/generallysa isfi d
25
(26.8)
70
(76.0)
-61%,36%
<0.001
Effectoftreatmentnsymptoms cured/acceptableimprovement
29
(32.2)
77
(84.9)
-64%,-40%
<0.001
Menstrualsymptomra ingcale none
2
(2.2)
34
(37)
-45%,24%
<0.001
mildoroderate
39
(41.9)
51
(53.4)
severe
42
(45.2)
6
(6.5)
verysevere
10
(10.8)
1
(1.1)
Wasthereatmentcceptable? yes
33
(35.5)
85
(93.4)
-67%,45%
<0.001
Preparedtohavsametreatmentgai yes
29
(31.2)
86
(92.5)
-72%,51%
<0.001
Wouldyourecommendurtreatment? yes
38
(40.9)
84
(90.3)
-61%,-38%
<0.001
Requiredaysoffwork? no
56
(70.9)
73
93.6**
-31%,5%
<0.001
Treatmentdesired none
3
(3.2)
82
(88.1)
-92%,78%
<0.001
medical(sameordifferent)
40
(43.0)
5
(5.4)
t.c.r.e.
49
(52.7)
2
(2.2)
hysterectomy
1
(1.1)
4
(4.3)
Asterisksdenotesignificantchangfromthebas l n(*p<0.05,* .01*p. 01) 95%C.I.fordiff=con idenceintervalsiff rencep portions(%) oo
Table3.5Semanticdifferentialngscoresfoceptabilityftr atment(r-3[b s ]—>+w r ]) Medicaln=93T.C.R.E.n
=93
Adjectivalpair
Mean
S.D.
Mean
S.D.
95%C.I.diff
Significance
painless-inful
-0.44
(1.74)
-0.71
(1.79)
-0.25,0.78
CO
o
II
Oh
happy-sad
-0.12
(1.56)
-1.42
(1.43)
0.87,1.74
p<0.001
pleasant-unpleasan
0.11
(1.55)
-0.58
(1.33)
0.27,1.10
p=0.002
positive-negati
-0.14
(1.81)
-1.80
(1.44)
1.19,2 4
p<0.001
safe-dangerous
-0.68
(1.65)
-1.75
(1.21)
0.65,1.49
p<0.001
attractive-unattracti
0.01
(1.04)
-0.40
(0.89)
0.13,69
p=0.004
mild-harsh
-0.52
(1.41)
-1.12
(1.32)
0.21,1.00
p=0.003
agreeable-disagre a l
-0.23
(1.92)
-1.30
(1.39)
0.59,1.57
p<0.001
active-passiv
-0.23
(1.12)
-0.77
(1.24)
0.20,89
p=0.002
easy-hard
-1.01
(1.79)
-1.58
(1.41)
0.11,1.04
p=0.016
fast-slow
-0.23
(1.69)
-1.69
(1.35)
0.88,1.77
p<0.001
good-bad
0.02
(2.03)
-2.09
(1.34)
1.61,2.61
p<0.001
95%C.I.diff=confidenceintervalsforiff rencem an 00 N>
Table3.6ShortFormHealthu veyQuestionnairmeanba elic r sa dcha gincotfou hll w up.Scoresrangefrom0—>100(w stbest) Medicaln=93 meanS.D.
T.C.R.E.n
mean
=93
S.D.
Pvalue
ShortForm36-baselinecores(S.D.) physicalfunctioning
78.88
(20.72)
81.94
(19.38)
0.30
socialfunctioning
69.10
(20.98)
69.06
(24.29)
0.99
role-physical
54.26
(37.86)
56.72
(39.38)
0.66
role-emotional
57.80
(42.10)
53.41
(44.00)
0.49
mentalhealth
58.32
(18.27)
59.14
(19.08)
0.77
energy/fatigue
41.24
(16.84)
41.51
(19.22)
0.92
pain
53.8
(24.84)
57.95
(25.16)
0.26
generalhealth
68.02
(18.85)
65.10
(20.05)
0.31
Shortform36-changeinsco(S.D.) physicalfunctioning
4.84*
(16.72)
10.16**
(16.51)
<0.05
socialfunctioning
7.57*
(26.26)
17.44**
(25.08)
<0.05
role-physical
15.32*
(46.78)
32.26**
(38.23)
<0.01
role-emotional
8.96*
(49.43)
31.54**
(45.94)
<0.01
mentalhealth
4.78*
(16.69)
15.01**
(19.00)
<0.01
energy/fatigue
7.07*
(20.23)
20.53**
(20.76)
<0.01
pain
8.84*
(26.39)
21.62**
(31.33)
<0.01
generalhealth
-0.25
(15.99)
10.49**
(20.85)
<0.01
Asterisksdenotesignificantchangfromtheba elin(*p<0.05,* .01) CO OJ
general
health
pain
energy /
fatigue
mental
health
role-
emotional
role-physical
social
functioning
physical
functioning
CO
0)
3
(0
>
0)
>
CO
E
L_
o
c
O 0)
O §
<D
V
CO
CO
JQ
o
E
II
J® CO
■O H5
1 1
s -
Cl>
CO
CO
n
c
o
E
Chapter 4
A Randomised Controlled Trial Comparing Medical Management
with Transcervical Resection of the Endometrium forWomen with
Heavy Menstrual Loss:-
clinical and quality of life outcomes at 24 months
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INTRODUCTION
Medium and long term follow-up data are now available for hysteroscopic
endometrial ablative techniques for women who would otherwise have undergone
hysterectomy(55,107,151). In contrast, there is a paucity of follow-up data of longer
than six months for women prescribed medical treatment for menorrhagia(51) and
evidence that problematic menses recur on cessation of therapy(30,186). The majority
of trials assessing medical treatments also adopt an explanatory, rather than
pragmatic(89,90) approach to investigation, the emphasis being on reduction in
measured menstrual blood loss in women with proven pathological loss
(>80mls/cycle). This represents less than half of all women complaining of heavy
menstrual loss(24,48) and of those referred for endometrial ablation(187). Few
medical studies have assessed satisfaction with, and acceptability of, treatment, or the
women's desire to continue the same treatment. More importantly, other than this
trial, no studies have evaluated the effect of medical treatments on health related
quality of life despite strong evidence that women complaining of heavy menstrual
loss suffer a significant reduction in this(52,171) (chapter 2).
The short term results of this randomised trial comparing medical treatment with
TCRE for women first attending a gynaecologist for treatment of heavy menstrual loss
have been reported in chapter 3. The trial recruited women who were not specifically
referred for surgical treatment and who were equally prepared to have medical
treatment or TCRE. This chapter presents the two-year follow-up of these women, re-
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evaluating their outcomes with respect to subsequent treatments received, satisfaction
with and acceptability of treatment, and change in health related quality of life.
PATIENTS AND METHODS
Eligibility
Full details of the original trial design, treatment allocation, and outcome measures at
four months have been reported and are described in the previous chapter. In
summary, women were eligible if they met the following entry criteria: consulting a
gynaecologist for the first time with a complaint of heavy menstrual loss; family
complete; a clinical diagnosis of dysfunctional uterine bleeding (uterus less than ten
weeks pregnancy size and normal endometrial pathology); and had not been referred
specifically for surgery. They also had to have no preference for either medical or
hysteroscopic management. One hundred and eighty seven (69%) from 273 eligible
women consented to randomisation, 94 allocated to medical treatment and 93 to
transcervical resection. The majority of those who refused randomisation had
expressed a preference for one or other treatment and have been reported
separately(163). After follow-up at four months, all recruits, irrespective of initial
management, could request further and/or different treatment. This policy reflected
normal clinical practice in keeping with the pragmatic design of the trial.
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Protocol
Postal questionnaires (Appendix 4.1) were sent two years after initial treatment
assessing gynaecological symptoms, satisfaction with treatment, and acceptability of
management. Changes in health related quality of life were measured using the SF-36
health survey(146,170) (Appendix la). Subsequent and additional treatments received
were also determined, both from the questionnaire and from the hospital surgical
database. As this is the only hospital with a gynaecological service for the district, we
can be certain of further hospital treatment received for those who had not left the
Grampian region of Scotland.
Sample size
The original sample size calculations (Chapter 3), indicated that a minimum of 180
women would be required to have 80% power to detect an absolute difference in
satisfaction with treatment of 20% at the 5% level of significance(178).
Statistics
Data was entered onto a database created on SPSS for windows, and all analyses were
undertaken using this programme or by InStat version 2 (GraphPad software).
Analysis was by 'intention to treat', that is women remained in the group to which they
were originally allocated, irrespective of subsequent treatment received. Independent
and paired t-tests were used for continuous variables (independent and related) with a
normal distribution, and the Mann-Whitney U test for ordinal or non parametric
continuous variables. The Chi-square or Fisher's Exact test were used for independent
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nominal data, and McNemar's and Wilcoxon's tests for paired nominal data describing
dichotomous and related variables respectively.
RESULTS
One hundred and eighty seven women were originally recruited between October 1994
and November 1995, 94 randomised to have medical treatment and 93 to TCRE. Postal
follow-up questionnaires two years (range 23 to 28 months) after initial treatment were
completed by 173 (92%) women, 86 in the medical group and 87 in the TCRE group.
Six of the fourteen not followed-up were known to have left the region.
Patient Characteristics
Table 4.1 summarises the baseline characteristics of those successfully followed-up;
they were very similar to the total trial group (table 3.1, chapter 3). At the time of
recruitment, almost 80% in each group were employed with about 30% requiring time
off work because of menstrual symptoms. Similar numbers had heavy menstrual flow
for more than one year (78% and 84% respectively). Hospital Anxiety and Depression
Scale (HADS) anxiety scores were elevated (9.35 and 8.78) whereas depression scores
were in the normal range (5.76 and 5.29)(179). Baseline SF-36 scores were also
comparable for each group all eight variables were reduced relative to women of the
same age in the general population(148) (figure 4.1 & table 4.6). Complete details,
including medical treatments received, are described in the previous chapter.
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Subsequent treatment received or continued at two years
Subsequent management is summarised in table 4.2. At two-year follow-up, 59% of
those randomised to medical treatment had undergone TCRE, hysterectomy or both,
and 82% of the initial operations had been undertaken within twelve months of trial
entry. 21% remained on medical treatment, although specific medications were not
determined. 17% of women allocated to TCRE had undergone repeat TCRE,
hysterectomy or both. One hysterectomy, in the TCRE arm, resulted from an
emergency laparotomy performed for acute sepsis and generalised peritonitis,
secondary to bilateral rupture of pyosalpinges, in an amenorrhoeic woman, 14 months
after initial TCRE. No women requested further surgery or medication after
completing the questionnaire. Operative data were obtained from the hospital surgical
database for the fourteen participants who did not complete two-year questionnaires.
Of eight women in the medical arm, four had undergone TCRE; amongst six in the
TCRE arm, one hysterectomy had been performed.
Menstrual status at follow-up
Changes in menstrual symptoms at two years are shown on table 4.3. There was a
highly significant and comparable reduction in bleeding and pain scores in both trial
groups. 60% of the medical arm and 64% of the TCRE arm reported no new pelvic pain
of any kind. 42% of those in the medical arm were either amenorrheoic or had very
light periods (spotting or bleeding score from 1 to 5), compared with 60% of the TCRE
arm (p= 0.02). Significantly fewer women in the TCRE arm regarded their menstrual
status as unchanged or worse. Significant reductions were present in three of the five
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premenstrual symptoms in the medical arm, whereas these had not been detected at
four months. Significant reductions in all five pre-menstrual symptoms in the TCRE
arm were evident, but with the exception of headaches and irritability, these benefits
were less than at four months. Overall there was no significant difference in
premenstrual symptoms between the two study groups.
Satisfaction / acceptability
Compared with the medical group, women allocated TCRE had significantly higher
levels of satisfaction and symptom improvement; they were also more likely to find
their treatment acceptable (table 4.4). These values were much improved in the
medical arm from the four month data, whereas those for TCRE were similar. Only
24% of women allocated to medical treatment would recommend this form of
treatment, compared with 78% in the surgical arm who would recommend TCRE
(p<0.001, difference -54%, 95% C.I. -66% to -44%). Of the 47 women in the medical arm
who underwent a TCRE, 40 (85%) of them would recommend this form of treatment.
Health related quality of life
Baseline and two-year SF-36 follow-up data are presented for women who had
completed both questionnaires (table 4.5). Change in SF-36 scores were higher for all
health scores at two years for those allocated TCRE, but not significantly so. Women in
the medical arm scored better than at baseline and significantly so for five of the eight
variables, in addition there was an overall improvement from four-month scores.
Seven of the eight health scores were significantly improved from baseline in the TCRE
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group, but scores were lower than those obtained at four months. Figure 4.1 shows
how the follow-up scores compare with baseline and with normative values for a
healthy female population of equivalent age(148). The number of working women
who were taking time off work each month because of their periods was significantly,
and comparably reduced from 30% at recruitment to 14% in the medical arm and to
10% in the surgical group at two years (p = 0.1, 95% C.I. of difference -5% to 15%).
DISCUSSION
This study represents the longest follow-up of women participating in a randomised
trial of medical treatment for women with heavy menstrual loss. It is also the longest
follow-up of women undergoing TCRE who were not initially referred for surgical
treatment of their periods. Its other strength is that the randomised cohorts are not
distorted by motivational bias, as those preferring treatments were identified at and
excluded at the outset (Chapter 2). This has allowed us to observe the treatment
progression in both arms in the knowledge that requests for TCRE's from those in the
medical arm have not resulted through "resentful demoralisation"(175), that is,
disappointment at their initial allocation. Analysis was by intention to treat and
therefore no women changed trial arms or were withdrawn from the study because of
subsequent treatments received.
Follow-up questionnaires were not obtained for eight women from the medical arm
and six from the TCRE arm. Since this is the only hospital offering gynaecological
92
services in the area, information on operative procedures, general practitioner
correspondence, and subsequent clinic attendance for these women was available. It is
unlikely that loss of 8% of the trial women has affected the generalisability of the
results as the further surgical treatment received by these women was similar to those
who were foliowed-up.
Medical arm
Only 21% of women initially allocated to take medical treatment continued to take this
at two years, although 41% of women in this group had avoided surgical treatment.
Individual medical treatments used by women at follow-up were not determined as it
was the aim of the trial to evaluate a medical policy rather than identify optimal
medical treatment. Stratified analysis on the basis of subsequent treatment received in
the medical arm, is also methodologically unsound, in view of the small numbers and
inherent bias created as many women eventually chose their subsequent treatments.
Satisfaction with, and acceptability of, treatment were much improved from four
months, but remained significantly less than amongst those allocated to TCRE.
Bleeding and pain scores were significantly less than at four months and were
comparable to the TCRE arm. Other menstrual parameters were also significantly
improved, but pelvic pain remained low and equivalent in both arms. These
improvements from the four-month results may be due to the 59% of women in this
arm who underwent TCRE or hysterectomy. Nevertheless, those women avoiding
surgical treatment can be presumed to be equally satisfied as they were aware that
surgery was available had they requested it. The fact that only 24% of women would
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recommend medical treatment compared to 85% (40/47) of those who subsequently
underwent TCRE in the medical arm, who would recommend TCRE, strengthens the
argument that TCRE has improved the medical arm results.
Surgical arm
17% of women in the TCRE arm had undergone surgical retreatment at two years, less
than reported in previous randomised single-centre trials comparing TCRE with
hysterectomy(55,151), but similar to the multi-centre MRC trial(107). These differences
between the trials mounted in our centre may represent variation at recruitment in both
severity of symptoms, and expectations of treatment, as women in this trial were
excluded from randomisation if initial referral was for surgical treatment. Satisfaction
with, and acceptability of, treatment remained high at about 80%, comparable to the
four-month follow-up, and significantly better than amongst women in the medical
arm. This also correlated well with the numbers who would recommend TCRE (78%)
as treatment for heavy menstrual loss. Bleeding and pain scores and number of heavy
days remained highly significantly better than at recruitment, similar to four-month
levels, with only the number of days heavy bleeding significantly less than amongst
those in the medical arm. The results for the surgical cohort are comparable to results
of previous trials assessing endometrial ablation(104-107), the important difference
being that these were women not initially seeking surgical treatment. Most
importantly, women in the surgical arm did not have higher hysterectomy rates than
those in the medical arm (10% v. 14%, 95% C.I. -16 to 4%), suggesting that early
recourse to TCRE does not increase the risk of hysterectomy.
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Health related quality of life
This trial represents the longest term evaluation of change in health related quality of
life for women with heavy menstrual loss. It could be argued that this should be the
definitive arbiter of treatment success, and its measurement was recommended by the
effective health care group(51) for outcome assessment of treatments for menorrhagia.
Heavy menstrual loss is known to cause significant deterioration in general health and
quality of life(52,171,185) which has often been overlooked in the evaluation of
treatment. The reduced SF-36 scores observed at baseline were consistent with the
scores reported for other women with menorrhagia(52). For women in the TCRE arm,
two-year health related quality of life scores, as measured by SF-36, remain at near
normative levels(148), are highly significantly improved from baseline for seven of the
eight health scales, and are similar to values obtained at two years post TCRE by
Sculpher et al(55). The scores are however, globally reduced from the four-month
results. One possible explanation is an initial high score achieved in a "honeymoon"
period occurring soon after relief of symptoms. Another is that there has been a
genuine fall off in the benefits of the operation, although this is not borne out by the
satisfaction and menstrual status results. Women in the medical arm also had higher
SF-36 scores than at baseline, but these remained lower than scores achieved in the
TCRE arm and substantially lower than normative values (figure 1). The increased
scores in the medical arm from the four-month data may reflect the number of women
undergoing surgical treatment since then.
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Patient preference
Women who exhibited a preference and who chose their treatments were not followed
up by questionnaire at two years because of the small numbers involved and the
difficulties analysing data from non-randomised observational cohorts. Nonetheless,
subsequent treatments received were determined from hospital records. Those
preferring TCRE at outset had a markedly higher re-operation rate than amongst those
randomised to TCRE (42% v. 17%). This is likely to reflect different expectations of
treatment amongst those preferring surgical treatment (chapter 2)(163), and indicates
that these should be clearly determined at outset, with hysterectomy discussed with
women wanting amenorrhoea. In contrast, of the women preferring medical treatment,
only two had undergone TCRE and none a hysterectomy, a much lower proportion
than those randomised to medical treatment (54% TCRE, 14% hysterectomy). This
confirms that those women with a strong preference for medical treatment have a good
chance of avoiding surgery, and can be encouraged to pursue this option.
Conclusion
At two years, women allocated to TCRE are still in better health than those initially
managed medically. The results therefore consolidate the conclusions made from the
four-month data and the findings apply to those women attending a gynaecologist for
the first time, for treatment of heavy menstrual loss, who do not have a treatment
preference. Early recourse to hysteroscopic surgery will afford these women better
relief of symptoms and improvements in health related quality of life. Reassuringly,
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over 80% of those managed by TCRE at outset have avoided further surgical treatment
and there was no detectable increase in hysterectomy rates at two years in this group
compared with those randomised to medical therapy. Nevertheless, 40% of women in
the medical arm have not undergone surgical treatment for their complaint, although
only half of these women continue to take any medical therapy. Alternative,
promising, non-surgical treatments, such as the Mirena coil(82), or less invasive
surgical techniques, such as microwave ablation(114) or thermal balloon(164,165),
should be evaluated in well constructed randomised trials, comparing them with a
rigorously evaluated hysteroscopic surgical technique, before accepting them as
effective alternative managements for menorrhagia.
PUBLICATION
The above trial was published in the British Journal of Obstetrics and Gynaecology in
March 1999(188)
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Table4.1Baselinecharacteristicsofe chrandom dg uptr cruit nt.V l rnumbers(perce tag )wom unlessstatedotherwise Randomised Medical(n=86)T.C.R.E.7 Meanage(S.D.)41.4(5.4)
41.9
(5.1)
Meanhaemoglobing/dl(S.D.)
12.79
(1.16)
12.61
(1.66)
Menstrualsymptoms irregularperiods
45
(52)
49
(58)
3-5daysbleeding
14
(16)
9
(11)
>5daysbleeding
72
(84)
78
(89)
meanno.daysheavybl eding(S.D.)
4.6
(2.43)
4.24
(2.19)
regulardysmenorrhoea
53
(56)
48
(52)
Menstrualsymptomra ingcale mildoroderate
6
(7)
4
(4)
severe
54
(63)
51
(59)
verysevere
26
(30)
32
(37)
Bleedingscore-m an(S.D.)
24.7
(8.6)
24.8
(7.3)
Painscore-mean(S.D.)
15.2
(9.6)
13.3
(10.2)
Premenstrualsymp oms bloating
64
(75)
70
(82)
breastdiscomfort
60
(71)
63
(74)
irritability
60
(71)
64
(75)
headaches
57
(67)
57
(61)
depression
49
(58)
50
(59)
HospitalAnxietyandDepress onScal( ADS) anxiety-meanscore(95%C.I.)
9.35
(8.47to10.22)
8.78
(7.85to9.70)
depression-meascore(95%C.I.)
5.76
(5.06to6.45)
5.29
(4.54to6.05)
co
Table4.2Subsequentmanagemenofth sfoll w d-upt2y rs.V lurnumb rs(perce tag )wome nonemedicalTCRErepeatTCRE
hysterectomy
TCRE& hysterectomy
Medical,n=86
18(21%)
17(20%)
38(44%)
0
4(4%)
9(10%)
TCRE,n=87
65(75%)
7(8%)
6(7%)
5(6%)
4(4%)
Table4.3Menstrualstat sandsymptomsttwo-yearfollow- p.V lueu bfom n(perce ges),l s statedotherwise. Medical n=86T.C.R.E. n=87
95%C.I.
fordifference
Pvalue
Menstrualstat s unchangedorheavier
16
(18)
5
(6)
3to22%
0.02
Durationofbleed none
26
(30)
33
(38)
-22to6%
1-3days
3
(9)
14
(16)
-16to4%
0.5
3-5days
49
(52)
31
(36)
-4to21%
>5days
8
(9)
9
(10)
-8to20%
Meanno.ofdaysh vybl eding(S.D )
20***
(2.8)
J
(1.3)
0.37to1.4
0.001
Bleedingscore-m an(S.D.)
6.8***
(9.9)
g4***
(8.1)
-1.4to4.
0.33
Painscore-mean-(S.D.)
4.1***
(7.4)
3.9***
(7.5)
-2.1to2.4
0.9
Dysmenorrhoea-samorw s
25
(29)
20
(23)
-7to19%
0.46
Dyspareunia-s meorwors
9
(11)
5
(6)
-3to13%
0.1
Premenstrualsymp oms breastdiscomfort
47*
(58)
49**
(58)
-17to13%
0.96
bloating
57
(70)
55**
(65)
-11to17%
0.44
irritability
55
(68)
47**
(55)
-5to25%
0.09
headaches
43*
(53)
34**
(40)
-4to26%
0.09
depression
30***
(37)
28***
(33)
-11to17%
0.58
Asterisksdenotechangfrombaselin(*p<0.05,* 1*p01) 95%C.I.fordifference=confidenceint rvalsmpr portions(%).
Table4.4P tientsatisfac ion,effectivenessndac eptabilityoftre tm nt,re om dedt . Valuesarnumbersofwom n(percentages)u l sstat dtherwis . Medical n=86
T.C.R.E n=87
95%C.I.
fordifference
Pvalue
Totallyrgenerallysatisfiedwithtreatm nt
48
(57)
68
(79)
-36to9%
0.002
Cureoracceptableimpr v m ntnsym toms
53
(59)
69
(81)
-31to4%
0.017
Treatmentcceptable
65
(77)
79
(93)
-26to4%
0.004
Whattreatmentwouldy urec mendfri nd? none
15
(17)
9
(11)
medical
21
(24)
2
(2)
TCRE
40
(47)
68
(78)
-61to33%
<0.001
hysterectomy
10
(12)
8
(9)
Asterisksdenotesignificantchangfromt eba elin(*p<0.05,* .01,*p.001) 95%C.I.fordifference=confidenceint rvalsproportions(%)
Table4.5ShortForm36Healthu veyQu stionnairme nba elincor sa dcha gincorttwo-yearfoll wup. Scoresrangefrom0—>100(w rstbest) ShortForm36-baselinescores(S.D.) physicalfunctioning socialfunctioning role-physical role-emotional mentalhealth energy/fatigue pain generalhealth Shortform36-changeinsco(S.D.) physicalfunctioning socialfunctioning role-physical role-emotional mentalhealth energy/fatigue pain generalhealthMedicaln=83TCREn=86 meanSDmeanSD
difference
Pvalue
95%C.I.
78.67
(21.14)
82.33
(18.56)
-3.66
0.23
-9.7to2.4
68.35
(21.04)
70.03
(24.05)
-1.68
0.63
-8.5to5.2
53.01
(38.33)
56.98
(39.23)
-3.97
0.51
-15.7to7.8
57.43
(43.03)
55.03
(43.62)
2.40
0.72
-10.8to15.6
58.20
(18.23)
59.43
(18.97)
-1.23
0.67
-6.9to4.5
40.36
(17.17)
41.49
(19.15)
-1.13
0.69
-6.7to4.5
53.55
(23.99)
58.14
(25.15)
-4.59
0.23
-12.1to2.9
68.17
(19.00)
65.90
(19.34)
2.27
0.45
-3.6to8.1
3.73
(17.19)
5.00*
(18.97)
-1.27
0.65
-6.4to4.2
3.94
(25.26)
10.59***
(26.52)
-6.65
0.10
-14.5to1.2
12.95**
(44.58)
18.60***
(45.73)
-5.65
0.42
-19.4to8.
11.25*
(45.17)
22.48***
(50.47)
-11.23
0.13
-25.8to3.3
7.17***
(19.20)
9.98***
(19.14)
-2.81
0.35
-8.7to3.1
10.06***
(19.57)
14.58***
(21.96)
-4.52
0.17
-11.0to2.0
11.38***
(28.51)
12.34***
(27.20)
-0.96
0.82
-9.4to7.5
-0.67
(13.90)
1.69
(18.83)
-0.97
0.36
-7.4to2.
Follow-upstatisticalcompar sonsbetweentri lgr upsarf hangeincor Asterisksdenotesignificantchangi corfromt eba elin(*p<0.05,* .01,*p. 01)
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Chapter 5
A Randomised Controlled Trial Comparing Microwave
Endometrial Ablation with Transcervical Resection of the
Endometrium forWomen with Heavy Menstrual Loss:
Patients, methods, operative details and clinical
and quality of life outcomes at four months.
INTRODUCTION
Hysteroscopic endometrial destructive techniques are proven alternatives to
hysterectomy for women with excessive menstrual loss without excessive
uterine size or abnormality(55,105-107). The most commonly used techniques
in the UK are laser ablation and combination resection rollerball(118,140).
These procedures achieve high satisfaction rates, have quick recovery times and
are safe(59,118). Complication rates determined through a large national audit
are around 1%, with bleeding and perforation the most frequent problem which
are more commonly encountered at resection rather than laser ablation(59). The
main problem with these hysteroscopic techniques is that they are technically
demanding, necessitating specialist training and equipment. In an effort to
simplify endometrial destruction a number of alternatives to the hysteroscopic
surgical techniques have evolved which claim to be easier to learn and use, but
have similar clinical effectiveness, with increased safety(112,114,184). To date
none of these new techniques have undergone rigorous comparison with TCRE
or laser ablation in a randomised controlled trial.
One of these procedures, microwave endometrial ablation, has undergone
testing equivalent to phase 1-3 for drug trials and the first series of treatments
were reported in the Lancet in 1995(114). In this small study of 23 women an
83% success rates was achieved with single treatment, with 56% amenorrhoea,
abolition of dysmenorrhoea in 95%, and very fast treatment times (1-2
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minutes). Endometrial sampling was undertaken in all cases, followed by
endometrial preparation with danazol, and peri-operative ultrasound to
determine size, presence of fibroids and correct probe siting. There were no
complications in any of the 78 women who had undergone MEA at that stage.
These results were achieved in pre-selected women with normal sized uterii
with regular endometrial cavities.
To properly evaluate MEA a randomised controlled trial was required
comparing it with a proven hysteroscopic surgical technique. We obtained
ethical committee approval to undertake a pragmatic(89,90) randomised
controlled trial comparing microwave endometrial ablation with transcervical
resection of the endometrium for women complaining of heavy menstrual loss.
This trial was partially funded by Microsulis PLC, the manufacturers of the
microwave equipment. Transcervical resection of the endometrium was chosen
as the hysteroscopic technique as this was the personal preference of the
surgeons undertaking the trial and also it is more likely that the equipment is
available outwith specialist centres, unlike laser, which should increase the
generalisability of the results.
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AIMS
The aims of the study were to compare MEA™ with TCRE for women referred
for or requesting endometrial ablative surgery as treatment for heavy menstrual
loss. The following issues were addressed:
a. Outcome in terms of effectiveness, operative details, recovery times and
morbidity. The principle outcome measure for this trial is short term
satisfaction at four months, although follow-up will be continued through one
and two years. The power study calculation is based on satisfaction rates which
are known to be around 80% from previous randomised trials(105,106,118).
Results of the other outcome measures are also well known for transcervical
resection of the endometrium, although mean operating times from the earlier
trials of 30 to 45 minutes(104-107) have been halved(131). It is thus essential to
undertake a prospective randomised controlled trial of MEA with TCRE rather
than compare MEA results obtained from previous trials evaluating TCRE.
Data pertaining to MEA are restricted to the one small uncontrolled study
mentioned in the above introduction^ 14), therefore most of these outcomes
measures are being collected on it for the first time. As this is a new technique
effects on bladder and bowel will be evaluated, to determine if any changes in
symptoms occur to these local structures, following treatment by each
technique. This was undertaken previously for TCRE(109,189), when no
adverse effect on bladder or bowel symptoms was found.
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b. Changes in health related quality of life resulting from treatment of heavy
menstrual loss with MEA compared with TCRE. When treating a chronic, non
life threatening condition such as heavy menstrual loss an important
consideration should be the effect of treatment on the quality of life of the
women. This area was identified as a deficiency of previous trials evaluating
treatments for menorrhagia by the Effective Health Care group(51). It has been
demonstrated that women suffering from heavy menstrual loss suffer
significant reduction in all aspects of health related quality of life as measured
by the short form 36(52). The validity and reliability of the SF-36 has been
established for US (146,190,191) and UK(52,148,180) patient populations.
Despite being a generic health questionnaire, there is also evidence for the
instrument's validity, reliability and responsiveness to changes in health related
quality of life for women with menorrhagia(53,171,182,192). One uncontrolled
observational study showed that quality of life was improved following
treatment for menorrhagia, with the greatest benefit following surgery(54).
Several randomised controlled trials evaluating surgical treatments for
menorrhagia have used SF-36 as a comparative outcome measure(83,105,108).
These trials commenced before the normative values for that countries
population were known, hence baseline measurement could not be made and so
the most important measurement, change in health was not established. The
only randomised controlled trials which have both baseline and follow-up SF-36
results for treatments for menorrhagia to date are contained in this thesis.
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PATIENTS AND METHODS
Eligibility
Women were eligible for this study if they were pre-menopausal, were referred
for and suitable for endometrial destructive surgery (as in Chapter 3) and
willing to be randomised to either surgical technique.
Sample Size
Power study calculations based on rates of satisfaction with transcervical
resection of the endometrium at four to six months of about 80%(105,106),
determined that 230 women would yield an 80% chance of detecting a
difference in satisfaction of 15%, which would be significant at the 5% level
(InStat 2, GraphPad software).
Recruitment
Two hundred and sixty three women were recruited to the trial over 18 months
between September 1996 and March 1998. Referrals for endometrial ablative
surgery from nine of eleven consultants were assessed for eligibility. As this
was a pragmatic study, pre-operative assessment by scan or hysteroscopy was
not routinely undertaken. Clinical examination by bi-manual examination and
endometrial biopsy were used to determine clinical eligibility. If eligible,
women were given a standard information sheet describing the two surgical
techniques, the principles of randomisation and the aims of the study
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(Appendix 5.1). Informed consent was obtained from those eligible and willing
to be randomised. Treatment allocation was ascertained by opening the next in
line of a series of sealed, opaque, sequentially numbered envelopes which
contained the treatment code as determined by computer generated random
number tables. These were stratified in balanced blocks of twenty and
randomisation was equal to both treatments.
Protocol
Eligible women were identified from those referred to the gynaecology out
patient department for endometrial ablative surgery and after obtaining
informed consent, women were randomised to either MEA or TCRE. Baseline
clinical and health related quality of life measurements were determined by
patient self completion of a clinical questionnaire and Short Form 36 (Appendix
la) at recruitment. The clinical questionnaire was based on a validated
menstrual questionnaire developed by the Health Services Research Unit in
Aberdeen(l82)(Appendix 5.2) Additional questions pertaining to bladder and
bowel symptoms were also included. A subcutaneous injection of goserelin
3.6mg was given to all those recruited, and five weeks later they were admitted
for operation.
All the operations were undertaken by two named operators, Dr K G Cooper
and Dr C Bain, who were senior specialist registrars. Both were experienced
hysteroscopic surgeons, and had attended one training session to learn
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microwave ablation and had performed five MEA's each prior to the trial
commencing. All procedures were performed rmder general anaesthesia and
concomitant rectal analgesia using the non steroidal anti-inflammatory,
diclofenac or if contra-indicated, paracetamol was administered. TCRE was
undertaken using a diathermy resectoscope and glycine as described in the
introductory chapter. Those allocated to MEA underwent ultrasormd scan to
determine endometrial thickness and carbon dioxide 5mm hysteroscopy to
identify any fibroids and confirm placement in the endometrial cavity.
Microwave ablation was then performed using the technique described in the
introductory chapter. An operative questionnaire was completed at this time by
the surgeon which determined operating times, complications, analgesia
requirements and post-operative stay (Appendix 5.3). Analgesia post¬
operatively was oral or intramuscular opiate, according to the patients' wishes.
Follow-up was undertaken at a minimum of four months following the
operation and consisted of a self completed questionnaire identical to that at
recruitment with additional questions to determine satisfaction with, and
acceptability of treatment and also bladder and bowel function (Appendix 5.4).
After completing the questionnaire a consultation with a clinician was
undertaken to answer questions and to remind the patient that postal
questionnaires would be sent at one and two years post procedure.
Ill
Statistics
Data were entered onto a database created on SPSS for windows and all
analyses were undertaken using this programme or by InStat version 2
(GraphPad software). Analysis was by 'intention to treat', that is women
remained in the group to which they were originally allocated, irrespective of
subsequent treatment received. Independent and paired t-tests were used for
continuous variables (independent and related) with a normal distribution, and
the Mann-Whitney U test for ordinal or non parametric continuous variables.
The Chi-square or Fisher's Exact test were used for independent nominal data,
and McNemar's and Wilcoxon's rank sum tests for paired nominal data
describing dichotomous and related variables respectively.
RESULTS
Patient Characteristics
Two hundred and sixty three women were randomised, 129 to MEA and 134 to
TCRE. Table 5.1 summarises the pre-operative details of the participants, and
confirms the comparability of the groups at entry. Table 5.5 shows baseline
quality of life scores, which again are comparable except for the pain
component, which shows a significantly higher (better) score in the TCRE arm.
65% having MEA and 60% allocated TCRE described their periods as very
heavy, with 60% in both arms having their problem for over three years. The
sexual function of 56% and 51% respectively of these women was either
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severely affected or prevented by excessive bleeding with just over 20% in each
arm also complaining of dyspareunia. Bladder and bowel symptoms were also
comparable at baseline for each group (table 5.4)
Operative data
The treatment actually received and the operative details are summarised in
table 5.2. 8% of the MEA arm and 10% of the TCRE arm were sterilised at the
time of the procedure and are not included in operating times. Four women in
the MEA arm underwent TCRE as a result of failure of the microwave
equipment. Operative times for the microwave, which were significantly
quicker than TCRE, did not include the ultrasound examination (performed
immediately pre-operatively), but did include the hysteroscopic assessment.
The mean fluid absorption at TCRE was 318 mis, and no deficit over 1500 mis
occurred. Blunt perforations with an inactive hysteroscope and microwave
probe occurred once in each arm, which caused bleeding resulting in immediate
hysterectomy in one case. A false passage was created during dilatation on one
patient in the TCRE arm, necessitating abandoning the procedure to a later date.
No damage occurred to any organ other than the uterus in any of the cases.
Bleeding requiring the placement of an intra-uterine 14 gauge Foley catheter for
six hours occurred in five women in the TCRE group. Post-operative bleeding
occurred in three women who underwent TCRE which settled with
conservative management. Re-admission was required for three women in the
MEA arm with secondary haemorrhage which settled with conservative
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management using antibiotics and for one woman with pain. Four women
were re-admitted in the TCRE arm; two with pain and two to have repeat
procedures. The majority of women felt that they had fully recovered within
four weeks of their operation (72% of MEA, 66% of TCRE, p = 0.83).
It was noticed that when operating on women with submucous fibroids using
the microwave, a marked drop in temperature occurs when the probe tip
encounters the fibroid. With the probe maintained in the same position, a slow
rise and return to optimal operating temperature is observed, following which
the procedure can be completed.
Menstrual status at follow-up
Data are available for 145 women, 122 allocated MEA, and 123 to TCRE. The
remaining 18 women have failed to attend their follow-up visit and postal
questionnaires have been sent. Changes in bleeding, pain and related
menstrual symptoms are summarised in table 5.3. Both techniques lead to
highly significant, and equivalent reductions for all parameters relating to
menstrual pain and bleeding. Transcervical resection of the endometrium
achieved higher rates of amenorrhoea and fewer women who bled for more
than seven days per cycle. New pelvic pain was reported by 6% in each arm,
whilst dysmenorrhoea was highly significantly and equally reduced in both
arms. Pre-menstrual symptoms were significantly reduced by both techniques,
except for breast discomfort in the MEA arm, although no significant
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differences were detected between the two procedures. Both MEA and TCRE
lead to a highly significant reduction in work-days lost due to menstrual
symptoms.
Table 5.4 summarises urinary and bowel symptoms reported by participating
women at baseline and follow up. Rates of reported symptoms are similar for
both surgical techniques at follow-up and unchanged from baseline for bowel
symptoms, whereas urinary symptoms are generally reduced at four months.
Patient satisfaction
Patient satisfaction at four months is reported in table 5.5. Similar numbers in
each arm were totally or generally satisfied with the outcome and around 90%
in each arm found the treatment acceptable and would recommend it to a
friend. Women who felt that they were cured or had an acceptable
improvement in symptoms were also comparable following MEA or TCRE.
Health related quality of life
Table 5.6 and figure 5.1 show SF-36 scores at baseline and four month follow-
up. Values at baseline are comparable in both cohorts except for the pain
component of TCRE which has a higher (better) value. Scores are improved by
both techniques for all eight health scales and significantly so for all eight
following MEA and six following TCRE. Improvements are equivalent in both
groups except for the pain scores which show significantly better improvement
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following MEA. Figure 5.1 shows total baseline and follow-up scores in both
arms compared with normative values for healthy women of equivalent age in
the UK(148).
Sexual function was equally and significantly improved by both operations as
were rates of dyspareunia (Wilcoxon's rank sum test, both p< 0.001). At
baseline 5% of women in each arm could undertake leisure activities unaffected
by their periods. Following treatment, this was significantly improved to 54%
and 63% for MEA and TCRE respectively (Wilcoxon's rank sum test, both p<
0.001).
Effect of cavity size, fibroids and endometrial thickness on MEA results
These stratified analyses are summarised on table 5.7. Menstrual outcomes and
rates of satisfaction with and acceptability of treatment are no different when
cavity lengths of under 8cms are compared with those greater than 8cms in the
MEA arm. The menstrual outcomes of women treated by MEA who had
submucous fibroids of greater than 2 cms size were worse than those with
normal cavities though not significantly so. Of those women who regarded
their operation as unsuccessful at follow-up, the most prevalent feature
common to this group was the presence of an endometrial thickness of greater
than 4 mms measured by transvaginal ultrasound at operation. Women with a
body weight of greater than 80 kg were just as satisfied as those lighter (78% v
73%, p = 0.52). Amenorrhoea rates were 16% for those over 80 kg and 31% in
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women under this weight (p < 0.33), although mean bleeding scores were
identical at 8.2.
DISCUSSION
This is the first randomised trial to evaluate a non hysteroscopic endometrial
ablative technique. All of the operations were undertaken by two registrars
who were experienced hysteroscopic surgeons, and who had imdergone one
training session for MEA and performed five cases each prior to the trial. The
number of recruits, 263 women, easily satisfied the power study requirements
and should allow for drop-outs over the two years over which follow-up is
planned. Data on the missing eighteen subjects so far is being sought, though it
is known from gynaecological records that none have been re-admitted for any
reason. The only previous report of MEA(114), recruited women for operation
with careful pre-operative assessment to ensure normal sized, regular cavities.
This trial adopted a pragmatic(89,90) approach, and entry was based on a
subjective complaint of intolerable menstrual loss. Also ultrasound and
hysteroscopic assessment were not utilised unless clinical examination dictated,
or an endometrial biopsy could not be obtained. This policy, which reflected
normal clinical practice, sought to recruit a diverse population with
"dysfunctional uterine bleeding." This lead to some women with larger
cavities, and submucous fibroids being recruited, but should increase the
generalisability of the results.
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Operative details
An important factor regarding blind ablative techniques is that confirmation of
correct placement in the uterine cavity is ensured. This is easily achieved with
an ultrasound examination. In this study, gas hysteroscopy was undertaken to
determine the presence of fibroids and establish their effect on outcome. An
additional benefit of undertaking hysteroscopy was that subsequent placement
of the microwave probe in the uterine cavity was ensured. Despite this
additional procedure, MEA was significantly quicker than TCRE in both actual
operating and total theatre time. In addition no irrigation fluid is required,
although no problems were encountered with this in the TCRE arm (mean
deficit 318 mis). Times for TCRE are significantly faster than reported in
previous randomised controlled trials(105,106,109), but similar to more recent
Aberdeen data(131). Technical failures with the equipment arose significantly
more often in the MEA arm, necessitating four women having TCRE's instead.
Conversion from TCRE to MEA was not undertaken as the efficiency of the
microwave energy is compromised by the fluid milieu following initial glycine
irrigation. This was the reason why gas rather than fluid hysteroscopy was
used prior to performing MEA.
The perforation and hysterectomy rates in this trial were similar to previously
reported National audit's and studies(59,103,105,118), though importantly none
occurred with activated equipment and no damage resulted to any organ other
than the uterus. All other operative parameters were similar in both arms and
all women received peri-operative antibiotic cover. Post-operatively analgesia
requirements were low and equivalent with over 70% of women requiring no
pain relief. Similar numbers felt that they had fully recovered within four
weeks of their operation, although fewer than the 80% rate reported in a
previous Aberdeen study(106).
The temperature drops noted when encountering a fibroid are likely to result
from the increased blood flow in the fibroid creating a "heat sink" effect. This is
compounded by the different properties and increased density of myomatous
tissue when compared to endometrium.
Menstrual status
All parameters pertaining to menstrual blood loss were highly significantly and
equally improved by both techniques. The exception to this were the lower
amenorrhoea rates achieved with the microwave. Amenorrhoea is a useful
benchmark as it is the only objective outcome measure available when
menstrual blood loss is not formally measured. It should not be a principal
determinant of treatment success however as ablative techniques should be
offered to women who want lighter bleeding, as these women will be more
satisfied than those desirous of amenorrhoea(163). The amenorrhoea rate for
TCRE is comparable to that achieved at four month follow-up in the medical v.
TCRE trial in Chapter 3, and by other recent randomised controlled trials(107),
but higher than other randomised controlled trial and a national
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811(111(105,106,109,118). These rates, as with other outcome measures are lower
than those achieved in some uncontrolled series reports(100,102), and
specifically the only series describing MEA(114). This highlights the
importance of randomisation and the need for caution when evaluating results
of uncontrolled series reports. Results for women with larger cavities are
reassuring, although menstrual results may not be quite as good if fibroids are
present.
Dysmenorrhoea was markedly reduced by both procedures and new pain
reported by a small proportion (6%) of women, once again dispelling previous
reports of pelvic pain being a contraindication to endometrial destructive
surgery. As in previous reports(106,109,181), associated peri-menstrual
symptoms were significantly improved by both techniques, with TCRE leading
to the largest changes. Whether this is purely achieved through a lessening of
the anticipation of a heavy period, as has been suggested(161), or whether
removal of an unknown endometrial product has occurred(193), still awaits full
clarification.
Bowel symptoms at follow-up are unchanged, whereas urinary symptoms,
including incontinence are improved following both ablative technique.
Previous trials(109,189), have demonstrated little effect on urinary function
following TCRE or laser ablation, so it is difficult to explain these
improvements, especially the highly significant reduction in stress incontinence
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following TCRE. What is more important is that MEA did not lead to any
deterioration in bladder or bowel symptoms.
Satisfaction
Satisfaction with, and acceptability of treatment rates were high and
comparable for both techniques, and remarkably similar to previous trials
evaluating endometrial ablation(105-108) (including TCRE v. Medical treatment
in chapter 3). These high levels of satisfaction are sustained for MEA even for
women with larger cavities and with submucous fibroids.
Health related quality of life
Heavy menstrual loss is known to cause significant deterioration in general
health and quality of life(52,171,185) which has often been overlooked in the
evaluation of treatment in previous trials. This in part was due to the lack of a
validated measurement tool that was sensitive to change, had been assessed in
women with menstrual problems, and for which normative values for the
healthy population were known. Short form 36 fulfils all of these criteria and
hence its use in this study. The reduced SF-36 scores observed at baseline in this
trial are reduced for all eight subscales from the mean normative values for
women of equivalent age in the UK(148), and are comparable to previous
studies involving women with heavy menstrual loss(52). The SF-36 recruitment
scores from the study population in chapter 3 of this thesis, comparing TCRE
with medical treatment, are similar except for a higher social functioning score.
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The general health scale is least affected for these women with heavy menstrual
loss. The significant difference at baseline in the pain subscale scores between
the two groups is at odds with the menstrual pain scores (table 5.1).
Scores following MEA show improvement in six of the health scales to
normative values, social functioning and pain, although being significantly
improved from recruitment, remain below normal levels. Transcervical
resection of the endometrium returned three of the health scales to normal, and
significantly improved six of the eight variables. This is surprising when
compared to the TCRE / medical trial in Chapter 3 where all SF-36 scores were
returned to normative levels by TCRE at four months, although these were
women who were not initially referred for surgical treatment. The differences
in baseline scores of the pain subscale can be corrected for by using an analysis
of co-variance (ANCOVA) test when comparing change in scores. When
undertaken change in scores for this variable becomes 0.06 (from 0.03). Neither
change in scores, nor final total scores are significantly different for any of the
other SF-36 scales in the MEA and TCRE cohorts.
The differences between the SF-36 outcome results of the two trials undertaken
in this thesis should indicate that caution should be used before comparing
results of different study groups and questions the reliability of comparisons
with a reference "normal" population from a different part of the country.
Ideally normative reference data with range and mean values should be
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available for each region. The SF-36 questionnaire is however sensitive to
change over time for women with menstrual problems(52,53), and gives
meaningful results which are amenable to statistical analysis when making
comparisons of outcome for two or more treatments.
Sexual function and dyspareunia rates were similarly improved following both
techniques, these effect has been previously reported (105,149), whilst there was
also a highly increased ability to undertake leisure pursuits unaffected. The
reduction in the number of days off work, lost through menstrual symptoms, is
a major benefit of these techniques, as a substantial amoimt of money is lost
annually because of this.
Conclusion
This trial has shown that microwave endometrial ablation has achieved
satisfaction rates and improvements in menstrual symptoms comparable to
transcervical resection of the endometrium. The results were not as good as
obtained in an uncontrolled series report of MEA, but those women were pre¬
selected to have normal sized cavities and no fibroids. Importantly MEA led to
highly significant improvements in all eight health scales of the quality of life
questionnaire, short form 36. The advantages of MEA over TCRE are that the
operative technique is very easy to learn, hysteroscopic surgical skills are not
required, and it is safe for both operator and patient. The technique, even with
concomitant hysteroscopy is significantly faster than TCRE.
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A disadvantage of this and all other blind ablative techniques is the inability to
evaluate the endometrial cavity and obtain an operative, pathological specimen.
Although MEA, as with other ablative techniques, should never be undertaken
without first excluding endometrial atypia, there are reports in the literature of
endometrial carcinoma detected in resection specimens from TCRE despite
previous negative endometrial biopsy(154,155). Long-term follow-up of these
patients and investigation of any changes in bleeding patterns will be required
to establish rates of subsequent neoplastic change and mode of presentation.
After one year results are in fact similar to those at four months. Amenorrhoea
rates are however 39% for both techniques, with hysterectomy rates of around
8%. Complete description of the results after one year can be found in the
Lancet paper cited below
PUBLICATION
The above trial containing the one year results of "a randomised trial comparing
microwave endometrial ablation with transcervical resection of the
endometrium for women with heavy menstrual loss", will be published in the
Lancet in November/December 1999.
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Table5.1Baselinecharacteristicsofe chrandom edgroupec ui ent.V l snumb r(per entag )wo nu l statedotherwise Randomised M.E.A(n=129)
Randomised T.C.R.E.(n=134)
Meanage(S.D.)
41.1
(6.7)
41.
(8.4)
Weight/kg(S.D.)
68.5
(14.0)
72.9
(17.4)
Menstrualsymptoms irregularperiods
66
(51)
76
(57)
3-7daysbleeding
58
(45)
54
(40)
>7daysbleeding
70
(54)
80
(60)
>3daysheavybl eding
88
(69)
82
(64)
dysmenorrhoea
91
(72)
90
(68)
Sanitaryprotec ionrequired single
18
(14)
21
(16)
doubleormo
111
(86)
113
(84)
Bleedingscore-m an(S.D.)
28.5
(9.6)
28.0
(9.2)
Painscore-mean(S.D.)
19.1
(11.4)
17.0
(12.5)
Premenstrualsymptoms bloating
107
(87)
115
(87)
breastdiscomfort
94
(76)
1.3
(79)
irritability
104
(86)
117
(87)
headaches
88
(74)
93
(73)
depression
71
(62)
79
(61)
Workdayslostuetmenses none
13
(10)
20
(15)
none,butw rksuffers
54
(43)
52
(39)
one
14
(11)
12
(9)
twoormo e
46
(36)
49
(37)
N>
Ul
Table5.2Operativedet ilsforMEAndCRE.V luernumb rs(percentag )fwom nu l sotherwi est ed Randomised M.E.A(n=129)Randomised T.C.R.E.(n=134)
95%C.I.
fordifference
Pvalue
Meanc vitylengthi ms(S.D.)
7.4
(0.9)
7.5
(0.8)
-0.33to0.07
0.2
Submucousfibroids>2cm
14
(11)
18
(14)
-5to10%
0.1
Meanoperatingtimeininutes(S.D.)
11.4
(10.5)
15.0
(7.2)
-5.7to1 4
0.001
Totaltheatreimeininutes(S.D.)
20.9
(11.3)
26.2
(8.7)
-7.7to2 8
<0.001
Intra-operativeproblems abandonedprocedure
5
(4)
5
(4)
-4to5%
0.57
equipmentfail r
11
(9)
3
(2)
1to2%
0.02
bluntperforation
1
(1)
1
(1)
haemorrhage
0
(0)
5
(4)
Treatmentreceived MEA
124
(97)
1
(1)
TCRE
4
(3)
129
(96)
repeatTCRE
0
(0)
2
(1.5)
Hysterectomy
1
(1)
2
(1.5)
Post-operativeanalgesia none
90
(71)
99
(74)
-15to7%
0.48
oral
23
(18)
19
(14)
injectable
14
(11)
16
(12)
Meanpostopstayinhours(S.D.)
13.4
(17.6)
16.7
(21.2)
-8.0to1.5
0.17
Re-admitted
4
(3)
7
(5)
-7to3%
0.17
95%C.I.fordifference=confidenceint valsiff rm apr portions(%). ON
Table5.3
Menstrualstat sandymptomstfourmon hollow- p.Val emberfwom n(perce tages),unl sd Randomised M.E.A(n=122)Randomised T.C.R.E.(n=123)
95%C.I.
fordifference
Pvalue
Menstrualstat s unchangedorheavier
17
(14)
8
(7)
-0.1to15%
0.08
Durationofbleed
0.01
amenorrhoea
34
(27)
45
(37)
-20to2%
1-3days
21
(17)
11
(9)
0to17%
3-7days
51
(42)
62
(50)
-21to4%
>7days
17
(14)
5
(4)
2to16%
sanitaryprotect onrequired single
68***
(76)
59***
(76)
-12to14%
0.24
doubleormo
21
(24)
19
(24)
>3daysheavybl eding
13***
(11)
g***
(7)
-2to11%
0.43
Bleedingscore-m an(S.D.)
8.2***
(9.9)
6.4***
(6.4)
-4.8to1.7
0.36
Painscore-mean(S.D.)
5.1***
(5.2)
4.3***
(4.3)
-1.1to5.0
0.22
Dysmenorrhoea-samorw s
15***
(12)
(9)
-4to11%
0.68
Premenstrualsymp oms breastdiscomfort
80
(66)
74**
(63)
-6to18%
0.58
bloating
90*
(75)
76***
(64)
0to23%
0.07
irritability
74***
(62)
83***
(70)
-19to5%
0.18
headaches
56***
(47)
63***
(53)
-18o7%
0.38
depression
50**
(42)
45***
(39)
-8to17%
0.69
Workdayslostuetmenses none
60***
(67)
55***
(71)
none,butw rks ffers
27***
(19)
22***
(14)
one
4
(5)
4
(5)
-8to8%
0.85
twoormo e
g***
(9)
g***
(10)
erisksdenotechangfrombaselin(*p<0.05,
**p<0.01,*. 01)
95%C.I.fordifference=confidenceint valsiffm apr portions(%). N> vi
Table5.4Urinarydbowelsymptomsta elinef urmonths.V l rnumb rofw m n(perc tages)unl ssta d otherwise Randomised95%C.I.Pvalu M.E.A(n=122)T.C.R E.3fordifference UrinarySymptomsatbaseline frequency48(40)47
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Chapter 6
Conclusions
a summary of the conclusions from the thesis
and recommendations for future research
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Dysfunctional uterine bleeding exerts a significant burden on society. A large
proportion of women presenting for treatment of heavy menstrual loss have monthly
blood loss within the normal range, but still request help. Women complaining of
heavy menstrual loss, "menorrhagia", make up 5% of all general practice patients,
accounting for £7m of prescription charges(51) and up to 12% of new referrals to
gynaecology clinics(47). There is considerable uncertainty about how best to treat these
women and this is reflected by the variations in hysterectomy rates both nationally and
internationally. Within five years of referral to a gynaecologist, up to 60% will have
had a hysterectomy(49), and by the age of 55, 20% of women in the UK will have had a
hysterectomy(50).
The statistics quoted above were gathered before the widespread implementation of
endometrial destructive surgery. These endometrial ablative techniques were expected
to reduce the hysterectomy rate, butmay not have had the desired effect(138) and some
suggest an increase in operative interventions. The figures in table 6.1, however,
represent national data for all hysterectomies for menorrhagia and does not identify
those that were suitable for ablation. Local data, from areas with good uptake of
proven endometrial surgical techniques, are more appropriate for inspection and can
demonstrate a reduction in benign hysterectomies for menorrhagia(194). National data
may be further confused by a preference towards hysterectomy amongst senior
gynaecologists as the surgical procedure for menorrhagia(195), which may skew audit
results by affecting uptake of endometrial surgery in eligible women. Finally, the
availability of these less invasive techniques may also have attracted women for
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surgical treatment who would not have considered a hysterectomy, hence the
increasing numbers, although the possibility that treatment thresholds have lowered
cannot be discounted. There is now good long-term data which suggests that
hysteroscopic surgery is an acceptable alternative to hysterectomy and can replace it
for the majority of women with dysfunctional uterine bleeding(107,151).
Endometrial surgery has been promoted as an alternative to hysterectomy, to be used
once medical treatment has failed. Whilst this may be desirable it may not be an
entirely appropriate statement. The correct place of these ablative techniques in the
treatment armamentarium has yet to be established and can only be so once a
combination of factors are known. Epidemiological data, preference and outcome
expectations need to be ascertained, as do effect on health related quality of life. It is
known that heavy menstrual loss has a significant impact on health related quality of
life and this has been identified as an essential component of treatment outcome(51,91).
Finally randomised trials with appropriate outcome measures are required comparing
these techniques with non surgical managements of menorrhagia, and with ablative
techniques themselves.
This work undertaken in this thesis has attempted to address some of these deficits in
our knowledge. It has outlined the patterns of referral for women with heavy
menstrual loss and established local epidemiological features including, preference,
expectations and variations in health related quality of life. Present medical therapy
was compared with transcervical resection of the endometrium in the context of a
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randomised controlled trial, with both short and medium term results. Finally the first
randomised controlled trial comparing a "new generation" endometrial ablative
technique with transcervical resection of the endometrium was made. Operative and
short term outcomes of this trial comparing microwave endometrial ablation with
transcervical resection of the endometrium were presented. These two randomised
controlled trials and the epidemiological data should help clarify the role of
endometrial destructive surgery in the management of women with heavy menstrual
loss. This concluding chapter aims to summarise these results and to make
recommendations for the effective and efficient use of ablative surgery. Future trends
in endometrial surgery are discussed and areas for future research identified.
The opening chapter provided an overview of our present understanding of
menorrhagia, from aetiology and epidemiology to available treatments. Chapter 2
describes a survey of women complaining of heavy menstrual loss who were referred
to the gynaecologist for the first time. The aims were to obtain socio-demographic
data, epidemiological features, patterns of G.P. referral and treatment, treatment
preferences and expectations, and effect of menorrhagia on health related quality of
life. Whilst these aims were generally achieved, some of the methods and questions
used could be improved upon if the survey were repeated. A standardised tool for
measuring social class would be a useful addition, as would a questionnaire to the
referring general practitioner outlining reasons for referral and expectations.
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The generic health questionnaire, short form 36 is quite cumbersome both to complete,
collect and analyse. It has wide ranging mean values and standard deviations for the
population of women in the studies undertaken in this thesis. This can make
interpretation of between and intra group results difficult as without normative
reference values for the population under investigation, the actual item scores attained
can have little meaning. Acceptable alternatives are not easily found. The Nottingham
health profile(196), whilst quick to complete has not been evaluated for menorrhagia
and is not as sensitive to change as SF-36(197). EuroQol suffers from similar
problems(198), does not have normative values and has not been as widely evaluated
or utilised as SF-36 for women with heavy menstrual loss. Short form 36, despite its
deficiencies has been shown to be acceptable, sensitive and valid for baseline
measurement of and change in health for women with menstrual problems(54,171,197),
including women from Grampian(52,53). The shortened version short form-12 may
prove easier to complete and collect, but awaits full evaluation. An alternative might
be to use a condition specific questionnaire, as introduced in the Chapter 5(182),
although this was itself compared with SF-36 and meaningful reference values are not
available as it has only been administered to a relatively small population.
The results obtained for the socio-demographic and epidemiological data for Grampian
differed from that obtained from the large Oxford studies. Care must of course be
taken when comparing these populations which, although both from the UK, may
have fundamentally different characteristics. A lower proportion of out patient
referrals in Grampian were for heavy menstrual loss (6% v 15%). This may represent
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different referral patterns from primary care as fewer (21%) in this region had been
referred within one year of consultation and more (80% v 55%) had received medical
treatment before referral. Also the Grampian figures may be lower as only women
who were first time referrals with heavy periods, who had normal pelvic findings, and
who were not requesting a hysterectomy were counted, as opposed to all-comers with
heavy menstrual loss. A high proportion of women (64%) are disabled for more than
two days per cycle, despite the aforementioned treatment rates in primary care. These
statistics have enormous resource implications through work days lost and possibly
ineffective prescribing, making the initiation of effective and acceptable treatment at
primary care level a priority.
Rates of preference for a medical or surgical treatment were 30% which is slightly
lower than other reported data. More surprising is that equal numbers exhibited
preferences for either medical or surgical treatment. These women differed from each
other in many ways, essentially those preferring medical treatment were less severely
affected by there complaint and had it for a shorter length of time. Those preferring
surgical treatment had all received medical treatment before, were less well educated
as a group, and had greater desires for amenorrhoea. The traits of women who had no
strong treatment preference tended to fall between the two preference groups.
Women referred for the first time with heavy periods have mean health related quality
of life scores significantly lower than normative levels. Women with a strong
preference for medical treatment have SF-36 scores that are near normal and have little
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scope for improvement irrespective of type of treatment. It would be sensible to concur
with their wishes, or if necessary demonstrate that no treatment is required so that any
medical interventions with increased morbidity, which may not afford them tangible,
benefit are avoided. Those with a surgical, or no preference were equally debilitated
by their heavy periods with respect to quality of life.
It must be again stated that the socio-demographic and indeed short form 36 data
obtained for the women of Aberdeen who participated in the studies may not be
representative of women with similar complaints from other parts of the UK. Ideally,
population data should be available, and used, which is representative of the
geographical catchment area under investigation, although this is often not possible.
The results obtained from the survey in this thesis can however serve as a reference for
future Aberdeen studies on women with excessive menstrual loss.
Chapters 3 and 4 described a randomised comparison of transcervical resection of the
endometrium with traditional medical treatments for women first referred to a
gynaecologist with heavy menstrual loss. The aims here were to establish the role of
endometrial ablation in the management of this condition. Outcomes were determined
by measuring at four months and two years, patient satisfaction and acceptability of
treatment, changes to menstrual status, changes to health related quality of life and
additional treatments required. Whilst these aims have been satisfactorily achieved
there are a number of different ways in which this study could have been undertaken
or improved.
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The menstrual scoring system used in the trials in this thesis was inherited from
previous trials assessing TCRE in Aberdeen (106,109). They are effective in
demonstrating change of score and for comparing treatments, but the scores
themselves do not inform the reader of the actual level of blood loss. They have also
not been adequately validated for the population under investigation. Pictorial blood
loss assessment charts(34), which have high sensitivity and specificity when compared
to objective menstrual blood loss measurement, would have been a useful addition to
this study. It would have informed us of the actual incidence of true menorrhagia, the
range of loss, and perhaps allowed more meaningful comparisons to be made. One
drawback however is that sanitary pads and tampons have changed markedly over the
last ten years and the chart system may require re-validation. An alternative would be
to use the technique described by Gannon which has been validated and assessed for
women undergoing ablative surgery (157).
The initial follow-up of four months may have been too short. Women who agreed to
randomisation and were allocated medical treatment could have realised that the
ability to have a TCRE existed after quite a short time. This could be viewed as a
"hedging" option whereby if medical treatment was good, surgery was avoided, but if
not, then TCRE could be requested after a relatively short time. Secondly, it is
recognised that the full effect of ablative surgery may not become apparent until at
least six months post operatively. Results at four months may therefore have
underestimated the effect of TCRE. If a similar trial was to be undertaken initial
follow-up should be at least six months after entry.
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The criteria for eligibility for entry into the trial could also be regarded as controversial.
In order to maximise recruitment, given the recruitment time limit of one year, and to
remain as close to standard practice as possible it was decided to include all first time
referrals complaining of heavy menstrual loss irrespective of number of previous
medical treatments. It could be argued that it was wrong to offer more medical
treatment to a woman who may have had two different treatments from her GP, or
conversely, offer a TCRE to a woman who had no prior medical treatment. We felt that
this was countered by allowing those women with a strong treatment preference to
declare themselves, therefore if a woman conceded to randomisation then she was
truly ambivalent to the treatment allocation. Secondly it was important that women
who had varying degrees of medical treatment were recruited as we were attempting
to establish the place of ablative surgery in the management of menorrhagia. This was
previously thought to be once a trial of medical treatment had failed. It would have
been interesting to have limited the study to those who had no previous treatment
although this would not have been pragmatic and would have increased recruitment
time to almost five years.
Criticism could also be made as to the actual medications prescribed. Some would
argue that one predetermined optimal treatment should have been used. This was
deemed inappropriate as it would naturally exclude referred patients that had already
had this, therefore increasing recruitment time. Also this was not in keeping with the
pragmatic nature of the trial which was to test a policy of medical treatment, not a
specific medication. No patient received a treatment which had been shown to be
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ineffective in the management of menorrhagia. The absence however of the Mirena
intrauterine system does detract from the external validity of the results but it was not
licensed at the time of the trial for the treatment of menorrhagia. This treatment merits
a large comparative trial with an ablative technique in the future.
The outcomes at four months of the pragmatic randomised trial comparing medical
treatment with TCRE were described in chapter 3. This revealed that women allocated
to have TCRE were more likely to be totally or generally satisfied (76% versus 27%,
p<0.001), to find the treatment acceptable (93% versus 36%, p<0.001), and willing to
have the treatment again (93% versus 31%, p<0.001). Although pain and bleeding were
significantly reduced by medical treatment the effect was modest in comparison to
transcervical resection (p<0.001). Elaemoglobin levels were significantly increased only
following TCRE, although mean baseline levels were already within normal limits.
Short form 36 scores were improved in both arms, although only transcervical resection
returned them to normative values.
Medical treatment was less effective than transcervical resection of the endometrium,
irrespective of previous treatment or type of medical management received. Early
hysteroscopic endometrial surgery should therefore be considered by woman as initial
gynaecological treatment of their heavy menstrual loss. The treatment choice should
be made by the woman after a full discussion of the advantages and disadvantages of
all the available options.
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The results after two years consolidate the findings at four months, and also informs
us of the surgical outcomes of those who refused initial randomisation because of a
treatment preference. Women allocated medical treatment were significantly less
likely to be totally or generally satisfied (57% v 79%, p = 0.002), to find their
management acceptable (77% v 93%, p = 0.004), or to recommend their allocated
treatment (24% v 78%, p< 0.001). 59% of women in the medical cohort had undergone
TCRE, hysterectomy or both, whereas 17% in the TCRE cohort had undergone further
surgery. Bleeding and pain scores were similar in the groups and highly significantly
better than at recruitment. Short form-36 health survey scores were significantly
improved from baseline for five of the eight health scores in the medical arm, and
seven in the TCRE arm.
Early recourse to hysteroscopic surgery will afford women with dysfunctional uterine
bleeding better relief of symptoms and improvements in health related quality of life.
Reassuringly, over 80% of those managed by TCRE at the outset have avoided further
surgical treatment and the hysterectomy rate at two years in this group was less than
for those randomised to medical therapy (11% v 14%). This finding is particularly
important as there was concern that the introduction of ablative surgery might lead to
an increase in hysterectomy rates. The present recommendations stating that
hysteroscopic endometrial surgery should be offered once medical treatment has failed
cannot be upheld by these findings. An effective endometrial ablative technique
should be one of a selection of treatments offered to all women who have completed
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their family, with a diagnosis of dysfunctional uterine bleeding, irrespective of what
treatment, if any, she received in primary care.
The second generation endometrial ablative technique, microwave endometrial
ablation was compared in a randomised trial with transcervical resection of the
endometrium and is described in chapter 5. The aims of the trial were to establish the
effectiveness of MEA in terms of patient satisfaction with, and acceptability of the
procedure, changes in menstrual symptoms, changes to health related quality of life,
operative data and recovery times. These aims were achieved although some
improvements could be made if a similar trial was undertaken in the future. Prototype
equipment, such as our first microwave generator, is prone to breakdown which unless
large numbers of recruits are involved can significantly effect results. Comparative
trials should only commence once the final commercial model is available. In view of
the geography of Grampian region, post operative stay was often dependent on the
time of day that the operation took place. Ideally morning lists should be used to
determine recovery and discharge times accurately. Again four month follow-up was
used which is undoubtedly too early to assess menstrual outcomes properly. Six
months should be the first assessment of treatment outcome, if not one year. Follow-up
should continue ideally for at least five years to monitor outcome and longer still to
ensure no longer term deleterious events.
Microwave ablation was shown to be a significantly faster technique than TCRE (11.4 v
15 minutes, p = 0.001). Post operative stay was less following MEA, though not
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significantly so, whereas analgesia requirements were low and equivalent for both
techniques(< 30%). Troublesome bleeding occurred in five cases of transcervical
resection of the endometrium and no microwave cases. Technical difficulties arose
more frequently with the microwave equipment (9% v 2%, p = 0.02), but may have
been a result of the prototype equipment available for the trial. Satisfaction with
treatment rates were lower following microwave endometrial ablation but not
significantly so (74% v. 81%), whilst acceptability of treatment (92% v 94%) were
equivalent. Health related quality of life was highly significantly improved following
microwave ablation and less so by transcervical resection of the endometrium.
Both microwave endometrial ablation and transcervical resection of the endometrium
achieve high satisfaction and acceptability rates and both have improved quality of life
at four months. Microwave ablation is quick to perform, has low rates of morbidity
and is a simple technique to learn and use. In the short term microwave endometrial
ablation is a suitable alternative to transcervical resection of the endometrium,
particularly for those unable to attain or maintain advanced hysteroscopic surgical
skills. Longer term follow-up results are awaited from this trial at one, two and five
years before its true worth is known.
Overall the aims of the work undertaken in this thesis have been achieved and some
important findings have been made. These have been published as full original articles
in peer reviewed journals, as referenced at the end of each chapter, and contained at
the end of the thesis. One notable deficiency of the clinical trial work is the absence of
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a health economic evaluation of the treatment regimens under investigation. This
should form an integral part of any clinical evaluation nowadays, but funding was
unfortunately not available for a health economist at the time of the work. Despite this
the following paragraphs outline the most salient points of the thesis.
The incidence of gynaecological referral for women with heavy menstrual loss is about
8% for women in Grampian, which is lower than reported for other regions of the UK.
Disappointingly, one fifth of those referred have not been prescribed treatment in
primary care. As a population these women suffer from significantly reduced levels of
health related quality of life as assessed using Short Form 36. Levels of treatment
preference for medical or surgical treatment were equivalent and made up 30% of all
the women referred to a gynaecologist with menorrhagia. Women with a strong
preference for medical treatment were less severely compromised by their periods
compared to women with no treatment preference or a surgical preference.
Medical treatment as prescribed by the gynaecologist achieved low levels of
satisfaction, and acceptability when compared to TCRE. Similarly, menstrual
symptoms were significantly more improved following TCRE, as were all components
of health related quality of life. These results improved after two years for the medical
arm, although they remained significantly poorer than the TCRE cohort, although by
this stage almost 60% of those in the medical cohort had undergone TCRE,
hysterectomy or both. Hysterectomy rates after two years were lower in the TCRE
group than in the medical group(ll v. 14%). Women with a preference for TCRE had
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higher hysterectomy rates, whilst those preferring medical treatment had loe surgery
rates and no hysterectomies. The present recommendations for TCRE to be offered as
treatment following a failed trial of medication cannot be upheld by these findings.
Microwave endometrial ablation was compared to TCRE in a randomised trial and was
demonstrated to be faster to undertake and yet is safe and easy to learn. Outcomes, in
terms of satisfaction, acceptability, menstrual symptoms and health related quality of
life are comparable for the two techniques. It is important that hysteroscopy is
undertaken prior to MEA™ to confirm presence in the uterine cavity. MEA™ is also
capable of treating large and fibroid cavities. Results at one year reveal hysterectomy
rates of around 8% for both MEA™ and TCRE.
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THE FUTURE
Hysteroscopic surgical techniques have undergone more rigorous assessment in
randomised trials than any other surgical technique. Long term results are now
available and confirm the worth of these techniques. Table 6.2 confirms that the benign
hysterectomy rate for menstrual disorders has been reduced from over 600 to less than
500 a year in Aberdeen since the introduction of endometrial surgery. Unfortunately
uptake has been hesitant except in a few centres in the UK. This may represent a
healthy scepticism and need to examine the results of these trials, before adopting these
new procedures, but the surgical skills and training involved may also have put people
off.
The new generation ablative techniques, such as microwave, thermal balloon and
others have been introduced to simplify endometrial ablation, but these techniques
require strict evaluation. They undoubtedly are fast, less morbid techniques, that are
easy to learn and have the potential to be undertaken in the out-patient setting.
Unfortunately, like transcervical resection of the endometrium, none at present can
guarantee amenorrhoea whilst the long-term sequelae are yet to be fully explored.
Technical improvements hold the key to there future success. Decreasing instrument
diameters to reduce cervical manipulation will increase there acceptability in the out¬
patient setting. A prototype microwave probe is presently undergoing testing which is
5.5 mm diameter. Ensuring total endometrial destruction whilst maintaining strict
energy safety levels remains the ultimate quest, and whilst this can occasionally be
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achieved in a well prepared small regular cavity, it ideally should work on unprepared
and irregular cavities. Once these newer ablative techniques become available it opens
up the possibility of a definitive one stop investigate and treat, menstrual clinic in the
out-patient setting.
Safe and acceptable non surgical techniques which are effective in the long-term would
obviously be a major breakthrough in the management of menorrhagia. Unfortunately
no drugs have been appropriately assessed over an adequate length of time or indeed
in a pragmatic manner. The levonorgestrel intrauterine system offers the best
immediate non-surgical alternative, with the obvious advantage of maintenance of
fertility. Although it has been subjected to randomised controlled trials which show its
potential, uptake and continuation rates need to be determined. The future however
will probably see the emergence of totally new medical therapeutic concepts, such as
targeted immunological destruction of the endometrial glands using monoclonal
antibodies, photo-coagulative endometrial destruction which is undergoing
investigative work already, or even gene therapy.
The impact of introducing ever new techniques seems to increase the number of
procedures that are undertaken for menstrual dysfunction. Is this due to a lowering of
the treatment threshold, or have women become less tolerant of menstruation? There
is no evidence that the incidence of true menorrhagia has changed over the last fifty
years, although as family sizes decrease the number of periods experienced by
individual women are greater. Women have also become more informed of what is
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available and what is and is not perceived to be acceptable, through increased media
coverage of women's issues. This may have created a degree of "menstrual
intolerance" in developed countries which is driving up demands for effective
treatment modalities. If a safe, cheap out-patient treatment becomes available which
can guarantee amenorrhoea, will we witness an explosion of "cosmetic" endometrial
destruction?
The opposite approach is to investigate strategies to de-medicalise menstruation
through effective education and counselling of those with normal menstrual loss with
perceived menorrhagia. The difficulties here are many. Firstly, an effective and
acceptable method for measuring total menstrual blood loss needs be developed. Also
menstrual loss needs to be averaged out over a number of periods. Repeat testing is
required if on successful counselling, a perceived increase in menstrual severity is
subsequently reported. These along with maintaining a supply of trained and available
menstrual counsellors potentially make this a prohibitively expensive and
unacceptable option. Finally, this approach ignores the effect on quality of life that
even perceived menorrhagia can have on women. Despite these drawbacks this
technique deserves investigation as it represents the ultimate conservative treatment,
although it might not be without associated morbidity. A trial exploring some of these
ideas is underway in Oxford.
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AREAS FOR FUTURE RESEARCH
• to develop effective and acceptable ways of measuring menstrual loss
• exploring methods of patient education to impart information in an effective,
understandable and efficient way, in an effort to reduce treatment rates
• to assess the effect of lifestyle alteration e.g. diet and exercise on menstrual loss
• determining local epidemiological data to investigate the effect of the introduction
of management protocols, including continuous audit.
• investigation of genetic aetiological factors with a possible view to treatment in the
future
• identification, development and assessment of effective drug therapies
• rigorous evaluation of the most promising treatments in order to identify effective
options for the women with heavy menstrual loss
• investigation and development of alternative therapies specifically targeting the
endometrium, e.g. immunilogical.
• Assessment of the surgical treatment of heavy menstrual loss in the out-patient
setting.
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CONCLUSION
The demand for treatment of menstrual dysfunction is increasing. For the time being
the condition remains a subjective assessment of the severity of menstrual loss and the
known effect it has on the women's quality of life. Epidemiological data on menstrual
dysfunction and its treatment varies from region to region, but suggests a need for
implementation of management guidelines at primary care and secondary care levels.
These guidelines will require a rolling audit programme with appropriate unbiased
upgrading, to successfully rationalise care. Hysterectomy rates in the UK, whilst
relatively low when compared to other Western countries, are still rising and there is a
need to reduce them as the vast majority of uteri have no demonstrable pathology.
Hysteroscopic surgical techniques can lower hysterectomy rates and are widely
available, but have not been widely utilised.
Transcervical resection of the endometrium is, in addition, an effective and acceptable
first line treatment for women attending the gynaecologist with heavy menstrual loss.
It should not be withheld in suitable women in an effort to pursue medical therapy.
Endometrial destructive techniques have the ability to return health related quality of
life to normative levels, which, along with the prevention of anaemia, remains the
ultimate treatment goal. Whilst these endometrial techniques undergo refinement to
simplify them we must be vigilant to maintain their safety and effectiveness through
continuing scrutiny in well constructed trials. The very long-term sequelae of all of
these endometrial surgical procedures is unknown and particularly with the blind
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ablative techniques utilising different types of energy, it is important to follow-up those
treated to ascertain subsequent rates of gynaecological malignancy.
Women seeking treatment for their heavy menstrual loss should be provided with
appropriate information and investigation of their complaint based on the best
available evidence. Treatment, whether reassurance and counselling, medical or
surgical, should likewise be evidence based. The final treatment choice should
however be made by the women after full and informed consideration of the pros and
cons of all the available therapeutic options. In the meantime researchers should strive
to improve the investigative and treatment armamentarium of menstrual dysfunction
in an effort to reduce the morbidity associated with the condition itself and also of the
available treatment options.
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Table6.1Hospitalstatisticsf rbenignhysterectomyandendom trialla ioniEngl nd Yearnding19901991
1992
1993
1994
Hysterectomy
73280
70675
71630
73169
73517
Endometrialablation
1699
4224
7878
9982
9945
total
74979
74899
79508
83151
83462
Source:- HospitalEpisodeStatisticsV lum1:FinishedC ul ntdbydi gnosis,operationanc ality. Ul
Table6.2Hospitalstatisticsf rthurgicalm nagementfe or hagiaiAberde 19901991
1992
1993
1994
1995
1996
1997
Benignhysterectomy-anyroute
605
680
620
622
537
560
456
480
Endometrialabla ion
44
116
118
164
290
364
315
307
total
649
796
738
786
827
924
771
787
Source:- Informationman gementa dtechnology.Patientadministrationsyst .Aberd eRoy lH p lsNHST us ,1998 01 <_n
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Appendices
Appendix la Short Form 36
The following questions ask for your views regarding your health and how you feel about
life in general. Answer all the questions, if you are unsure then think about your overall
health and give the best answer you can.
1/ In general, would you say your health is ? (circle one)
excellent 1
very good 2
good 3
fair 4
poor 5
2/ Compared to four months ago, how would you rate your general health now ?
(circle one)
much better 1
somewhat better 2
about the same 3
somewhat worse 4
much worse 5
3/ The following questions are about activities you might do during a typical day. Does your
health limit you in these activities ? If so, how much ?
(circle one number for each question)
YES, YES, NO, NOT
ACTIVITIES LIMITED LIMITED LIMITED
A LOT A LITTLE AT ALL
a/ vigorous activities, such as running, lifting
heavy objects or strenuous sports ? 12 3
b/ moderate activities such as moving a table,
hoovering,bowling or golf ? 12 3
c/ lifting or carrying groceries ? 12 3
d / climbing several flights of stairs ? 12 3
e/ climbing one flight of stairs ? 12 3
f/ bending, kneeling or stooping ? 12 3
g/ walking more than a mile ? 12 3
h/ walking half a mile ? 12 3
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1/ walking 100 yards
)/ bathing or dressing yourself
4/ During the past 4 weeks , have you had any of the following problems with your work or
other regular daily activities as a result of your physical health ?
(circle one number for each question )
a/ cut down on the amount of time you spent
on work or other activities ?
b/ accomplished less than you would have
liked ?
c/ were limited in the kind of work or activities
?
YES NO
d/ had difficulty performing the work or other
activities (e.g. it took extra effort)?
5/ During the past 4 weeks , have you had any of the following problems with your work or
other regular daily activities as a result of any emotional problems ( such as feeling depressed or
anxious)?
YES NO
a/ cut down on the amount of time you spent
on work or other activities ? 12
b/ accomplished less than you would have 1 2
liked ?
c/ didn't do work or other activities as carefully
as usual ? 12
6/ During the past 4 weeks, to what extent has your physical health or emotional problems
interfered with your normal social activities with friends, family or groups ?
(circle one)
not at all 1
slightly 2
moderately 3
quite a bit 4
extremely 5
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7/ How much bodily pain have you had in the past 4 weeks ? (circle one )
none
very mild
mild
moderate
severe
very severe
.1
.2
.3
.4
.5
.6
8/ During the past 4 weeks, how much did pain interfere with your normal work
(including both work outside the home and housework ) ? ( circle one )
not at all
a little bit
moderately
quite a bit
extremely
.1
.2
.3
.4
.5
9/ These questions are about how you feel and how things have been with you during the past 4
weeks.
For each question, please give the one answer that comes closest to the way you have been
HOW MUCH TIME IN All of Most of A good Some of A little None of
THE LAST 4 WEEKS the time the time bit of the time of the the time
the time time
a/ did you feel full of life ?
b/ have you been nervous
7
2
2
3
3
4
4
5
5
c/ have you felt so down in
the dumps that nothing 1
could cheer you up ?
d/ have you felt calm and 1
peaceful ?
e/ did you have a lot of 1
energy ?
f/ have you felt 1
downhearted and low ?
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g/ did you feel worn out ? 1 2 3 4 5 6
h/ have you been happy ? 1 2 3 4 5 6
1/ did you feel tired ? 1 2 3 4 5 6
10/ During the past 4 weeks, how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting with friends, relatives ,etc.) ?
(circle one)
all of the time 1
most of the time. 2
some of the time 3
a little of the time 4
none of the time.... 5
11/ How TRUE or FALSE is each of the following statements for you
(circle one number for each question)
DEFINITELY MOSTLY DON'T MOSTLY DEFINITELY
TRUE TRUE KNOW FALSE FALSE
a/ I seem to get
ill more easily
than other people
b/ I am as
healthy as
anybody I know
c/ I expect my
health to get
worse
d/ My health is
excellent
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Appendix lb
Hospital Anxiety and Depression Scale
tick one box for each question
I feel tense or wound up
most of the time
a lot of the time
occasionally
not at all
I still enjoy the things I used to
definitely not as much
not quite as much
only a little
hardly at all
I get a sort of frightened feeling as if
something awful is about to happen
very definitely, and quite badly
yes, but not to badly
a little, but it does'nt worry me
not at all
I can laugh and see the funny side of
things
as much as I always could
not quite so much now
definitely not as much now
not at all
Worrying thoughts go through my mind
a great deal of the time
a lot of the time
from time to time, but not too often
only occasionally
I feel cheerful
not at all
not often
sometimes
most of the time
I can sit at ease and feel relaxed
definitely
usually
not often
not at all
I feel as if I'm slowed down
nearly all the time
very often
sometimes
not at all
I get a sort of frightened feeling like
butterflies in my stomach
not at all
occasionally
quite often
very often
I have lost interest in my appearance
definitely
I donut take as much care as I should
I may not take quite as much care
I take just as much care as ever
I feel restless as if I have to be on the
move
very much indeed
quite a lot
not very much
not at all
I look forward with enjoyment to things
as much as I ever did
rather less than I used to
definitely less than I used to
hardly at all
I get sudden feelings of panic
very often
quite often
not very often
hardly at all
I can enjoy a good book or TV
programme
often
sometimes
not often
very seldom
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Appendix lc
Semantic Differential Technique
The following questionnaire involves marking a score on a scale between two opposite words
(e.g. good and bad) to find out what you felt about the procedure you have just had. The words
represent different ways you may feel about the procedure. If you think that a pair of words are
not relevant, or it is neither one nor the other, then mark the central '0' rather than missing it out.
Put one circle around your score on each line
e.g. if you thought the procedure was slightly unpleasant you might circle the number 1 in that
line
painless -3 -2 0 2 3 painful
happy -3 -2 0 2 3 sad
good -3 -2 0 2 3 bad
pleasant -3 -2 0 2 3 unpleasant
positive -3 -2 0 2 3 negative
safe -3 -2 0 2 3 dangerous
attractive -3 -2 0 2 3 unattractive
mild -3 -2 0 2 3 harsh
agreeable -3 -2 0 2 3 disagreeable
active -3 -2 0 2 3 passive
easy -3 -2 0 2 3 hard
fast -3 -2 0 2 3 slow
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Appendix 2.1
Socio-demographic Questionnaire.
Unit number Post Code
We are conducting a survey in the gynaecology department to find out if we need to
change the service that we provide for you. We are particularly interested in women
who are coming to see us for the first time with heavy periods. We would be very
grateful if you could complete this anonymous questionnaire which will help greatly
our efforts to improve the service we provide.
(Tick one box for each question)
1. What age group are you in? 20 - 29
30-39
__
40-49
50 or over
2. Do you have children? none
one
two
more than two
3. How old were you when you completed 16 or less
your education? 17 to 18
19 or over
4. Are you working? student
unemployed
part-time
full-time
housewife
5. Which group fits you best? single
married / cohabiting
widowed / separated
6. What kind of house do you live in? rented
council
own flat
own house
other (describe below)
7. Do you smoke? no
less than ten a day
more than ten a day
8. How long have you had heavy periods? Less than six months
6-12 months
more than a year
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9. Have you seen a doctor, prior to this episode,
regarding your heavy period?
yes
no
10. If yes, did the doctor prescribe tablets for them? yes
no
11. Did you take the tablets as prescribed? always
sometimes forgot
often forgot
stopped them
12 How many days each month do your periods none
stop you from performing normal daily activities? one day
two days
more than two days
13. Following treatment for your heavy periods, what improvement in your symptoms
do you expect?
bleeding: lighter periods
no bleeding at all
pain: less painful periods
no pain at all
answer question 14 only if you are not taking part in the trial comparing medical
treatment with the transcervical resection of the endometrium (TCRE).
14. Did you feel unable to participate in the study
comparing medical treatment to TCRE because -
you do not agree with medical trials?
it would take up too much time?
you specifically wanted a certain treatment?
you did not want any treatment?
you wanted the doctor to choose your treatment?
other - (describe below)
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Appendix 2.2
Reasons for Preference
You have told us that you have a strong preference for a particular from of
management for your heavy periods.
What things were important in making you decide this?
1. The treatment was recommended by my family doctor yes
no
2. The treatment was recommended by a friend yes
no
3. I read about it in a magazine / saw it on TV yes
no
4. I did not want to take tablets at all yes
no
5. I did not want an operation at all yes
no
6. I have tried tablets and they did not work yes
no
7. Other reasons - please write below
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Appendix 3.1
TRANSCERVICAL RESECTION OF THE ENDOMETRIUM ( T.C.R.E.)
WHAT IT IS :
T.C.R.E. is an operation which has become available for treating heavy periods. Instead
of removing the whole womb, only the lining of the womb (endometrium) is removed.
Rather than stopping the periods completely, although this does happen in some
women, this operation makes your periods much lighter. Unless you have been
sterilised already , there is still a chance of becoming pregnant after the operation, so
you must continue using contraception. However , a sterilisation operation can be
carried out at the same time as the T.C.R.E. if desired.
HOW IS IT DONE :
T.C.R.E. is usually done under a general anaesthetic and takes about 20 - 30 minutes.
No cuts are required. When you are asleep, a telescope is passed through the neck of
the womb (cervix) which allows the surgeon to see inside the womb. The womb is
filled with fluid to help see clearly. The operation can then be performed by removing
the endometrium from the whole of the inner surface of the womb. This is done using
diathermy (an electric current) with a small metal loop passed down the telescope. The
operation is easier if the endometrium is thin. Five weeks before the operation you will
receive a drug which will make the endometrium thin.
It is important for you to be aware that, like any other operation, unexpected problems
sometimes occur. During the operation, there is a slight possibility that some damage
might be done to the wall of the womb. This usually means that the operation cannot
be completed, but there is a very small risk that a bigger operation (such as a
hysterectomy) might need to be carried out. This is only done if absolutely necessary.
WHAT TO EXPECT IMMEDIATELY AFTERWARDS :
When you wake up you may feel some cramp, like a period pain, and have some
bleeding. Rarely, you may wake up with a catheter in the bladder or the womb. This is
put in if you have absorbed fluid from the operation or if there has been bleeding, but
is removed after a short time. Most women go home the same, or the next day.
WHAT HAPPENS AFTER GOING HOME ?
You may have some cramps for a few days. While the inside of the womb is healing ,
you will have a discharge from the vagina. This may last a few weeks and be quite
watery, but this is normal. If it becomes nasty smelling and you get pain with it, then
you should see your own doctor in case there is some infection. This is easily cleared
up by a course of antibiotics. About one month after the operation it is usual to have a
bleed like a period; this does not mean the operation hasn't worked.
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WHEN CAN I GO BACK TO WORK ?
You can return to all normal everyday activities as soon as you feel able. The average
time to get over this operation is 2 weeks.
WHEN WILL I KNOW IF THE OPERATION HAS BEEN A SUCCESS ?
Some people have no bleeding at all after this operation . More commonly the periods
get gradually lighter over a few months, so if the first two periods don't seem much
better, then it is worth waiting to see what happens over the next few months. In a few
women, however, the lining of the womb grows back and the periods continue to be
heavy. If this happens repeating the procedure can be successful, although we would
discuss options with you.
WHAT ABOUT THE FUTURE ?
You will still need to have cervical smears as the neck of the womb is still present.
When you reach the menopause, this operation does not prevent you from taking
hormone replacement therapy, but discuss with your doctor which would be the best
to take.
If you have any further questions, please ask to speak to one of the doctors.
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Appendix 3.2
PATIENT INFORMATION SHEET
TRIAL OF MEDICAL TREATMENT VERSUS T.C.R.E. FOR HEAVY PERIODS
Your doctor has referred you to see a gynaecologist because of your heavy periods.
Now that you have seen the specialist, you will have discussed the treatment options
available to you (medical or surgical). There are a number of medical treatments
available that can help your problem (these involve taking tablets). You may have to
continue taking the tablets to keep the periods light. Surgical treatment includes
hysterectomy, which is not felt necessary for you at present, or transcervical resection
of the endometrium (T.C.R.E.). The other information sheet you were given explains
how T.C.R.E. works and how it is performed. This operation can reduce your heavy
monthly bleeding.
Both medical treatment and T.C.R.E. are recognised treatments for women with heavy
periods, but at the moment it is not possible to say which one is better. To find out
what is the best treatment, doctors need to perform a study. The most effective way to
carry out this study is to ask women to have their treatment chosen by chance. This
means that you would have a 50:50 (equal) chance of receiving either tablets or
T.C.R.E..
If you are to receive medical treatment then the gynaecologist who saw you will
prescribe a course of tablets for you. An explanation of how the tablets work, how they
are taken and possible side effects will be given. The treatment should be continued for
four months if possible. If you are to have a T.C.R.E., then arrangements will be made
for you to have your operation in 6 - 8 weeks. Four months after your treatment you
will be seen again to find out how effective and acceptable it has been. You can
withdraw from the study at any time if you wish.
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Appendix 3.3
TCRE / medical: recruitment questionnaire.
Study number Date of birth
Height (cms)
1. Marital status
Weight (kg)
2. How long have you had heavy periods for?
3. Are your periods regular? (once a month)
4. How long is it from the first day of one period
to the first day of the next?
5. How long do your periods last?
6. For how many days is the period heavy?
7. Are your periods painful?
8. If painful, for how many days do you have pain?
9. Do you take pain-killers for period pain?
single 1
married 2
steady partner 3
separated 4
divorced 5
widowed 6
yes
no
more than six weeks
four to six weeks
three to four weeks
less than three weeks
totally unpredictable
less than three days
three to five days
five to seven days
seven to ten days
more than ten days
no bleeding at all
yes
no
sometimes
yes
no
Less than six months 1
six to twelve months 2
one to two years 3
two to five years 4
over five years 5
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10. For each day of your period please show how severe the symptoms were
by giving a score of between 1-5 (1 = mild bleeding or pain, 5 = the worst
bleeding or pain you can think of)
Day of period bleeding score pain score
1
2
3
4
5
6
7
8
9
10
11. Do you work? yes
no
12. Do you take time of work with each period? yes
no
(if no go to question 15 ) sometimes
13. How many days off do you take on average?
14. Is this because of pain, bleeding, or both? pain
bleeding
both
15. Do you get any of the following symptoms before or during a period?
Yes
1
breast discomfort
bloatedness
irritability
headaches
depression
16. Do you get hot flushes or sweats? yes
no
sometimes
17. Do you have pain at intercourse?
18. Have you had any drug treatment from your
doctor for your heavy periods?
19. If treated, which of the following tablets have you used,
and what did they do for you?
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yes no
non-steroidal (e.g. Ponstan, Brufen)
progestogens (Provera, Primolut)
danazol (Danol)
tranexamic acid (Cyclokapron)
ethamsylate (DicyneneO
combined pill (contraceptive pill)
other - please specify below
none 1
condoms 2
diaphragm 3
combined pill 4
mini pill 5
coil 6
sterilised 7
partner had vasectomy 8
depot provera 9
20. What contraception do you use?
21. How many children have you had?
22. Have you had any gynaecological operations? no
d & c
sterilisation
caesarean section
laparoscopy
cone biopsy
other - describe below
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Appendix 3.4 TCRE / medical: four month follow-up questionnaire.
1. Following your treatment have your periods stopped?
continued, but lighter?
stayed the same?
if your periods have stopped go to question 8 continued, but heavier
2. How long is it from the first day of one period
to the first day of the next?
more than six weeks
four to six weeks
three to four weeks
less than three weeks
totally unpredictable
3. How long do your periods last? less than three days
three to five days
five to seven days
seven to ten days
more than ten days
4. For how many days is the period heavy?
5. Do you have pain with your period? no
less than before
same as before
worse than before
6. If painful, for how many days do you have pain?
7. Do you take pain-killers for period pain? yes
no
8. For each day of your period please show how severe the symptoms were by giving a score
of between 1-5 (1 = mild bleeding or pain, 5 = the worst bleeding or pain you can think of)
Day of period bleeding score pain score
1
2
3
4
5
6
7
8
9
10
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7. Do you take time of work with each period? yes
no
sometimes
8. Do you get any of the following symptoms before or during a period?
Yes
breast discomfort
bloatedness
irritability
headaches
depression
9. Do you get hot flushes or sweats?
10. Do you have pain at intercourse?
11. Since treatment are you experiencing any
new or different pelvic pain?
yes
no
sometimes
never
sometimes
often
always
does not apply
no
sometimes
continually
12. Overall, what effect has the treatment had on worse
your symptoms? no effect
improved, but not sufficiently
improved to an acceptable level
cured completely
13. Did you find the treatment acceptable?
14. If not acceptable, then why was this?
tick all that apply
yes
no
treatment unpleasant
did not help the bleeding
did not help the pain
side effects were bad
did not want any periods
other - please describe below
1
2
3
No
2
1
2
3
4
5
1
2
3
1
2
3
4
5
1
2
3
1
2
3
4
5
1
2
1
2
3
4
5
6
15. If you ticked side effects for question 14, please write what they were below
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16. If your treatment involved taking tablets, did you
always take them as prescribed
occasionally missed them
regularly missed them
stopped them
17. Would you be prepared to continue with the same
treatment or have it again if necessary
yes
no
18. Please indicate how you would rate your overall satisfaction with your treatment.
( please circle the number that is closest for you )
totally
satisfied
generally
satisfied
fairly
satisfied
fairly
dissatisfied
generally
dissatisfied
totally
dissatisfied
19. Please indicate the severity of your symptoms now
( please circle the number that is closest for you)
1
none
2
mild moderate severe very severe
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Appendix 4. TCRE / medical: two year follow-up questionnaire.
Your original treatment in this trial was.
1. Have your periods
if your periods have stopped go to question 8
2. How long is it from the first day of one period
to the first day of the next?
3. How long do your periods last?
stopped? 1
continued, but lighter? 2
stayed the same? 3
continued, but heavier 4
more than six weeks 1
four to six weeks 2
three to four weeks 3
less than three weeks 4
totally unpredictable 5
less than three days 1
three to five days 2
five to seven days 3
seven to ten days 4
more than ten days 5
4. For how many days is the period heavy?
5. Do you have pain with your period? no
less than before
same as before
worse than before
6. For each day of your period please show how severe the symptoms were by giving a score
of between 1-5 (1 = mild bleeding or pain, 5 = the worst bleeding or pain you can think of)
Day of period
1
2
3
4
5
6
7
8
9
10
bleeding score pain score
192
7. Do your periods stop you from carrying out
your work, housework or daily activities?
8. What further treatment have you had for your
periods since the original treatment you were given
in the study (see start if you can't remember)
9. Do you get any of the following symptoms
before or during a period?
breast discomfort
bloatedness
irritability
headaches
depression
10. Do you have pain at intercourse?
no, not at all
no, but work suffers
yes, but only one day
yes, more than one day
none
different tablets
TCRE operation
repeat TCRE
hysterectomy
Yes
1
11. Since treatment are you experiencing any
new or different pelvic pain?
no
yes, but less than before
yes, the same as before
yes, worse than before
no
sometimes
regularly
12. Overall, what effect has the treatment had on worse
your symptoms? no effect
improved, but not sufficiently
improved to an acceptable level
cured completely
13. Did you find the treatment acceptable? yes
no
14. What treatment would you recommend
to a friend with heavy periods?
medical (tablets) 1
TCRE operation 2
hysterectomy 3
none 4
15. Please indicate how you would rate your overall satisfaction with your treatment.
( please circle the number that is closest for you )
1 2 3 4 5 6
No
2
1
2
3
4
5
1
2
3
4
1
2
3
1
2
3
4
5
1
2
totally
satisfied
generally
satisfied
fairly
satisfied
fairly
dissatisfied
generally
dissatisfied
totally
dissatisfied
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Appendix 5.1 PATIENT INFORMATION SHEET
study of transcervical resection of the endometrium (T.C.R.E). versus microwave
endometrial ablation (M.E.A.)
Each month a lining (endometrium) forms inside the womb and is shed as your period.
Sometimes this bleeding can become heavy and even unpredictable. Removing this
lining can result in periods stopping altogether or becoming lighter. It has been
decided that this is the most appropriate treatment for your heavy periods.
There are many different ways of removing the endometrium. They are all performed
by passing an instrument up through the neck of the womb (cervix) whilst you are
asleep. The commonest method at present is to perform a T.C.R.E. which involves
removing the lining using a small electric loop. This has been proven to be a successful
and acceptable treatment. A newer method of removing the lining has been developed
which involves using a small microwave probe (M.E.A.). The energy waves produced
cause the endometrium to be destroyed to a similar depth as T.C.R.E.. This new
microwave technique seems to be just as effective and safe at treating heavy periods as
T.C.R.E., but it may be quicker and easier to use.
To find out how useful M.E.A. is doctors need to do a study. If you were to take part in
the study you would be allocated to having one or other operations by chance. This
means that you would have a 50:50 chance of having a T.C.R.E. or a M.E.A.. We would
ask you to complete questionnaires before the operation and at six and twenty-four
months afterwards. These would allow us to find out how effective M.E.A. is at
treating heavy periods and also how acceptable it is. You would be able to withdraw
from the study at any time if you wished.
It is important to add that neither operation guarantees that you can not fall pregnant
in the future, although it is unlikely. If you wish, a sterilisation can be performed at the
same time as the operation which should not increase your stay in hospital.
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Appendix 5.2 M.E.A. versus T.C.R.E. trial: recruitment questionnaire
Unit number
Date of birth
Parity
Study number
Date of clinic
Weight (kg)
1/ How long have you had trouble with your periods?
2/ On average, are your periods regular or irregular ?
3/ How many days are there from the first day of one
period to the first day of the next ?
4/ Would you describe your periods as
51 On average, for how many days does your period
last ?
6/ On average, for how many days is the bleeding
heavy ?
less than 1 year
1 to 3 years
more than 3 years
regular
irregular
less than 21
21 to 35
more than 35
light
moderate
heavy
very heavy
less than 3 days
between 3 and 7 days
between 8 and 10 days
more than 10 days
not heavy
1 to 3 days
4 to 6 days
7 or more days
1
2
3
1
2
1
2
3
1
2
3
4
1
2
3
4
1
2
3
4
7/ Imagine an average period for you ; for each day please show how severe your
bleeding and pain were by giving each day a score from 1 to 5
(1 is mild bleeding/pain, increasing up to 5, the worst bleeding/pain you can think of)
Day of Period Bleeding score Pain score
1
2
3
4
5
6
7
9
10
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8/ Are your periods usually painful ? yes
no
9/ Do your periods stop you from carrying out
your work, housework or other daily activities ?
10/ Do your periods interfere with leisure activities ?
11/ Do your periods affect your sex life ?
12/ At any time in the last three months, have you
needed to use more than one form of protection
at the same time
no, not at all
no, but work suffers
yes, but only one day
yes, more than one day
no, not at all
mildly affected
moderately affected
severely affected
totally prevents it
no, not at all
mildly affected
moderately affected
severely affected
totally prevents it
no
tampon and pads
two pads
tampon and two pads
more than this (e.g. towel)
13/ Do you get any of the following symptoms just before or during a period ?
Yes No
breast discomfort
bloatedness
irritable
headaches
depression
14/ Do you have any of these bladder problems ?
a/ leaking when coughing or straining
b/ leaking before you make it to the toilet
c/ going frequently (more than 7 times/day)
d/ getting up more than once a night
15/ Do you have problems with your bowels ?
Yes No
none
constipation
diarrhoea
16/ Is sexual intercourse usually painful for you ? Yes
No
Appendix 5.3 M.E.A. versus T.C.R.E. study
Operative Questionnaire
Please complete the relevant portions of this questionnaire at the time of the operation and
then put it in the case notes. The clinical research fellow will complete the rest of it and make
follow up arrangements.
Operative Details for coding yes = 1 no = 2
Day Case Yes / No Study number
Antibiotics Yes / No Unit number
Randomised M.E.A.(1) / T.C.R.E.(2) Date of operation
1 / Operating time taken mins
2/ Total time (operating and anaesthetic) mins
3/ Intraoperative complications ?
if yes, tick appropriate boxes
Yes / No
failed instrumentation
uterine perforation
inadequate view
haemorrhage
equipment failure
bowel damage
urinary tract damage
fluid overload
major vessel damage
uterine catheter required
other (specify below)
4/ If uterine perforation occurred was it with sound 1
with dilator 2
with hysteroscope 3
with M.E.A. probe 4
with resectoscope 5
5/ Procedure abandoned ? Yes / No
6/ For T.C.R.E., fluid deficit post procedure mis
7/ Laparoscopy performed ? Yes / No
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8/ If yes, was this planned diagnostic 1
emergency diagnostic 2
sterilisation 3
L.U.N.A. 4
9/ Actual treatment received ?
10/ Findings at hysteroscopy ?
11/ If fibroids how many > 2cms ?
12/ Cavity length cms
13/ Postoperative complications ? Yes / No
if yes, what ?
M.E.A.
T.C.R.E.
Hysterectomy
Normal cavity
Irregular cavity
Submucous fibroid
Uterine septum
Chest infection
U.T.I.
Return to theatre
D.V.T.
P.E.
Pulmonary oedema
Uterine bleeding
Uterine infection
Admitted to I.T.U.
Other, explain below
1
2
3
1
2
3
4
1
2
3
4
5
6
7
8
9
10
14/ Was post operative pain relief required on the ward? Yes / No
1
2
3
15/ Post operative hospital stay days nights total hours
16/ Was readmission required ? Yes / No
if yes, why ?
if yes, what was the strongest required ? Oral
Suppository, e.g. Voltarol
Injectable
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Appendix 5.4 M.E.A. versus T.C.R.E. study: 4 month follow-up questionnaire
Unit number
Date of clinic
Study number
It is now four months since your operation for heavy periods. We would be grateful if you
would complete the following questionnaire for us.
1/ How long after the operation did you feel that
you had completely recovered ?
2/ When were you able to return to your normal
everyday activities (housework, work etc.)
3/ Have your periods
* if stopped, then go straight to question 13*
4/ How many days are there from the first day of
one period to the first day of the next ?
5/ On average, for how many days does your
period last ?
6/ On average, for how many days is the bleeding
heavy ?
7/ Do you have pain with your period ?
1 have not recovered yet
less than 2 weeks
2 to 4 weeks
4 to 8 weeks
2 to 3 months
3 to 4 months
less than 2 weeks
2 to 4 weeks
4 to 8 weeks
2 to 3 months
3 to 4 months
still unable
stopped
continued but lighter
continued as before
continued but heavier
less than 21
21 to 35
more than 35
less than 3 days
between 3 and 7 days
between 8 and 10 days
more than 10 days
not heavy
1 to 3 days
4 to 6 days
7 or more days
no
less than before
same as before
worse than before
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8/What is an average period like for you now ? For each day please show how severe your
bleeding and pain are by giving each day a score from 1 to 5
(1 is mild bleeding/pain, increasing up to 5, the worst bleeding/pain you can think of)
Day of Period
1
2
3
4
5
6
7
8
9
10
Bleeding score Pain score
9/ Do your periods stop you from carrying out
your work, housework or other daily activities ?
10/ Do your periods interfere with leisure activities ?
11/ Do your periods affect your sex life ?
12/ At any time in the last three months, have you
needed to use more than one form of protection
at the same time
no, not at all 1
no, but work suffers 2
yes, but only one day 3
yes, more than one day 4
no, not at all 1
mildly affected 2
moderately affected 3
severely affected 4
totally prevents it 5
no, not at all 1
mildly affected 2
moderately affected 3
severely affected 4
totally prevents it 5
no 1
tampon and pads 2
two pads 3
tampon and two pads 4
more than this (e.g. towel) 5
13/ Do you get any of the following symptoms just before or during a period ?
Yes No
breast discomfort
bloatedness
irritability
headaches
depression
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14/ Do you have any of these bladder problems ?
a/ leaking when coughing or straining
b/ leaking before you make it to the toilet
c/ going frequently (more than 7 times/day)
d/ getting up more than once a night
e/ having to run to the toilet quickly
Yes No
15/ Do you have problems with your bowels ? none
constipation
diarrhoea
1
2
3
16/ Is sexual intercourse painful for you ? no
yes, but less than before
yes, the same as before
yes, worse than before
1
2
3
4
17/Since the operation are you experiencing any
new or different pelvic pain ?
no
sometimes
regularly
continually
1
2
3
4
18/ Overall, what effect has the operation had on your symptoms ?
No effect
improved, but not sufficiently
improved to an acceptable level
cured completely
1
2
3
4
19/ Did you find the operation acceptable ? Yes
No
20/Would you recommend this treatment to a friend with heavy periods
Yes
No
21/ Please indicate how you would rate your overall satisfaction with your treatment.
( please circle the number that is closest for you )
1
totally
satisfied
generally
satisfied
3
fairly
satisfied
4
fairly
dissatisfied
generally
dissatisfied
6
totally
dissatisfied
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The impact of using a partially randomised patient
preference design when evaluating alternative
managements for heavy menstrual bleeding
Kevin G. Cooper Clinical Research Fellow, Adrian M. Grant Director, Andrew M. Garratt Research Fellow
Health Services Research Unit, University ofAberdeen
Objective To identify the advantages and disadvantages of using a partially randomised patient
preference design rather than a conventional randomised controlled design when evaluating
alternative managements for heavy menstrual bleeding.
Design Randomised controlled comparison of two clinical trial designs with subsequent follow up of the
cohorts ofwomen generated.
Participants Women attending a general gynaecology clinic for the first time because of heavy
menstrual bleeding.
Interventions Partially randomised patient preference clinical trial design and conventional randomised
controlled design.
Main outcome measures Overall participation; participation in randomised clinical trial of medical
management compared with transcervical surgical resection of the endometrium; prognostic
characteristics (socio-demographic and Short Form 36) of clinical trial groups; outcomes (clinical
and Short Form 36) of clinical trial groups.
Results Overall, more women participated in the partially randomised patient preference design
(130. 135 vs 97 138; difference 27%, 95% CI 18% to 34%) but there was no difference in the
numbers who agreed to be randomised (90/135 vs 91 138; difference -3%, 95% CI -15% to 7%).
Women who chose medical management tended to have better general health, to be less restricted by
their menstrual problems, with fewer having been previously treated by their general practitioner.
Those who chose transcervical resection of the endometrium had all tried medical management and
had higher bleeding scores. Follow up satisfactions and acceptability rates, and Short Form 36 scores
were highest after transcervical resection of the endometrium, whether chosen or randomised.
Acceptability and a desire to continue the same treatment was greater among those who chose
medical management than those randomly allocated it.
Conclusions Use of the partially randomised patient preference design did not affect recruitment to the
randomised controlled trial suggesting that a conventionally designed trial would not be biased by
motivational factors in this context. Data from the preference groups informed the generalisability of
the results but did tend to confirm conclusions that anyway reasonably followed from the
randomised controlled trial. The extra resource implications of using the partially randomised patient
preference design were significant reflecting the additional 40% who participated and the extra
analyses entailed.
INTRODUCTION
It is widely accepted that a randomised controlled trial
is usually the research design of choice when evaluating
a new treatment or comparing management policies. A
potential problem with this design is that to be recruited
a participant must be prepared to accept any of the
health care options being compared. Eligible women
may, however, have strong opinions regarding the rela-
Correspondence: Dr K. G. Cooper. Department of Obstetrics and
Gynaecology. Aberdeen Royal Infirmary. Foresterhill. Aberdeen
AB25 2ZB. UK.
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tive acceptability of treatments'2. This may lead to the
recruits being a small proportion of those otherwise eli¬
gible, which could affect the generalisabi 1 ity of results.
Also, some people who agree to randomisation may do
so in an effort to obtain the new or alternative therapy.
This may be especially true when participating in the
trial is the only way of getting the new treatment, or
allows it to be obtained earlier. In this case, randomisa¬
tion will initially create like groups until the allocated
treatment is known when those allocated their preferred
treatment may be pleased while those who receive the
alternative management may be disappointed". Despite
1367
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PRPP
(i = 135)
Refused
(n= 5)
Preferred
medical
(rt=19)
Preferred
TCRE
(i = 21)
Randomised
medical
(i = 45)
Randomised
TCRE
(1 = 45)
CRCT
(i= 138)
Randomised
medical
(i = 49)
Randomised
TCRE
(i = 48)
Refused
(i = 41)
Fig. 1. Derivation of study cohorts. TCRE = transcervical resection of the endometrium; PRPP = partially randomised patient preference;
CRCT = conventional randomised controlled trial.
random allocation, the trial groups may then differ in
respect of motivation. If those disappointed with the
allocation tended to decide to withdraw, this would
introduce selection bias. Additionally, motivational
differences could affect compliance with the allocated
management, particularly when the treatments under
investigation differ dramatically4-"' and when evaluating
participative interventions6. Motivation may also intro¬
duce bias in the measurement of outcome particularly
if these measures are subjectively assessed by those
participating in the trial; this applies, for example, to
treatment success, satisfaction, acceptability and quality
of life following management of menstrual disorders".
The partially randomised patient preference (PRPP)
trial design6 aims to deal with these issues. Potential
participants with a strong preference for one or other
treatment receive it, while the remainder, without a
preference, are randomised. Two groups of recruits are
generated in whom motivational factors are optimised
by allowing them to have their preferred treatment,
while two randomised groups are created in whom
motivational factors are equalised (Fig. 1). There are
a number of putative advantages: larger numbers of
people are likely to participate in the overall study;
analysis of the randomised groups will allow relatively
unbiased measurement of any differential effects of the
treatments; the preference groups, which can be viewed
as part of a nonrandomized prospective cohort study,
may give information on the factors which determine
preference or refusal to be randomised; and the effects
ofmotivational factors on outcome can be addressed by
comparing those who chose a treatment with those who
were randomly allocated to that treatment*.
Nevertheless, the value of the PRPP design remains
controversial. Not only do the preference arm compar¬
isons have all the potential limitations of observational
studies9 (which randomisation aims to avoid), but mak¬
ing preference choices could reduce the number of peo¬
ple recruited to the randomised comparison-10 ". This
in turn would reduce the statistical power and might if
motivation is not a strong influence on outcome, reduce
rather than increase the generalisability. The resources
required are also greater; arguably, these may be better
used to increase the size of the randomised comparison
to give clearer, more precise information.
We explored these issues in the context of a com¬
parison of medical management with hysteroscopic
treatment of heavy menstrual bleeding, a condition
where the issues of patient preference are felt to be
important12. The results of the randomised comparison
are reported in detail in the accompanying report. In the
element of the study reported here, we assessed
the impact of using a PRPP design by addressing the
following questions:
1. Do more people participate in a PRPP study than in a
conventional randomised controlled trial?
2. Does making the option of preferred management
more explicit reduce the number of people who
agree to be randomised? If so, does this change the
characteristics of the group who make up the ran¬
domised comparison?
3. Are there differences between the preference and
randomised groups at trial entry? If so, does know¬
ing about them improve the interpretation and use¬
fulness of the study?
4. Are there differences between the preference groups
and randomised groups in outcome? If so, does
knowing about them improve the interpretation and
usefulness of the study?
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5. If the interpretation and usefulness of the study is
improved by the PRPP design, is this worth the extra
resources required for a PRPP design?
METHODS
From 1 October 1994 to 30 September 1995, women
with heavy menstrual loss who were first time attenders
at the clinic of nine of eleven general gynaecologists in
a single University hospital were identified by screen¬
ing referral letters. Following local research ethics com¬
mittee approval, the women were randomly allocated to
either a PRPP or a conventional randomised controlled
trial design. Formal entry and randomisation was sig¬
nalled by opening the next in a series of sealed, opaque
envelopes. The allocation sequence was pre-determined
from a computer generated list of numbers. A woman's
hospital notes were then labelled to identify the type of
trial design to which she had been allocated. Impor¬
tantly, at this stage, the women were unaware that they
were participating in a randomised trial.
Once a gynaecologist had checked that a potential
participant had none of the exclusion criteria (a uterus
larger than ten weeks of gestational size, fertility
desired, specifically referred for surgical treatment,
requesting hysterectomy, or a finding of significant
gynaecological pathology), she was informed of the
different treatments available within the clinical trial
(medical management or transcervical resection of the
endometrium (TCRE)) and given the patient informa¬
tion sheet corresponding to her allocated study design.
These information sheets outlined the reasons for
undertaking the trial, the timescale, the treatments avail¬
able within the trial, and the principle of randomisation.
The patient information sheet for the PRPP trial differed
from that of the conventional randomised controlled
trial by only two sentences which read: 'We do realise
that some women may have a preference for one of the
treatments. If you feel strongly that you want one treat¬
ment in particular, then please tell us'. All the women
were then seen by the same investigator. Those in the
conventional randomised controlled trial arm were told
about randomisation and its importance to the trial.
Those in the PRPP arm were counselled in a similar
way, but it was also pointed out that if they had a strong
preference for one of the treatments then they could
have it. All women, whether or not recruited, completed
a questionnaire which described certain socio-demo-
graphic and clinical characteristics. It also specifically
asked those who did not agree to join the study why
they had decided this. Informed consent was obtained
from those agreeing to participate in the clinical trial.
Participants had their haemoglobin level measured and
completed a trial booklet which contained a detailed
clinical questionnaire (including expectations of treat-
Table I. Baseline characteristics of all eligible women by allocated
trial design. Values are given as n (M. PRPP = partially randomised
patient preference; CRCT = conventional randomised controlled
trial.
PRPP CRCT
«/->II (/;= 138)
Age < 40 50 (37) 42 (30)
Two or more children 113 (84) 114 (83)
Married 117 (87) 122 (89)
Living in own property 88 (67) 98 (72)
Unemployed 24 (18) 31 (23)
Smoker 53 (42) 46 (35)
Heavy periods > 1 year 113 (84) 103 (75)
Previous medical treatment 107 (80) 103 (76)
ment), the hospital anxiety and depression scale13, and
Short Form 36 health survey14-16. These measurements
except hospital anxiety and depression scale were
repeated four months after starting treatment to assess
outcome.
Women who agreed to random allocation to medical
management or TRCE were managed accordingly.
Those in the PRPP group who expressed a preference
received the treatment chosen. Those who refused to
participate were referred back to their original gynae¬
cologists for treatment (most of whom did not perform
TCREs).
The sample size was largely dictated by the numbers
of participants sought in the randomised clinical trial
(see accompanying report). However, the sample size of
270 for the study reported here had over 95% power to
detect a difference in participation rates of 20%; 85%
power for a 15% difference; and 50% power for a 10%
difference (all 2P < 0 05). Comparisons of categorical
data were made using the x2 test, ar|d of continuous
data with normal distribution, using Student's t test.
Changes over time were compared for categorical
variables using McNemar's test and for continuous vari¬
ables using Student's paired t test.
RESULTS
A total of 273 women were eligible for the study; 135
were randomised to the PRPP design and 138 to the con¬
ventional randomised controlled trial design. Figure 1
shows the allocation of women within the trial and
Table 1 shows the baseline characteristics and compara¬
bility of these groups.
Of the 135 in the PRPP arm 90 (66-7%) agreed to be
randomised and 40 (30%) expressed a definite prefer¬
ence, so the total number participating was 130 (96 7%)
(Table 2). 97 (70%) of the 138 eligible in the con¬
ventional randomised controlled trial group agreed to
participate all being randomised (difference in overall
participation 27%, 95% CI 18% to 34%). There was,
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Tabic 3. Characteristics of participating w omen by study group. Note: Randomised medical and randomised transcerv ical resection of the endo¬
metrium (TCRE) groups from both trial designs (PRPP and C'RCT) have been combined as there are no significant differences between these
groups for any descriptive variable. Values are given as n (0 o) or score [SD]. Key as for Table 1: HADS = hospital anxiety and depression scale:
GP = general practitioner.
Preferred medical Preferred TCRE Randomised medical Randomised TCRE Refused CRCT
(ti = 19) ('t = 21) (n = 94) (n = 93) (n = 41)
Age < 40 7 (37) 8 (38) 31 (33) 29 (31) 15 (37)
Two or more children 14 (74) 15 (71) 82 (87) 81 (87) 31 (78)
Married IS (95) 17 (81) 79 (84) 84 (90) 37 (93)
Living in own property 15 (S3) 12 (60) 63 (68) 63 (69) 28 (68)
Unemployed 4 (21) 2 (10) 21 (22) 19 (21) 11 (25)
Smoker S (44) 6 (33) 34 (38) 39 (45) 12 (30)
Heavy periods > 1 year 17 (89) 19 (90) 71 (76) 79 (85) 26* (63)
> 1 GP consultation for menorrhagia 17 (89) 19 (90) 86 (91) 86 (92) 31 *(76)
Previous medical treatment 11 (63) 19*(100) 73 (78) 77 (83) 28 (70)
Restricted for > 2 days 8 (44) 13 (67) 60 (64) 62 (69) 24 (60)
Hoping for amenorrhoea 0 (0) 5*(24) 6 (6) 8 (9)
Bleeding score 24 [8-26] 31 [9-13] 24 [8-52] 25 [7-59]
Pain score 14 [10 2] 20 [14 3] 15 [9-53] 14 [ 10-7]
HADS
Anxiety 71* 8-9 8-2 8-9
Depression 41 5-7 6 1 5-3
"Significant results (P< 0 05).
Table 2. Numbers in the study groups and reasons for not participat¬
ing. Values are given as n (°o). Key as for Table I: TCRE = transcer¬
vical resection of the endometrium.
100
=-
£
e CRCT °o difference
(u-138) (95% CI |
Study ami
Preferred medical 19 (14)
Preferred TCRE 21 (16)
kaudomised medical 45 (33) 49 (35)
Randomised TCRE 45 (33) 48 (35)
Refused 5 (3) 41 (30)
Wanted tablets 0 17
Wanted surgery 0 19
Wanted doctor to choose 1 1
W anted no treatment 4 4
TOTAL
Recruited 130 (97) 97 (70) -27 1-18 to -34;
Randomised 90 (67) 97(70) -3 |-15 to-7;
however, no clear difference in the numbers of women
who agreed to be randomised (difference -3%, 95% CI
-15% to +7%). Of those within the conventional ran¬
domised controlled trial arm who refused to participate,
17 wanted medical treatment and 19 TCRE; this was
similar to the numbers who chose their treatments in
the PRPP cohort. Of those who agreed to participate, no
woman in the PRPP group and one woman in the
conventional randomised controlled trial group subse¬
quently 'dropped out'.
Characteristics of the groups at the start of the study
are shown in Table 3. The social, demographic and clin¬
ical characteristics and baseline Short Form 36 scores
«> Cp^ V ,
s *
Fig. 2. Baseline Short Fonn 36 scores. ■ prefers medical: □ ran¬
domised medical; A = prefers TCRE; O = randomised TCRE.
(Fig. 2) of those agreeing to randomisation within the
PRPP design were very similar to those in the conven¬
tional randomised controlled trial group and data for
these groups have therefore been combined in Table 3 to
form randomised medical and randomised TCRE
groups. Compared to those randomised, women who
refused randomisation in the conventional randomised
controlled trial group were significantly less likely to
have had heavy periods for more than one year and to
have consulted their general practitioner more than once
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Table 4. Outcome four months after starting treatment. V alues are given as n ( reduction mean [SD] or increase J SD!. TCRE = transcervical
resection of the endometrium.
Preferred medical Randomised medical Preferred TCRE Randomised TCRE
(n= 19) (n = 94) (n = 21) (u = 93)
Bleeding score 7-36+ [9-44] 6-08); [11-26] 24-3 If [11-41] 20-00J [8-76]
Pain score 2-78 [8-27] 5 31 f [10-57] 14-63* [12-82] 10-53* [12-17]
Haemoglobin increase (g. dL) -0-29 10-99; 0-18 [1-29] 0-33 (107| 0-76J [l-62(
Satisfied with treatment 8 (42) 25 (27) 15 (71) 70 (76)
Treatment acceptable 12 (63) 33 (36) 17 (81 ) 86 (93)
Continue same treatment 12 (63) 29 (31) 16 (76) 86 (93)
Significant changes from baseline scores: *P < 005; +/><0-01;*P < 0-001
Table 5. Mean change in Short Fonn 36 scores at 4 months. Values are given as score [SD], Key as for Table 4.
Preferred medical Randomised medical Preferred TCRE Randomised TCRE
(n=19) (« = 94) (« = 21) (n = 93)
Physical functioning 6-58 [16-51] 4-84* [16-72] 12-86* [27-68] 10-16+ [16-51]
Social functioning 8-19* [25-08] 7-57* [26-26] 19-051 [23-35] 17-44+ [25-08]
Role physical 10-52 [38-23] 15-32* [46-78] 35-71 + [45-12] 32-26+ [38-23]
Role emotional -1-75 [45-94] 8-96* [49-43] 30-16* [49-33] 31-54+ [45-94]
Mental health -0-84 [19-00] 4-78* [16-69] 10-1* [20-77] 15-01+ [19-00]
Energy / fatigue 4-47 [20-76] 7-07* [20-23] 21-67+ [20-70] 20-53+ [20-76]
Pain -0-58 [31-33] 8-84* [26-39] 12-7* [22-85] 21-62+ [31-33]
General health 5-47* [20-85] -0-25 [15-99] 6-71 [15-62] 10-49+ [20-85]
Significant changes in scores: *P < 0 05; +P <001.
regarding their heavy periods. They were also less
likely to be smokers or to have received treatment for
excessive menstruation previously (P = 0 06 and P =
0 08, respectively). Those in the preferred TCRE group
had previously received treatment for heavy periods,
were more likely to hope for amenorrhoea (despite
choosing to avoid hysterectomy), and had higher base¬
line bleeding and pain scores than those randomised or
preferring medical treatment. The preferred medical
group scored significantly better than the other groups
in all components of Short Form 36 except physical
functioning and general health (Fig. 2) while their
hospital anxiety and depression scale anxiety scores
were also significantly better than those randomised or
preferring TCRE (Table 3).
Outcome for the randomised groups has been
described in detail in the accompanying paper; in sum¬
mary there were highly significant differences in favour
of TCRE for all parameters measured, including all
eight components of Short Form 36 (Tables 4 and 5).
There were no significant differences between those
preferring TCRE and those randomised to this group,
although satisfaction and acceptability levels were
lower in the preferred TCRE group, reflecting a greater
desire for amenorrhoea and subsequent requests for
hysterectomy (5/21 women). Comparison of those who
preferred medical treatment with those randomised
to medical showed that women in the preference arm
were significantly more likely to find the treatment
acceptable and want to continue with it. They were also
more likely to be satisfied with treatment, although this
difference was not conventionally significant. Follow
up Short Form 36 scores were also higher in the pre¬
ferred medical arm (Fig. 3), but changes in Short Form
36 scores are difficult to compare as scores in the pref¬
erence arm were significantly higher at baseline for six
of the eight components. Nevertheless, women in the
preferred medical group still had significantly poorer
results for all parameters outlined on Table 4 than
those randomised to TCRE (ranging from P = 0-014 for
change in haemoglobin concentration to P < 0 001 for
bleeding score, acceptability and continuation). Follow
up Short Fonn 36 scores were higher for all parameters
except social functioning in those randomised to TCRE
(Fig. 3).
DISCUSSION
We decided in advance to assess the advantages and dis¬
advantages of using a PRPP design in a comparison of
alternative managements of heavy menstrual bleeding.
We believe that this is the first randomised controlled
comparison of the two designs.
Not surprisingly, we found that nearly all women in
the PRPP group (97%) agreed to participate in the study
compared with 70% in the conventional randomised
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Fig. 3. Follow up Short Form 36 scores. ■ = prefers medical: □ =
randomised medical; A = prefers TCRE; O = randomised TCRE.
controlled trial group. This represented about a 40%
relative increase. It was not associated with any increase
in drop-outs. The difference in overall participation was
entirely explained by those who agreed to join one of
the preference groups. Making the option of preferred
management more explicit did not therefore appear to
reduce the number who agreed to allow their treatment
to be chosen by random allocation, and this was rein¬
forced by the finding of similar reasons for not agreeing
to randomisation in the two trial design groups. Never¬
theless, the confidence interval around our estimate
(-15% to 7%) is too wide to rule out an important dif¬
ference in this respect. Our rate of expressed preference
(30%) is similar to that described by Coulter et a/.l;.
There were systematic differences at the start of the
study between the preference groups and those who
agreed to be randomised. Women who chose medical
management tended to have better general health, were
less restricted by their menstrual problems, and fewer
had been treated previously by their general practi¬
tioner. Those who chose TCRE had all tried medical
management, had higher bleeding and pain scores, and
had a greater desire for amenorrhoea. The randomised
comparison involved women who were prepared to
accept either management and they tended to fall
between the preference groups in terms of their
menstrual history. There was, however, no evidence
that making the option of preference more explicit
influenced recruitment to the trial. A conventional
randomised controlled trial in this context would not
therefore be biased by motivational factors.
Figure 3 shows that the follow up Short Form 36
scores were highest in the two groups managed with
TCRE but not clearly different from the preferred
medical group. Satisfaction levels were lower in the
preferred medical group than in the two TCRE groups.
The appearance in Fig. 3 that the Short Form 36 scores
of the preferred medical group were clearly better that
the randomised medical group is potentially misleading
because it reflects the marked differences at baseline
(Fig. 2). There was relatively little scope for the pre¬
ferred medical group's scores to improve and in fact the
changes in scores were greater in the randomised
medical management group (Table 5). On the basis of
these results, despite TCRE performing better in the
randomised comparison, it is clearly reasonable to man¬
age women medically who wish to avoid surgery, while
recognising that outcome following medical manage¬
ment may be suboptimal even in this group.
Satisfaction was lower in the preferred TCRE group
than following randomised TCRE. This may reflect the
higher expectations in the preferred group (Table 3).
Specifically, some of these women expressed dis¬
appointment in not achieving amenorrhoea; arguably
hysterectomy should be considered for these women.
We found that the additional 40% of participants in
the PRPP design represented a very significant extra
workload; we also found the interpretation of the results
of the preference groups much more difficult because
they were based on observational comparisons. Infor¬
mation on the number and characteristics of eligible
patients who are not entered into randomised clinical
trial is considered important by some in the assessment
of generalisability31718 and this is potentially the major
contribution of the preference groups in this study.
Although the finding that women who preferred med¬
ical management were less severely affected and had
received less prior treatment underscored the need to
extrapolate the findings of the randomised comparison
prudently, this would, anyway be a sensible conclusion
from the results of the randomised comparison alone.
Obviously it is good practice to support women who
wish to avoid surgery and who choose to try medical
management. In respect of surgical management, those
who preferred TCRE tended to be less satisfied than
those randomised to it. Again, however, this would
not be surprising if women hoped for amenorrhoea. It
would be good clinical practice to clarify women's
expectations, and if amenorrhoea is important to a
woman to discuss hysterectomy as one of the possible
options.
Data from the preference groups in this study thus
tends to confirm conclusions that follow from the
randomised comparison. The resource implications of
getting this extra information are significant, however.
Given that randomised comparisons are often too small
to give reliable answers, these resources may be better
used to increase recruitment to a randomised compari-
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son to ensure more robust results. In a situation in which
there is concern that motivational factors may introduce
bias into a randomised comparison, the most efficient
way to address this may be by recording any preference
at trial entry and then examining in the analysis whether
preference does modify any differential effects'1'.
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Objectives To compare medical with hysteroscopic management in women referred to a gynaecologist
complaining of heavy menstrual loss.
Design Single-centre randomised trial.
Setting A teaching hospital in the United Kingdom.
Participants One hundred and ninety-seven women seeking specialist treatment of heavy menstrual loss
for the first time and willing to accept either treatment.
interventions 1. Medical treatments not previously used by the women prescribed by experienced
gynaecologists in standard doses and timings for a minimum of three cycles (n = 94), and
2. transcervical resection of the endometrium performed under general anaesthesia five weeks after
goserelin preparation (n = 93).
Main outcome measures Treatment satisfaction and acceptability, relief of symptoms, change in
haemoglobin, and improvement in health related quality of life, all after four months.
Results Women allocated transcervical resection were more likely to be totally or generally satisfied
(76% versus 27%, P < 0-001), to find the treatment acceptable (93% versus 36%, P < 0-001), and
willing to have the treatment again (93% versus 31%, P < 0 001). Although pain and bleeding were
significantly reduced by medical treatment this was modest in comparison with transcervical
resection (P < 0-001). Haemoglobin levels were significantly increased only following transcervical
resection. Short form 36 scores were also improved in both arms, although only transcervical
resection returned them to normal values.
Conclusions Medical treatment was less effective than transcervical resection of the endometrium,
irrespective of previous treatment or type ofmedical management. Early hysteroscopic endometrial
surgery should be considered by such woman with the choice made by the woman after a full
discussion of the advantages and disadvantages of all the options.
INTRODUCTION
Heavy menstrual loss is a common complaint account¬
ing for about 12% of all referrals to gynaecology outpa¬
tient departments'. Many of these women are initially
prescribed medical treatments by gynaecologists; these
are known to reduce blood loss in a significant propor¬
tion of women with objectively proven tnenorrhagia2 s.
Among those seeking surgery, hysteroscopic techniques
for endometrial ablation, such as transcervical resection
of the endometrium, have been shown to be effective,
achieving high rates of patient satisfaction9 "12. At pre¬
sent it is recommended that these techniques are offered
Correspondence: Dr K. G. Cooper, Department of Obstetrics and
Gynaecology, Aberdeen Royal Infinnary, Foresterhill. Aberdeen
AB25 2ZB, UK.
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as an alternative to hysterectomy after medical manage¬
ments have failed". We undertook this pragmatic13
randomised comparison of medical treatment with
transcervical resection of the endometrium to clarify the
place of hysteroscopic surgery in the management of
women when first referred to a gynaecologist with
heavy menstrual loss. The women who participated
were equally willing to accept medical or hysteroscopic
management.
METHODS
With local research ethics committee approval, women
were recruited from the general gynaecology clinics of
9 of the 11 consultants at this large teaching hospital
between October 1994 and September 1995. They were
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eligible if consulting a gynaecologist for the first time
with a complaint of heavy menstrual loss, their family
was complete, they had a clinical diagnosis of dys¬
functional uterine bleeding (uterus less than ten weeks
pregnancy size and normal endometrial pathology) and
had not been referred specifically for surgery. They also
had to be willing to be randomised to either medical or
hysteroscopic management.
After giving infonned consent, a clinical question¬
naire, the hospital anxiety and depression scale14, and
Short Form 36l-'vlfi were completed, and blood was taken
for haemoglobin estimation. Bleeding and pain scores
were determined by assigning a score from zero to five
for heaviness of bleeding or severity of pain for each
menstrual day, for a maximum of 10 days. These mea¬
surements, except for the hospital anxiety and depres¬
sion scale, were repeated four months after starting
treatment to assess outcome. Satisfaction, acceptability
(using direct questioning and by Semantic Differential
Technique17), and preferred subsequent treatment were
also ascertained then.
Women were randomly allocated to either 'transcervi¬
cal resection' or 'medical treatment' by opening sealed,
serially numbered, opaque envelopes; the order was
determined by computer generated random numbers
within balanced blocks of twenty. The actual choice of
medical treatment, which should not have been used by
the patient before as treatment for heavy menstrual loss
was selected by the senior gynaecologist responsible for
the clinic and continued for at least three cycles.
Women allocated surgery received an injection of the
gonadotropin releasing hormone analogue, goserelin
3-6 mg. Five weeks later they were admitted under the
care of one of the three participating gynaecologists
who performed hysteroscopic surgery. Transcervical
resection of the endometrium was performed under
general anaesthesia using rollerball coagulation to the
fundus and cornua with resection of the cavity walls
using a 90°, 7 mm diameter loop, with 1-5% glycine
solution as the distending medium.
Based on expected satisfaction rates of approxi¬
mately 80% at four to six months after transcervical
resection of the endometrium9 11 it was calculated that a
minimum of 180 women would be required to have
80% power to detect an absolute difference of 20% at
the 5% level of significance18. Analysis was by inten¬
tion-to-treat. Independent and paired t tests were used
for continuous variables (independent and related) with
a normal distribution and the Mann-Whitney U test for
ordinal or non parametric continuous variables. The
test was used for independent nominal data and
McNemars test for paired data describing dichotomous
variables. Secondary analyses were stratified according
to the number of medical treatments used prior to
gynaecological referral.
Table 1. Baseline characteristics of each randomised group at recruit¬
ment. Values are given as n (To) ofwomen, mean [SD] or mean score
with {95% CI} below. TCRE = transcervical resection of the endo¬
metrium: HADS = hospital anxiety and depression scale.
Randomised
Medical TCRE
(n = 94) (n = 93)
Mean age 4T4 [5-2] 41-7 [5-2]
Mean haemoglobin (g dL) 12-79 [1-19] 12-65 [1-63]
Menstrual symptoms
Irregular periods 49 (52) 52 (56)
3-5 days bleeding 15 (16) 11 (12)
>5 days bleeding 79 (84) 82 (88)
No. days heavy bleeding 4-56 [2-35] 4-28 [2-22]
Regular dysmenonfioea 53 (56) 48 (52)
Menstrual symptom rating scale
Mild or moderate 1 (1) 0 (0)
Severe 59 (63) 53 (58)
Very severe 28 (30) 36 (39)
Bleeding score 24-2 [8-5] 25-0 [7-6]
Pain score 14-7 [9-5] 13-5 [10-7]
Premenstrual symptoms
Bloating 71 (76) 75 (82)
Breast discomfort 65 (70) 65 (71)
Irritability 65 (70) 68 (75)
Headaches 63 (68) 54 (59)
Depression 53 (57) 51 (56)
HADS
Anxiety 8-96 8-85
J 7-8— io-i; [7-6-10-11
Depression 5-62 5-31
{4-7- 6-61 14-3-6-51
RESULTS
One hundred and eighty-seven of 273 eligible women
(69%) consented to randomisation, 94 were allocated
to medical treatment and 93 to transcervical resection.
The majority of those who refused randomisation had a
preference for one or other treatment. The results for
these women are described in the accompanying paper.
All women but one were assessed at follow up at an
average of nineteen weeks following TCRE or starting
medication.
Patient characteristics
The participants are described in Table 1; the trial
groups had similar expectations of treatment and were
also of equivalent height, weight and social status.
Almost 80% in each group were employed with about
30% requiring time off work because of menstrual
symptoms. Similar numbers had heavy menstrual flow
for more than one year (78% and 84%, respectively)
while 24/82 women (29%) in the medical ann and
22/85 (26%) in the surgical arm had haemoglobin levels
of less than 12 g/dL. Baseline Short Form 36 scores
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Table 2. Short form 36 health survey questionnaire mean baseline
scores and change in score at four month follow up. Scores range
from 0 to 100 (worst to best). Values are given as mean [SD], Key as
for Table 1.
Medical TCRE
Short Form 36 (,n =193) (n-= 93) P
Baseline scores
Physical functioning 78-88 [20-72] 81-94 [19-38] 0-30
Social functioning 69-10 [20-98] 69-06 [24-29] 0-99
Role
Physical 54-26 [37-86] 56-72 [39-38] 0-66
Emotional 57-80 [42-10] 53-41 [44-00] 0-49
Mental health 58-32 [18-27] 59-14 [19-08] 0-77
Energy/fatigue 41-24 [16-84] 41-51 [19-22] 0-92
Pain 53-8 [24-84] 57-95 [25-16] 0-26
General health 68-02 [18-85] 65-10 [20-05] 0-31
Change in score
Physical functioning 4-84* [16-72] 10-16+ [16-51] <0-05
Social functioning 7-57* [26-26] 17-44+ [25-08] <0-05
Role
Physical 15-32* [46-78] 32-26f [38-23] < 0 01
Emotional 8-96* [49-43] 31-54+ [45-94] < 0-01
Mental health 4-78* [16-69] 15-01 + [19-00] < 0-01
Energy/fatigue 7-07* [20-23] 20-53t [20-76] < 0 01
Pain 8-84* [26-39] 21-62+ [31-33] < 0-01
General health -0-25 [15-99] 10-49+ [20-85] < 0-01
Footnote marks denote significant changes from the baseline:
*P< 0 05, tP< 0-01.
were also comparable for each group (Table 2). 22% of
women had received no previous medical treatment,
56% one, and 22% two different treatments, from their
general practitioner. 60% of women in both amis
reported self treatment with analgesics perimenstrually.
Overall, baseline anxiety scores were elevated (8-96 and
8-85) whereas depression scores were in the normal
range (5-62 and 5-32)14-19.
Medical treatment
Table 3 shows the actual treatment prescribed to the
medical group. Progestogens were prescribed from day
12-25, or 5-25 if there was also dysmenorrhoea. The
combined oral contraceptive pill preparations recom¬
mended were second generation containing 30 pg
oestradiol. Tranexamic acid was prescribed at a dose of
1 g four times a day for the first five days of the period
in women with regular periods, with mefenemic acid
500 mg three times a day added if there was associated
dysmenorrhoea. Danazol was prescribed at a dose of
200 mg per day continuously for 90 days. No women
received a treatment that she had previously tried. Only
women with heavy and irregular periods received pro¬
gestogens. Eighty percent of women reported complet¬
ing the treatment as prescribed, 9% occasionally missing
tablets, and 11% stopping medication prior to follow
up. There was no significant difference in satisfaction or
Table 3. Drug treatments received by those randomised to medical
treatment, and rates of satisfaction, acceptability and desire to con¬
tinue the same treatment at follow up. Values are given as n (%) of
women. Progestogens day 5-25 = 22/31 women, 12-25 = 9/31
women. HRT= hormone replacement therapy, NSAID= non steroidal
anti-inflammatory drug
Treatment
n = 94 Satisfactory Acceptable Continue
Progestogens
day 12-25/5-25 31 (33) 10 (34) 11 (36) 6 (19)
Combined pill 24 (26) 8 (33) 8 (33) 6 (25)
Tranexamic acid 22 (23) 7 (34) 6 (29) 4 (18)
Danazol 15 (16) 5 (33) 7 (47) 3 (20)
HRT (with NSA1D) 2 (2) 1 (50) 1 (50) 2 (100)
acceptability rates between the medical treatments used
(Table 3). One woman underwent transcervical resection
after continual bleeding for two months on her allocated
medical treatment.
Transcervical resection of the endometrium
All those allocated transcervical resection were initially
managed this way. The only operative complication was
persistent uterine bleeding which occurred in six
women. This abated in all cases following the insertion
of a uterine foley catheter at the end of the procedure
with removal six hours later. One woman had a two
stage hysteroscopic procedure and one woman later had
a hysterectomy, both because of submucous fibroids.
Menstrual status at follow up
Transcervical resection of the endometrium reduced
bleeding and dysmenorrhoea significantly better than
medical treatment (Table 4, P < 0-001 for all variables)
and achieved amenorrhoea in 37%. Although the num¬
ber of heavy days, and bleeding and pain scores, were
significantly reduced by medical therapy the effect size
was significantly smaller than after surgery. This was
reflected in changes in mean haemoglobin levels. Medi¬
cal treatment did not significantly improve any of the
five premenstrual symptoms, whereas all were signifi¬
cantly improved following transcervical resection.
Satisfaction/acceptability
Transcervical resection resulted in significantly greater
levels of satisfaction, symptom improvement and
acceptability (Table 5). Semantic differential rating
scores were better on all parameters for hysteroscopic
surgery and significantly so for all except pain (Table 6).
The most common reason for dissatisfaction with
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Table 4. Menstrual status and symptoms at 4 months follow up. Values are given as n (%) ofwomen or mean [SD]. TCRE = transcervical resec¬
tion of the endometrium; Hb = haemoglobin (medical: n = 82 [<12 g/dL: n = 24], TCRE: n = 85 [<12 g/dL: n = 22]): 95% CI = 95% confi¬
dence intervals for difference in means or proportions (%).
Randomised medical (n = 93) Randomised TCRE (n = 93) 95% CI P
Mean increase in Hb level (g/dL) 0-18 [1-29] 0-76J [1-62] —1-04 to -o-i:
Mean increase in Hb if baseline <12 g/dL 0-93+ [1-5] 2-53+ [1-94] -2-64 to —0-5(
Menstrual status
Unchanged or heavier 48 (52) 7 (8) 33 to 56
Duration of bleed
None 3 (3) 34 (37)
< 3 days 3 (3) 17 (18) 37 to 59
3-5 days 29 (31) 24 (26)
> 5 days 58 (62) 17 (18)
No. of days heavy bleeding 3-15 + [2-8] 0-76+ [1-3] 1-75 to 3-03
Bleeding score 17-8+ [915] 5*1 + [6-97] 10-25 to 15-2'
Pain score 9-7+ [8-92] 28+ [614] 4-51 to 9-24
Dysmenorrhoea—same or worse 42 (46) 14 (15) 18 to 53
Premenstrual symptoms
Breast discomfort 55 (60) 40+ (44) 2 to 31
Bloating 73 (79) 53J (58) 8 to 35
In'itability 62 (67) 49+ (54) 1 to 28
Headaches 57 (62) 34+ (37) 11 to 39
Depression 51 (55) 21 + (23) 19 to 46
0-014
0-003
<0-001
<0-001
<0-001
<0-001
<0-001
<0-001
0-03
0-002
0-06
<0-001
<0-001
Footnote marks denote changes from baseline: *P< 0 05, \P < 0-01, %P< 0 001.
medical treatments was no change in the severity of
bleeding or pain, although 'bad side effects' were cited
by twenty seven (45%) of the sixty women who found
treatment unacceptable. A total of forty six (48%) in the
medical arm and twelve (13%) in the transcervical
resection arm reported symptoms which they consid¬
ered to be side effects, specifically nausea, headaches
and weight gain in the medical group and new pain
equally in both groups. One woman prescribed danazol
suffered a cerebro-vascular accident two months into
treatment, while another developed hypertension which
resolved on stopping the combined pill.
Health related quality of life
There was significantly greater improvement in all eight
subscales of the Short Form 36 following transcervical
resection (Table 2). The number of women requiring
time offwork each month in the medical arm (29%) did
not change with treatment, but was significantly
reduced (P < 0-001), in the surgical cohort (6%).
Secondary analysis stratified by previous medical
management
Outcome in respect of bleeding and pain scores,
menstrual symptoms, satisfaction, and acceptability was
significantly better among women allocated hystero-
scopic management in all strata characterised by the
number of previous medical treatments, including the
22% who had not previously had medical treatment.
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DISCUSSION
The results of the hysteroscopic surgery group are
clearly better than those of the medically managed
group. But are the results trustworthy and if so to whom
do they apply?
Bias between the two study groups in the way that
they were selected, if it exists, is likely to be small; the
groups were randomly allocated, there was only one
loss to follow up, and the groups were similar at entry
(Table 1). We used established and recognised question¬
naires measuring clinical and quality of life parameters,
satisfaction and acceptability of treatment914 l7-20-21. We
recognise that these are subjective. To minimise ascer¬
tainment bias, we limited participation in the trial to
women who were willing to accept either management.
Those who would not accept randomisation were stud¬
ied separately and are discussed in the accompanying
paper. We know that some commentators will argue that
the optimal medical treatments might not have been
used for each patient and that significant reduction in
menstrual blood loss only occurs when the original loss
is objectively pathological. In this pragmatic13 trial
experienced clinicians prescribed what they regarded to
be the most appropriate standard medical treatment for
each woman based on their findings at consultation
(Table 3). The individual drug therapies were prescribed
in doses and timing used in studies demonstrating the
effectiveness of these medications and as recommended
by the British National Formulary2-8'22. We would
emphasise that 22/31 women prescribed progestogens
had these from days 5 to 25 which has been shown to
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Table 5. Patient satisfaction, menstrual symptom rating scale, effectiveness and acceptability of treatment and desired future treatment. Values
are given as n (%) ofwomen. 95% CI = 95% confidence interval for difference in proportion (%).
Randomised medical (n = 93) Randomised TCRE (n = 93) 95% CI P
Totally or generally satisfied with treatment 25 (27) 70 (76) sC10NO1 <0-001
Cure or acceptable improvement in symptoms 29 (32) 77 (85) o*-f10-tSO1 <0-001
Menstrual symptom rating scale
None 2 (2) 34 (37) -45 to -24 <0-001
Mild or moderate 39 (42) 51 (53)
Severe 42 (45) 6 (6)
Very severe 10 (11) 1 (1)
Treatment acceptable 33 (35) 85 (91) -67 to -45 <0-001
Prepared to have same treatment again 29 (31) 86 (92) -72 to -51 <0-001
Would recommend the treatment 38 (41) 84 (90) -61 to -3 8 <0-001
Did not require days offwork 56 (71) 73 (94) -31 to -5 <0-001
Treatment desired
None 3 (3) 82 (88) -92 to-78 <0-001
Medical (same or different) 40 (43) 5 (5)
TCRE 49 (53) 2 (2)
Hysterectomy 1 (1) 4 (4)
Table 6. Semantic differential rating scores for acceptability of treatment (score -3 [best] to -3 [worst]). Values are given as mean [SD],
95% CI = 95% confidence interval for difference in mean.
Adjectival pair Medical (n= 93) TCRE (n= 93) 95% CI P
Painless-painful -0-44 [1-74] -0-71 [1-79] -0-25-0-78 0-3
Happy-sad —0-12 [1-56] -1-42 [1-43] 0-87-1-74 <0-001
Pleasant-unpleasant 0-11 [1-55] -0-58 [1-33] 0-27-1-10 0-002
Positive-negative -0-14 [1-81] -1-80 [ 1 -44] 1-19-2-14 <0-001
Safe-dangerous -0-68 [1-65] -1-75 [1-21] 0-65-1-49 < 0-001
Attractive-unattractive 0-01 [1-04] -0-40 [0-89] 0-13-0-69 0-004
Mild harsh -0-52 [1-41] -11- [132] 0-21-1-00 0-003
Agreeable-disagreeable -0-23 [1-92] -1-30 [ 1 -39] 0-59-1-57 <0-001
Active-passive -0-23 [112] -0-77 [1-24] © 1 -J © 6o 0-002
Easy-hard -1-01 [1-79] -1-58 [1-41] 0-11-1-04 0-016
Fast-slow -0-23 [1 '69] -1-69 [1-35] 0-88-1-77 <0-001
Good-bad 0-02 [2-03] rr>rI1 1-61-2-61 <0-001
significantly reduce menstrual blood loss8':;. More
specifically no women received progestogens in a dose
or timing previously shown to be of little use in
the management of menorrhagia. Furthermore, the trial
results consistently favoured hysteroscopic manage¬
ment, irrespective of the type of medical treatment
prescribed by the gynaecologist or whether medical
treatment had previously been tried or not. Also, satis¬
faction, acceptability and willingness to continue the
same treatment were similar for all the medical treat¬
ments used (Table 3) (although we acknowledge these
were not randomly allocated). We recognise that some
women in the medical ann, as in the surgical group,
may have had fibroids that were not detected on clinical
examination or endometrial biopsy and which might not
have responded to medical treatment.
Although the medically managed group showed
improvement at follow up this was consistently less than
in the resection group. This applied to all assessments of
menstrual status, including premenstrual symptoms and
dysmenorrhoea (Table 4). Premenstrual symptoms have
previously been shown to improve following endo¬
metrial ablation9-23. Satisfaction and acceptability were
also clearly higher in the transcervical resection group
(Tables 5 and 6), and this was reflected in the numbers
of women who would have the same treatment again,
would recommend it to another person, and desired fur¬
ther treatment. Transcervical resection of the endo¬
metrium achieved satisfaction and acceptability rates
which were comparable to those obtained in previous
randomised trials91012, even though women in this trial
were not specifically seeking surgical treatment.
Heavy menstrual loss is known to cause significant
deterioration in general health and quality of life21"24""25
which has often been overlooked in the assessment of
treatment. The reduced Short Form 36 scores observed
at baseline were consistent with the scores reported
for other women with menorrhagia25. After medical
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treatment there were significant improvements in all
parameters except for general health, but normal scores
were not attained for any of the eight parameters. In
contrast, scores equal to or better than normal for all
eight Short Form 36 scales were observed after trans¬
cervical resection (Table 2)20. This concurs with the
findings ofCoulter and colleagues26.
Objective measurement of blood loss was not under¬
taken as this is not yet routine clinical practice. An
assessment of severity of menstrual loss and treatment
success was undertaken by measuring haemoglobin
level at recruitment and follow up. The significantly
greater mean increase in haemoglobin concentration
among women allocated transcervical resection is con¬
sistent with the differences in the subjective measures of
outcome.
It is noteworthy that 48% of women in the medical
ami reported side effects and over half deemed these
unacceptable. None of the six surgical complications
was serious. However, these women did undergo a gen¬
eral anaesthetic and we recognise that significant risks
of hysteroscopic surgery exist, but are too uncommon to
evaluate reliably in a trial of this size.
These results should be generalisable to women first
seeking advice from a gynaecologist for management of
heavy menstrual bleeding who have no treatment prefer¬
ence. Seventy percent of those fulfilling the entry criteria
agreed to randomisation. In the accompanying report
we describe the results for those who refused randomi¬
sation who had a preference for transcervical resection
or medical treatment in equal proportions. Those who
had a preference for medical management (and so were
not randomised) fared better than those randomised to
medical treatment, but their results were still not as
satisfactory as those following transcervical resection.
A formal economic evaluation was not conducted.
The cost of hysteroscopic surgery has been estimated at
£56027 which will be offset to some extent by the costs
of medical management. However, the resource implica¬
tions of introducing transcervical resection of the endo¬
metrium to all gynaecological centres and the training
requirements involved could be considerable, and these
would need to be included in any assessment of cost-
effectiveness. Also, new, technically less demanding
ablative techniques that can be undertaken using local
anaesthesia have recently been reported28 30, while the
progestogen loaded coil seems effective in reducing
menstrual loss22-21. A more conservative approach could
be adopted through reassurance and counselling for
those determined to have menstrual loss within normal
limits. All these methods ofmanagement require formal
evaluation in randomised controlled trials before
accepting them as effective advances in the manage¬
ment of women complaining of heavy menses. Also,
those who believe that the medical management tested
in this trial was sub-optimal should test this assumption
in further rigorous trials against endometrial ablative
surgery.
In the meantime, this trial indicates that early ablative
surgery should be one of the options considered by
women consulting a gynaecologist for the first time
seeking treatment of excessive menstrual loss, with the
choice made by her after a full discussion of the advan¬
tages and disadvantages of all the various treatment
options.
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Objective To assess clinical status and changes in health related quality of life after two years in women
randomised to medical management or transcervical resection of the endometrium (TCRE) for treat¬
ment of heavy menstrual loss.
Design Two-year follow up using postal questionnaires and operative databank review.
Setting Gynaecology department of a large UK teaching hospital.
Participants Women who had joined a randomised comparison of medical treatment with TCRE for
heavy menstrual loss two years previously.
Main outcome measures Women's satisfaction with treatment, gynaecological symptoms, changes in
health related quality of life, and additional treatments received at two years.
Results Women allocated medical treatment were significantly less likely to be totally or generally
satisfied (57% vs 79%. difference -22%. 95% CI -36, -9%). to find their management acceptable
(77% vs 93%. difference -16%. 95% CI -26. —4%). or to recommend their allocated treatment
(24% v.? 78%. difference -54%. 95% CI -61. —33%). In the medical cohort 59% of women had
undergone TCRE. hysterectomy or both, whereas 17% in the TCRE cohort had undergone further
surgery. Bleeding and pain scores were similar in the groups and highly significantly better than at
recruitment. Short Form-36 health survey scores were significantly improved from baseline for
five of the eight health scores in the medical arm. and seven in the TCRE arm.
Conclusions The results at two years consolidate the findings and conclusions based on the four-month
follow up data. A policy of early TCRE is effective and safe and does not result in an increase in
hysterectomies. It should not be routinely withheld in an effort to try alternative medical therapies.
INTRODUCTION
Medium and long term follow up data are now avail¬
able for hysteroscopic endometrial ablative techniques
for women who would otherwise have undergone hys¬
terectomy' \ In contrast, there is a paucity of follow up
data of longer than six months for women prescribed
medical treatment for monorrhagia4, and there is evi¬
dence that problematic menses recur on cessation of
therapy5'1. The majority of trials assessing medical
treatments also adopt an explanatory, rather than prag¬
matic approach to investigation K. the emphasis being
Correspondence: Dr K. G. Cooper. Department of Obstetrics
and Gynaecology. Aberdeen Royal Infirmary. Foresterhill.
Aberdeen AB25 2ZB. UK.
on reduction in measured menstrual blood loss in
women w ith proven pathological loss (> 80 mL/cycle).
who represent less than half of all women complaining
of heavy menstrual loss'"" and of those referred for
endometrial ablation11. Few studies have assessed sat¬
isfaction with treatment or the women's desire to con¬
tinue the same treatment. More importantly, no other
studies have evaluated the effect of medical treatments
on health related quality of life, despite strong evi¬
dence that women complaining of heavy periods suffer
a significant reduction in this'- IJ.
We have reported14 the short term results of this ran¬
domised trial comparing medical treatment with TCRE
for women attending a gynaecologist for the first time
for treatment of heavy menstrual loss. The trial
involved women who were not specifically referred for
258 © RCOG 1999 British Journal ofObstetrics and Gynaecology
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surgical treatment and who were equally prepared to
have medical treatment or TCRE15. The present report
is a description of the two-year follow up of these
women, re-evaluating their outcomes with respect to
subsequent treatments received, satisfaction with and
acceptability of treatment, and change in health related
quality of life.
METHODS
Full details of the original trial design, treatment allo¬
cation, and outcome measures at four months have
been reported previously14. In summary, women were
eligible if they met the following entry criteria: con¬
sulting a gynaecologist for the first time with a com¬
plaint of heavy menstrual loss; family complete; a
clinical diagnosis of dysfunctional uterine bleeding
(uterus < 10 weeks of pregnancy size and normal
endometrial pathology); and had not been referred
specifically for surgery. They also had to have no pref¬
erence for either medical or hysteroscopic manage¬
ment. Of 272 eligible women, 187 (69%) consented to
randomisation, 94 being allocated to medical treatment
and 93 to transcervical resection. The majority of those
who refused randomisation had expressed a preference
for one or other treatment and were evaluated sepa¬
rately1-. After follow up at four months, all recruits,
irrespective of initial management, could request fur¬
ther and/or different treatment. This policy reflected
normal clinical practice in keeping with the pragmatic
design of the trial.
Postal questionnaires were sent two years after initial
treatment, assessing gynaecological symptoms, satis¬
faction with treatment, and acceptability of manage¬
ment. Changes in health related quality of life were
measured using the Short Form-36 health survey (SF-
36)lh l . Subsequent treatments were also determined,
both from the questionnaire and from the hospital surgi¬
cal database. As this is the only hospital with a gynaeco¬
logical service for the district, we can be certain of
further hospital treatment received for those who had
not left the Grampian region of Scotland.
The original sample size calculations indicated that
180 women would be the minimum number required for
the study to have 80% power to detect an absolute differ¬
ence in satisfaction with treatment of 207c at the 57c
level of significance1*. Analysis was by intention-to-
treat: that is, women remained in the group to which they
were originally allocated, irrespective of subsequent
treatment, t tests were used for variables with a normal
distribution, using the non-paired version for indepen¬
dent comparisons and the paired version otherwise. Sim¬
ilarly the Mann-Whitney U test and the paired Wilcoxon
signed rank test were used for non-parametric data. Inde¬
pendent nominal data were analysed using either the x
test or Fisher's exact test, depending on sample size.
McNemar's test was used for paired dichotomous data.
RESULTS
One hundred and eighty-seven women were originally
recruited between October 1994 and November 1995.
94 randomised to have medical treatment and 93 to
TCRE. Postal follow up questionnaires two years (range
23 to 28 months) after initial treatment were completed
by 173 (92%) women, 86 in the medical group and 87 in
the TCRE group. Six of the 14 not followed up were
known to have left the region.
Participants
Table 1 summarises the baseline characteristics of those
successfully followed up: they were very similar to the
total trial group14. At the time of recruitment almost 807c
in each group were employed, with about 30% requiring
time off work because of menstrual symptoms. Similar
numbers had heavy menstrual flow for more than one
year (78% and 84%. respectively). Hospital Anxiety and
Depression Scale anxiety scores were elevated (9-35
and 8-78). whereas depression scores were in the normal
range (5-76 and 5-29)w. Baseline SF-36 scores were also
comparable for each group and globally reduced relative
to women of the same age in the general population-
(Table 2 and Fig. 1). Complete details, have already
been reported14, and a reminder of the actual medical
treatment allocated and stratified results at four months
is given in Table 3.
Subsequent treatment received or continued at
two years
Subsequent management is summarised in Table 4. At
two-vear follow up. 59% of those randomised to medical
treatment had undergone TCRE. hysterectomy or both:
82% of the initial operations had been undertaken within
12 months of trial entry. Twenty percent of the women
remained on medical treatment, although specific medi¬
cations w ere not determined. 17% of women allocated to
TCRE had undergone repeat TCRE. hysterectomy or
both. One hysterectomy, in the TCRE arm. resulted from
an emergency laparotomy performed for acute sepsis and
generalised peritonitis, secondary to bilateral rupture of
pyosalpinges in an amenorrhoeic woman 14 months after
initial TCRE. No women requested further surgery or
medication after completing the questionnaire. Operative
data were obtained from the hospital surgical database for
the fourteen participants who did not complete two-year
questionnaires. Of eight women in the medical arm. four
had undergone TCRE; among six in the TCRE arm. one
hysterectomy had been performed.
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Tabic 1. Baseline characteristics of each randomised group at recruitment. Values are given as n CTl of women or mean [SD| unless otherwise
indicated. TCRE = transcervical resection of the endometrium.
Randomised medical Randomised TCRE
(/; = 86) (n = 87)
Age (years) 414 [5-4] 41 9 [5-1 ]
Haemoglobin (g/dL) 12-79 [116] 12 61 [ 1 66]
Menstrual symptoms
Irregular periods 45(52) 49(58)
3-5 days bleeding 14(16) 9(11)
> 5 days bleeding 72(84) 78(89)
No. of days heavy bleeding 4-6 [2-4.3] 4-24 [2-19]
Regular dysmenorrhoea 53(56) 48(52)
Menstrual symptom rating scale
Mild or moderate 6(7) 4 (4)
Severe 54(63) 51(59)
Very severe 26(30) 32(37)
Bleeding score 24-7 [8-6] 24-8 [7-3]
Pain score 15 2 [9-6] 13-3 [10-2]
Premenstrual symptoms
Bloating 64(75) 70(82)
Breast discomfort 60(71) 63(74)
Irritability 60(71) 64(75)
Headaches 57(67) 57(61)
Depression 49(58) 50(59)
Hospital Anxiety and Depression Scale
Anxiety: mean score (959 CI) 9-35 (8-47 to 10-22) 8-78 <7-85 to 9-70)
Depression: mean score (959 CI I 5-76 (5-06 to 6-45) 5-29 (4-54 to 6-051
Menstrual status at follow up reduction in bleeding and pain scores in both trial groups.
Similar numbers in both cohorts reported no new pelvic
Changes in menstrual symptoms at two years are shown pain of any kind (60% medical. 64% TCRE. P = 0-44).
in Table 5. There was a highly significant and comparable Significantly fewer women in the medical arm w ere
Table 2. Short Form-36 Health Survey Questionnaire: mean (SDi baseline scores and change in score at two-year follow up. Scores range
from 0 —> 100 (worst —> best).
Medical TCRE Actual
(// = S3) <// = S6i difference P 959 CI
Short Form-36: baseline scores
Physical functioning 78-67 (21-14) 82-33 118-56) - 3-66 0-23 -9-7 to 2-4
Social functioning 68-35 (21-04) 70-03 (24-05) - 1 -68 0-63 -8-5 to 5-2
Role: physical 53-01 (38-33) 56-98 (39-23) - 3-97 0-51 - 15-7 to 7-8
Role: emotional 57-43 (43-03) 55-03 (43-62) 2-40 0-72 - 10-8 to 15-6
Mental health 58-20 (18-23) 59-43 (18-97) - 1-23 0-67 -6-9 to 4 5
Energy/fatigue 40-36 (17 17) 41-49 (19-15) - 113 0-69 -6-7 to 4-5
Pain 53-55 (23-99) 58-14 (25-15) -4-59 0-23 - 12-1 to 2-9
General health 68-17 (19-00) 65-90 ( 19-34) 2-27 0-45 -3-6 to 8-1
Short Form-36: change in score
Physical functioning 3-73 ( 17-19) 5-00 (18-97)* -1-27 0-65 -6-4 to 4-2
Social functioning 3-94 (25-26) 10-59 (26-52) -6-65 0-10 -14-5to 1-2
Role: physical 12-95 (44-58)** 18 60 (45 73) -5-65 0-42 - 19 4 to 8-1
Role: emotional 11-25 (45-171* 22-48 (50-47) - 11 -23 0-13 -25-8 to 3-3
Mental health 7-17 ( 19-20) 9-98 (19-14) -2-81 0-35 -8-7 to 3-1
Energy/fatigue 10-06 (19-57) 14-58 <21 96) -4-52 0-17 - 11-0 to 2-0
Pain 11-38 (28-51) 12 34(27-20) -0-96 0-82 -9-4 to 7-5
General health -0-67 (13-90) 1 69 (18-83) -0-97 0-36 -7-4 to 2-7
Follow up statistical comparisons between trial groups are for change in score.
Asterisks/daggers denote significant changes in score from the baseline (*P < 0 05. **P < 0-01. P < 0 001).
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Fig. 1. Short Form-36 scores. A baseline medical; baseline TCRE; ■ normative values; ♦ 24 month medical; 24 month TCRE.
amenorrhoeic or had very light periods (spotting / bleed¬
ing score from 1 to 5). than in the TCRE arm (44% com¬
pared with 60%), while significantly more women in the
medical arm regarded their menstrual status as unchanged
or worse (18% compared with 6%). Significant reduc¬
tions were present in three of the five premenstrual symp¬
toms in the medical ami. whereas no significant
differences had been detected at four months. Significant
reductions in all five premenstrual symptoms in the
TCRE arm were evident, but with the exception of
headaches and irritability, these benefits were less than at
four months. Overall there was no significant difference
in premenstrual symptoms between the two study groups.
Satisfaction/acceptability
Compared with the medical group, women allocated
TCRE had significantly higher levels of satisfaction and
symptom improvement. They were also more likely to
find their treatment acceptable (Table 6). These values
were much improved in the medical arm from the four
month data, whereas those for TCRE were similar. Only
24% of women allocated to medical treatment would rec¬
ommend this form of treatment, compared with 78% in
the surgical arm who would recommend TCRE (P
< 0 001. difference -54%. 95% CI -66% to -44%). Of the
47 women in the medical arm who underwent a TCRE. 40
(85%) of them would recommend this form of treatment.
Health related quality of life
Baseline and two-year SF-36 follow up data are pre¬
sented for women who had completed both question¬
naires (Table 2). The changes in SF-36 scores were
Table 3. Drug treatments received by those randomised to medical treatment at recruitment. Rates of satisfaction, acceptability and desire to
continue the same treatment at four-month follow up. Values are given as n (Ti of women. Progestogens: days 5-25 = 22 of 31 women.
12-25 = 9 of 31 women. HRT = hormone replacement therapy; NSAID = non steroidal anti-inflammatory drug.
it = 94 Satisfied with treatment Treatment acceptable Continue treatment
Progestogens: days 12-25/5-25 31(33) 10(34) 11(36) 6(19)
Combined pill 24 (26) 8 (33) 8 (33) 6 (25)
Tranexamic acid 22(23) 7 (34) 6 (29) 4(18)
Danazol 15 ( 161 5 (33) 7 (47) 3 (20)
HRT (with NSAIDl 2 (2) 1 (50) 1 (50) 2(100)
Table 4. Subsequent management of those followed up at two years. Values are given as n (T) of women.
None Medical TCRE Repeat TCRE Hysterectomy TCRE and hysterectomy
Medical in = 86) 18(21) 17(20) 38(44) 0 4(4) 9(10)
TCRE (ii = 87) 65(75) 7 (8) 6 (7) 5 (6) 4 (4)
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Table 5. Menstrual status and symptoms at two-year follow up. Values are given as n (7c) of women or mean [SD|.
Medical (n = 86) TCRE (n = 87) Difference (7c) 957c CI for difference P
Menstrual status
No bleeding or very light 36 (42) 50(58) -16 1 o 0 1 0-04
Unchanged or heavier 16(18) 5 (6) 12 3 to 22 0-02
Duration of bleed (days)
None 26(30) 33(38) -8 -22 to 6
1-3 7(8) 14(16) -8 - 16 to 4 0-5
3-5 45(53) 31(36) 17 -4 to 21
>5 8 (9) 9(10) - 1 - 8 to 20
No. of days heavy bleeding 2-0 [2-8]" 1-1 [1-3] 0-9 0-37 to 1 -4 0-001
Bleeding score 6-8 [9-9]" 5-4 [81]- -1-4 - 1 -4 to 4-1 0-33
Pain score 4-1 [7-4] 3-9 [7-5] 1-2 -21 to 2-4 0-9
Dysmenorrhoea: same or worse 25(29) 20(23) 6 -7 to 19 0-46
Dyspareunia: same or worse 9(11) 5 (6) 5 -3 to 13 0-1
Premenstrual symptoms
Breast discomfort 47 (58)* 49(58)** 0 - 17 to 13 0-96
Bloating 57 (70) 55 (65)** 5 - 11 to 17 0-44
Irritability 55 (68) 47 (55)** 13 -5 to 25 0-09
Headaches 43 (53)* 34 (40)** 13 -4 to 26 0-09
Depression 30 (37)" 28(33) 4 -11 to 17 0-58
Asterisks/daggers denote changes from baseline (*P < 0 05. **P < 0-01. P < 0 001).
Difference in means or proportions (7c).
957c CI for difference = 957c confidence intervals for difference in means or proportions (7c ].
higher for all health scores at two years for those allocated
TCRE. but not significantly so. Women in the medical
arm scored better than at baseline and significantly so for
five of the eight variables, and in addition there was an
overall improvement from four-month scores. In the
TCRE group seven of the eight health scores were signif¬
icantly improved from baseline, but scores were lower
than those obtained at four months. Figure 1 shows how
the follow up scores compare with baseline and with nor¬
mative values for a healthy female population of equiva¬
lent age20. The number of women who were taking time
off work each month because of their periods was signifi¬
cantly, and comparably reduced from 309f at recruitment
Table 6. Patient satisfaction, effectiveness and acceptability of treatment, and recommended treatment. Values are given as n (7c) of women.
Medical (n = 86) TCRE (n = 87) Difference (7c) 957c CI for difference P
Totally or generally satisfied
with treatment 48(57) 68(79) _ 22 - 36 to -9 0-002
Cure or acceptable improvement
in symptoms 53(61) 69(81) -20 - 31 to -4 0-017
Treatment acceptable 65(77) 79(93) - 16 - 26 to —4 0-004
What treatment would you
recommend to a friend?
None 15(17) 9(11)
Medical 21(24) 2(2)
TCRE 40(47) 68(78) -31 -45 to-18 <0-001
Hysterectomy 10(12) 8(9)
957c CI for difference = 95% confidence intervals for difference in proportions (7c).
to 149c in the medical ami and 10% in the surgical arm at
two years (P = 0-1. 95% CI of difference -5% to 15%).
Patient preference
The parallel, nonrandomised cohorts of women, charac¬
terised by a preference for medical treatment or TCRE.
described previously", were not followed up by question¬
naire at two years. Subsequent surgical treatment received
at two years was determined for these women from the
surgical database. Two women of the 19 in the preferred
medical arm had had a TCRE. but no hysterectomies had
been performed in this group of women. Of the 21 women
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in the preferred TCRE arm. eight had had a hysterec¬
tomy and one had had a repeat TCRE.
DISCUSSION
This study represents the longest follow up of women
participating in a randomised trial of medical treatment
for heavy menstrual loss. It is also the longest follow up
of women undergoing TCRE who were not referred ini¬
tially for surgical treatment of their periods. Its other
strength is that the randomised cohorts are not distorted
by motivational bias, as women preferring treatments
were identified and studied separately from the outset.
This has allowed us to observe the treatment progres¬
sion in both cohorts in the knowledge that requests for
TCREs from those in the medical arm have not resulted
from 'resentful demoralisation"1: that is, disappoint¬
ment at their initial allocation. Analysis was by inten-
tion-to-treat, and therefore no women changed trial
arms or were withdrawn from the study because of sub¬
sequent treatments received.
Follow up questionnaires were not obtained from
eight women in the medical arm and six in the TCRE
arm. most of whom had left the region. Since this is the
only hospital offering gynaecological services in the
area, information was available on operative procedures,
general practitioner correspondence, and subsequent
clinic attendance for the women who remained in the
region. It is unlikely that loss of 8% of the original partic¬
ipants has affected the generalisability of the results as
the further surgical treatment received by these women
was similar to those who were followed up.
Medical arm
Only 20% of women initially allocated to take medical
treatment continued to take this at two years, although
41% of women in this group had avoided surgical treat¬
ment. Individual medical treatments used bv women at
follow up were not determined as it was the aim of the
trial to evaluate a medical policy rather than identify
optimal medical treatment. Stratified analysis on the
basis of subsequent treatment received in the medical
arm is also methodologically unsound, in view of the
small numbers and inherent bias created as women
chose their subsequent treatments. Satisfaction with,
and acceptability of, treatment were much improved
from four months, but remained significantly less than
among those allocated to TCRE. Bleeding and pain
scores were significantly less than at four months and
were comparable to the TCRE arm. Other menstrual
parameters were also significantly improved, but pelvic
pain remained low and equivalent in both arms. These
improvements from the four-month results may be due
to the 59% of women in this arm who underwent TCRE
or hysterectomy. Nevertheless, those women avoiding
surgical treatment can be presumed to be equally satis¬
fied as they were aware that surgery was available had
they requested it. The fact that only 24% of women
would recommend medical treatment, compared with
85% (40/47) of those who subsequently underwent
TCRE in the medical arm, who would recommend
TCRE, strengthens the argument that TCRE has
improved the medical arm results.
Surgical arm
Of women in the TCRE arm, 17% had undergone surgi¬
cal retreatment at two years, less than the proportion
reported in previous randomised single-centre trials
comparing TCRE with hysterectomy1:, but similar to
that in the multi-centre Medical Research Council
(MRC) trial1. These differences between the trials
mounted in our centre may represent variation at
recruitment in both severity of symptoms, and expecta¬
tions of treatment, as women in the present trial were
excluded from randomisation if they were seeking sur¬
gical treatment. Satisfaction with, and acceptability of.
treatment remained high at about 80%. comparable to
the four-month follow up. and significantly better than
among women in the medical arm. This also correlated
well with the numbers who would recommend TCRE
(78%) as treatment for heavy menstrual loss. Bleeding
and pain scores and number of heavy days remained
highly significantly better than at recruitment, similar
to four-month levels, with only the number of days
heavy bleeding significantly less than among those in
the medical arm. Premenstrual symptoms also re¬
mained significantly reduced from baseline but the
effect had diminished in comparison with the four-
month results. Importantly, women in the surgical arm
did not have higher hysterectomy rates than those in the
medical arm (10% vs 14%. 95% CI -16 to 4%). sug¬
gesting that early recourse to TCRE does not increase
the risk of hysterectomy.
Health related quality of life
This trial represents the longest term evaluation of
change in health related quality of life for women with
heavy menstrual loss. It could be argued that this should
be the definitive arbiter of treatment success, and its
measurement was recommended by the effective health
care group4 for outcome assessment of treatments for
menorrhagia. Heavy menstrual loss is known to cause
significant deterioration in general health and quality of
life1-14 which has often been overlooked in the evalua¬
tion of treatment. The reduced SF-36 scores observed at
baseline were consistent with the scores reported for
other women with menorrhagia". For women in the
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TCRE arm, two-year health related quality of life
scores, as measured by SF-36, remain at near normative
levels2", are significantly improved from baseline, and
are similar to values obtained at two years post-TCRE
by Sculpher et air. The scores are however, globally
reduced from the four-month results. One possible
explanation is an initial high score achieved in a honey¬
moon period occurring soon after relief of symptoms.
Another is that there has been a genuine fall off in the
benefits of the operation, although this is not borne out
by the satisfaction and menstrual status results. Women
in the medical arm also had higher SF-36 scores than at
baseline, but these remained lower than scores achieved
in the TCRE arm and substantially lower than normative
values (Fig. 1). The increased scores in the medical arm
from the four-month data may reflect the number of
women undergoing surgical treatment since then.
Patient preference
Women who had exhibited a preference and chosen
their treatments were not followed up by questionnaire
at two years because of the small numbers involved and
the difficulties of analysing data from these nonran-
domised observational cohorts. Nonetheless, subse¬
quent treatments received were determined from
hospital records. These confirmed the conclusions of the
four-month follow up data. Those preferring TCRE had
a markedly higher re-operation rate than among those
randomised to TCRE (429c vs 1797). This is likely to
reflect different expectations of treatment among those
preferring surgical treatment'" and indicates that these
should be clearly determined at outset, with hysterec¬
tomy discussed with women wanting amenorrhoea. In
contrast, of the 19 women preferring medical treatment,
only two had undergone TCRE and none a hysterec¬
tomy. a much lower proportion than those randomised to
medical treatment (5497 TCRE. 1497 hysterectomy).
This confirms that those women with a preference for
medical treatment have a good chance of avoiding
surgery, and can be encouraged to pursue this option.
CONCLUSION
At two years, women allocated to TCRE are still in bet¬
ter health than those initially managed medically. The
results therefore consolidate the conclusions drawn
from the four-month data. The findings apply to women
seen by a gynaecologist for the first time for treatment
of heavy menstrual loss, and who do not have a treat¬
ment preference. Early recourse to hysteroscopic
surgery will afford these women better relief of symp¬
toms and improvements in health related quality of life.
Reassuringly, over 8097 of those managed by TCRE at
the outset have avoided further surgical treatment and
there was no detectable increase in hysterectomy rates at
two years in this group compared with those randomised
to medical therapy. Nevertheless, 4197 of women in the
medical arm have not undergone surgical treatment for
their complaint, although only half of them continue to
take any medical therapy. Less invasive surgical tech¬
niques. such as microwave ablation22 or thermal
balloon2-24 as alternatives, should now be evaluated in
well constructed randomised trials, comparing them
with hysteroscopic endometrial ablation, before accept¬
ing them as effective alternative management for mon¬
orrhagia. Results from two small randomised trials
comparing the Mirena coil with TCRE are available
which demonstrate a significantly greater reduction in
pictorially assessed blood loss25 following TCRE2"" .
Larger randomised studies comparing the Mirena coil
and TCRE. with longer follow up. are required to
demonstrate meaningful differences in outcome other
than pictorially assessed blood loss.
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